Pyrimidine compounds, compositions thereof, and their pharmaceutical uses
Patent Information
- Application Number
- JP2023526348
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-26
- Filing Date
- 2021-10-30
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2041-10-30
AI Technical Summary
Current treatments for lung cancer with EGFR mutations, particularly insertions in exon 20, lack effective therapeutics, leaving a significant unmet need for targeted therapies.
Development of novel compounds, represented by Formula I, which are selective inhibitors of EGFR and potentially other EGFR family kinase variants, including those with exon 20 insertions, offering improved safety and therapeutic profiles.
These compounds provide therapeutic benefits for treating lung cancer and other diseases associated with EGFR mutations, including improved safety and toxicity profiles, and are effective against drug-resistant variants.
Smart Images

Figure 2022094354000001 
Figure 2022094354000002 
Figure 2022094354000003
Abstract
Description
[Background technology]
[0001] cross reference This application is filed in U.S. Provisional Patent Application No. 63 / 108,185, filed on October 30, 2020, U.S. Provisional Patent Application No. 63 / 236,194, filed on August 23, 2021, and October 26, 2021. claims the benefit of U.S. Provisional Patent Application No. 63 / 271,991, filed on July 1, 1999, each of which is incorporated herein by reference in its entirety.
[0002] Lung cancer is the most common cause of cancer death, and approximately 85% of lung cancer cases are non-small cell lung cancer (NSCLC). The development of targeted therapies for lung cancer has focused primarily on tumors that exhibit mutations in specific oncogenic drivers, namely epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Although three generations of tyrosine kinase inhibitors (TKIs) have been developed for cancers harboring the most frequently observed EGFR mutations, research and development remains limited for other oncogenic drivers in the EGFR family of receptor tyrosine kinases. Some oncogenic drivers, including insertions in the exon 20 gene of EGFR, have no current approved therapeutics to treat these cancers.
[0003] Given that a large number of patients with mutations in EGFR do not receive clinical benefit from currently available treatments against these targets, the development of novel therapies for the treatment of cancers associated with EGFR mutations is There remain important unmet needs. [Summary of the invention]
[0004] In one aspect, Formula I: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof, in which: X is -NH- or -O-; R 1 is -(C(R 4 ) 2 ) n R 5 and R 5 is unsubstituted or one R 5’ has been replaced with n is 0, 1, 2, or 3; Each R 4 are independently hydrogen, alkyl, halo, haloalkyl, hydroxy, alkoxy, or heteroalkyl; R 5 is C 4~10 cycloalkyl, aryl, or heteroaryl; Each R 5’ are independently deuterium, aryl, heteroaryl, alkyl, C 3 ~C 6 Cycloalkyl, 3-8 membered heterocycloalkyl, oxo, halo, heteroalkyl, haloalkyl, cyano, hydroxy, amino, -NH 2 ,-NHR 6 , -N(CH 3 )R 6 , -N(R 6 ) 2 , -C(=O)NH 2 , -C(=O)NHR 6 , -C(=O)N(R 6 ) 2 ,-NR 6 C(=O)R 6 , -NHC(=O)R 6 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 N.H. 2 , -S(=O) 2 NHR 6 , -S(=O) 2 N(R 6 ) 2 , -S(=O) 2 heteroaryl, alkoxy, or haloalkoxy; Each R 6 is independently alkyl, aminoalkyl, cycloalkyl, aryl, or heteroaryl; R 2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, and the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl has at least one R 7 and 0, 1, or 2 R 8 has been replaced with Each R 7 is independently, [ka] and Y is -C(=O)-, -S(=O)-, or -S(=O) 2 and R 9 ,R 9’ , and R 9’’ are independently hydrogen, deuterium, halo, alkyl, haloalkyl, cycloalkyl, heteroalkyl, or (alkyl)heterocycloalkyl; R 10 is hydrogen, alkyl, haloalkyl, or cycloalkyl; Each R 8 are independently aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, halo, heteroalkyl, haloalkyl, cyano, hydroxy, amino, -N(R 11 ) 2 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 heteroaryl or alkoxy; Each R 11 are independently alkyl, cycloalkyl, aryl, or heteroaryl; R 3 is 0, 1, 2, or 3 R 12 is a heteroaryl substituted with Each R 12 are independently aryl, heteroaryl, alkyl, heteroalkyl, haloalkyl, halo, cyano, alkoxy, heterocycloalkyl, -N(R 13 ) 2 , -S(=O) 2 N.H. 2 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 heteroaryl, or cycloalkyl, in which each aryl, heteroaryl, heterocycloalkyl, or cycloalkyl is independently unsubstituted or has 0, 1, or 2 R 14 has been replaced with Each R 13 are independently hydrogen, alkyl, cycloalkyl, aryl, or heteroaryl; Each R 14 are independently deuterium, aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, halo, heteroalkyl, haloalkyl, cyano, hydroxy, amino, -N(R 15 ) 2 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 heteroaryl or alkoxy; Each R 15 is independently alkyl, cycloalkyl, aryl, or heteroaryl, or a pharmaceutically acceptable salt or stereoisomer thereof is provided herein.
[0005] In some embodiments, X is -NH-.
[0006] In some embodiments, n is 0.
[0007] In some embodiments, R 5 is phenyl, naphthyl, anthracenyl, phenanthrenyl, C-bonded pyridyl, C-bonded pyrimidinyl, C-bonded pyrazolyl, C-bonded imidazolyl, or C-bonded indolyl, where R 5 is 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is non-substituted. In some embodiments, R 5 is 1 R 5’ has been replaced with
[0008] In some embodiments, each R 5’ are independently alkyl, haloalkyl, 3- to 8-membered heterocycloalkyl, halo, cyano, hydroxy, -N(R 6 ) 2 , -N(CH 3 )R 6 , -C(=O)NHR 6 , -NHC(=O)R 6 , -S(=O) 2 N.H. 2 , alkoxy, or haloalkoxy. In some embodiments, each R 5’ are independently methyl, ethyl, tert-butyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, fluoro, chloro, cyano, hydroxy, -N(R 6 ) 2 , -C(=O)NHR 6 , -NHC(=O)R 6 , -S(=O) 2 N.H. 2, methoxy, ethoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, or trifluoromethoxy. In some embodiments, each R 5’ are independently methyl, morpholinyl, fluoro, chloro, cyano, -C(=O)NHMe, -NHC(=O)Me, -S(=O) 2 N.H. 2 , methoxy, fluoromethyl, difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy.
[0009] In some embodiments, each R 6 are independently alkyl or aryl. In some embodiments, each R 6 are independently methyl, ethyl, isopropyl, tert-butyl, phenyl, or naphthyl. In some embodiments, each R 6 are independently methyl or phenyl.
[0010] In some embodiments, R 2 is monocyclic. In some embodiments, R 2 R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is phenyl, cyclohexyl, or pyrrolyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, where the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is 1 R 7 and R 8 is not replaced by . In some embodiments, R 2 is 1 R 7 and 1 R 8 has been replaced with In some embodiments, R 2 is 1 R 7 and 2 R 8 has been replaced with
[0011] In some embodiments, R 2 is 1 R 7 has been replaced with
[0012] In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is.
[0013] In some embodiments, Y is -C(=O)-. In some embodiments, Y is -S(=O) 2 -is.
[0014] In some embodiments, R 9 ,R 9 , and R 9’’ are independently hydrogen, halo, alkyl, heteroalkyl, haloalkyl, or (alkyl)heterocycloalkyl. In some embodiments, R 9 ,R 9 , and R 9’’ are independently hydrogen, fluoro, chloro, methyl, hydroxyethyl, methoxyethyl, methoxymethyl, dimethylaminomethyl, 1-piperidinylmethyl, 1-morpholinylmethyl, or fluoromethyl. In some embodiments, R 9 and R 9’ are independently hydrogen, halo, alkyl, heteroalkyl, haloalkyl, or (alkyl)heterocycloalkyl. In some embodiments, R 9 and R 9’ are independently hydrogen, fluoro, chloro, methyl, hydroxyethyl, methoxyethyl, methoxymethyl, dimethylaminomethyl, 1-piperidinylmethyl, 1-morpholinylmethyl, or fluoromethyl.
[0015] In some embodiments, R 10 is hydrogen, methyl, ethyl n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, trifluoromethyl, or cyclopropyl. In some embodiments, R 10 is hydrogen or methyl.
[0016] In some embodiments, R 2 is R 8 is not replaced by . In some embodiments, R 2 is 1 or 2 R 8 has been replaced with In some embodiments, R 2 is 1 R 8 has been replaced with In some embodiments, R 2 is two R 8 has been replaced with In some embodiments, each R 8 are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, fluoro, chloro, heteroalkyl, cyano, hydroxy, amino, -N(R 11 ) 2 , methoxy, ethoxy, or trifluoromethoxy. In some embodiments, each R 8 are independently methyl, ethyl, isopropyl, tert-butyl, fluoro, chloro, -N(R 11 ) 2 , hydroxyethyl, methoxyethyl, or cyano.
[0017] In some embodiments, each R 11 are independently alkyl or aryl. In some embodiments, each R 11 are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, phenyl, naphthyl, anthracenyl, or phenanthrenyl. In some embodiments, each R 11 are independently methyl, ethyl, isopropyl, tert-butyl, phenyl, or naphthyl. In some embodiments, each R 11 are independently methyl or phenyl.
[0018] In some embodiments, R 3 is pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, indolyl, indazolyl, benzimidazolyl, azaindolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, or naphthyridinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is imidazolyl, pyrazolyl, triazolyl, indolyl, indazolyl, thiazolyl, isothiazolyl, or pyridinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with
[0019] In some embodiments, R 3 teeth, [ka] , where R 3 is 0 to 3 R 12 has been replaced with
[0020] In some embodiments, R 3 teeth, [ka] [ka] It is.
[0021] In some embodiments, R 3 teeth, [ka] It is.
[0022] In some embodiments, R 3 is non-substituted. In some embodiments, R 3 is at least one R 12 has been replaced with In some embodiments, R 3 is at least 2 R 12 has been replaced with
[0023] In some embodiments, each R 12 are independently aryl, heteroaryl, alkyl, heteroalkyl, haloalkyl, halo, cyano, heterocycloalkyl, -N(R 13 ) 2 , -S(=O) 2 N.H. 2 , or cycloalkyl. In some embodiments, each R 12 are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, hydroxyethyl, methoxyethyl, trifluoromethyl, trifluoroethyl, pentafluoroethyl, fluoro, Chloro, cyano, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, -N(R 13 ) 2 , cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, each R 12 are independently methyl, isopropyl, tert-butyl, hydroxyethyl, methoxyethyl, trifluoromethyl, trifluoroethyl, chloro, cyano, morpholinyl, or cyclopropyl. In some embodiments, each R 12 are independently methyl, hydroxyethyl, methoxyethyl, trifluoroethyl, or chloro. In some embodiments, each R 12 are independently methyl or chloro.
[0024] In some embodiments, each R 13 are independently alkyl or cycloalkyl. In some embodiments, each R 13 are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, each R 13 are independently methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, or cyclohexyl. In some embodiments, each R 13 are independently methyl, cyclopropyl, or cyclohexyl.
[0025] In some embodiments, R 12 aryl, heteroaryl, heterocycloalkyl, or cycloalkyl is unsubstituted. In some embodiments, R 12 aryl, heteroaryl, heterocycloalkyl, or cycloalkyl contains 1 or 2 R 14 has been replaced with
[0026] In some embodiments, each R 14 are independently alkyl, cycloalkyl, heterocycloalkyl, halo, cyano, -N(R 15 ) 2 , or alkoxy. In some embodiments, each R 14 are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, fluoro, chloro, cyano, -N(R 15 ) 2 , methoxy, ethoxy, or trifluoromethoxy. In some embodiments, each R 14 are independently methyl, ethyl, isopropyl, tert-butyl, pyrrolidinyl, piperidinyl, morpholinyl, fluoro, chloro, -N(R 15 ) 2 , or methoxy.
[0027] In some embodiments, each R 15 are independently alkyl or cycloalkyl. In some embodiments, each R 15 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[0028] In some embodiments, each R 13 are independently methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, or cyclohexyl. In some embodiments, each R 13 are independently methyl, cyclopropyl, or cyclohexyl.
[0029] In some embodiments, X is -NH- or -O-; n is 0, R 5 is 0 or 1 R 5’ phenyl substituted with R 2 is at least one R 7 and 0, 1, or 2 R 8 phenyl substituted with R 3 is 0, 1, 2, or 3 R 12 pyrazolyl substituted with
[0030] In some embodiments, X is -NH-.
[0031] In some embodiments, R 5’ is fluoromethyl, difluoromethyl, or trifluoromethyl.
[0032] In some embodiments, R 7 teeth, [ka] and R 8 is a halo.
[0033] In some embodiments, R 8 is fluoro, Y is -C(=O)-, R 9 and R 9’ is hydrogen, R 10 is hydrogen.
[0034] In some embodiments, R 12 is alkyl.
[0035] In some embodiments, R 12 is methyl.
[0036] In some embodiments, the compound has Formula I-A, Formula I-B, Formula I-C, Formula I-D, Formula I-E, Formula I-F, or Formula I-G: [ka] [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0037] In some embodiments, the compound has formula I-A: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the compound has formula I-A: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0038] In some embodiments, the compound has formula I-B: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments of compounds of formula I-B, R 1 is R 5 It is. In some embodiments of compounds of formula I-B, R 5 is 0 or 1 R 5’ has been replaced with In some embodiments of compounds of formula I-B, R 5 is non-substituted. In some embodiments of compounds of formula I-B, R 5 is 1 R 5’ has been replaced with
[0039] In some embodiments, the compound has formula I-C: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments of compounds of formula I-B, R 1 is R 5 It is. In some embodiments of compounds of formula I-C, R 5 is 0 or 1 R 5’ has been replaced with In some embodiments of compounds of formula I-C, R 5 is non-substituted. In some embodiments of compounds of formula I-C, R 5 is 1 R 5’ has been replaced with
[0040] In some embodiments, the compound has formula I-D: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the compound has formula I-D: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0041] In some embodiments, the compound has formula I-E: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the compound has formula I-E: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0042] In some embodiments, the compound has formula I-F: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the compound has formula I-F: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0043] In some embodiments, the compound has formula I-G: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments of compounds of formula I-G, R 1 is R 5 It is. In some embodiments of compounds of formula I-G, R 5 is 0 or 1 R 5’ has been replaced with In some embodiments of compounds of formula I-G, R 5 is non-substituted. In some embodiments of compounds of formula I-G, R 5 is 1 R 5’ has been replaced with
[0044] In some embodiments, the compound is [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof.
[0045] In some embodiments, the compounds described herein are selective inhibitors of EGFR over HER2.
[0046] In some embodiments, the compounds described herein have an improved safety profile. In some embodiments, the compounds described herein have an improved toxicity profile. In some embodiments, the compounds described herein have an improved therapeutic index.
[0047] In another aspect, provided herein is a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier.
[0048] In another aspect, a method of inhibiting an epidermal growth factor receptor (EGFR) family kinase variant in a subject in need of inhibiting an epidermal growth factor receptor (EGFR) family kinase variant, the method comprising: Provided herein are methods comprising administering to the subject a compound of Formula I, or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the EGFR family kinase variant comprises a substitution in exon 18, a deletion in exon 19, a substitution in exon 20, an insertion in exon 20, a mutation in the extracellular domain, or a substitution in exon 21. In some embodiments, the EGFR family kinase variant is del19 / T790M EGFR, L858R / T790M EGFR, L858R EGFR, L861Q EGFR, G719X EGFR, 763insFQEA EGFR, 767insTLA EGFR, 769insASV EGFR, 769insGE EGFR, 770insSVD EGFR, 77 0insNPG EGFR , 770insGT EGFR, 770insGF EGFR, 770insG EGFR, 771insH EGFR, 771insN EGFR, 772insNP EGFR, 773insNPH EGFR, 773insH EGFR, 773insPH EGFR, EGFRvii, EGFRviii, A767_dupASV EGFR, 773insAH EGFR, M766_A 767insAI EGFR, and any combination thereof Ru.
[0049] In another embodiment, a method of inhibiting an epidermal growth factor receptor (EGFR) variant in a subject in need of inhibiting an epidermal growth factor receptor (EGFR) variant, the method comprising: a therapeutically effective amount of a compound of formula I; or a pharmaceutically acceptable salt or stereoisomer thereof to the subject. In some embodiments, the EGFR variant comprises a substitution in exon 18, a deletion in exon 19, a substitution in exon 20, an insertion in exon 20, a mutation in the extracellular domain, or a substitution in exon 21. In some embodiments, the EGFR variant is del19 / T790M EGFR, L858R / T790M EGFR, L858R EGFR, L861Q EGFR, G719X EGFR, 763insFQEA EGFR, 767insTLA EGFR, 769insASV EGFR, 769insGE EGFR, 770insSVD EGFR, 770ins NPG EGFR, 770insGT EGFR, 770insGF EGFR, 770insG EGFR, 771insH EGFR, 771insN EGFR, 772insNP EGFR, 773insNPH EGFR, 773insH EGFR, 773insPH EGFR, EGFRvii, EGFRviii, A767_dupASV EGFR, 773insAH EGFR, M766_A767insAI EG FR, and any combination thereof.
[0050] In another aspect, a method of inhibiting a drug-resistant epidermal growth factor receptor (EGFR) variant in a subject in need of inhibiting the drug-resistant epidermal growth factor receptor (EGFR) variant, the method comprising: Provided herein are methods comprising administering to the subject an amount of a compound of Formula I, or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the drug-resistant EGFR variant is del19 / T790M EGFR or L858R / T790M EGFR.
[0051] In another embodiment, a method of inhibiting epidermal growth factor receptor (EGFR) in a subject in need of inhibiting epidermal growth factor receptor (EGFR), comprising: a therapeutically effective amount of a compound of Formula I or a pharmaceutically thereof; provided herein is a method comprising administering to the subject a salt or stereoisomer that is acceptable for .
[0052] In some embodiments, the EGFR variant comprises a substitution in exon 18, a deletion in exon 19, a substitution in exon 20, an insertion in exon 20, a mutation in the extracellular domain, or a substitution in exon 21. In some embodiments, the EGFR variant is del19 / T790M EGFR, L858R / T790M EGFR, L858R EGFR, L861Q EGFR, G719X EGFR, 763insFQEA EGFR, 767insTLA EGFR, 769insASV EGFR, 769insGE EGFR, 770insSVD EGFR (or D77 0_N771insSVD EGFR) , 770insNPG EGFR (or D770_N771insNPG EGFR), 770insGT EGFR, 770insGF EGFR, 770insG EGFR, 771insH EGFR, 771insN EGFR, 772insNP EGFR, 773insNPH EGFR (or H773insNPH EGFR), 773insH EGFR, 773insPH EGFR, EGFRvii, EGFRviii, A767_dupASV EGFR, 773insAH EGFR , M766_A767insAI EGFR, and any combination thereof. In some embodiments, the EGFR variant is del19 / T790M EGFR or L858R / T790M EGFR.
[0053] In another aspect, a method of treating a disease or disorder associated with an epidermal growth factor receptor (EGFR) family kinase in a subject in need of treatment for a disease or disorder associated with an epidermal growth factor receptor (EGFR) family kinase. Provided herein are methods comprising administering to the subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the EGFR variant comprises a substitution in exon 18, a deletion in exon 19, a substitution in exon 20, an insertion in exon 20, a mutation in the extracellular domain, or a substitution in exon 21. In some embodiments, the EGFR variant is del19 / T790M EGFR, L858R / T790M EGFR, L858R EGFR, L861Q EGFR, G719X EGFR, 763insFQEA EGFR, 767insTLA EGFR, 769insASV EGFR, 769insGE EGFR, 770insSVD EGFR, 770ins NPG EGFR, 770insGT EGFR, 770insGF EGFR, 770insG EGFR, 771insH EGFR, 771insN EGFR, 772insNP EGFR, 773insNPH EGFR, 773insH EGFR, 773insPH EGFR, EGFRvii, EGFRviii, A767_dupASV EGFR, 773insAH EGFR, M766_A767insAI EG FR, and any combination thereof.
[0054] In some embodiments, the disease or disorder in the subject comprises an EGFR mutation. In some embodiments, the EGFR mutation comprises a substitution in exon 18, a deletion in exon 19, a substitution in exon 20, an insertion in exon 20, a mutation in the extracellular domain, or a substitution in exon 21. In some embodiments, the EGFR mutation is del19 / T790M EGFR, L858R / T790M EGFR, L858R EGFR, L861Q EGFR, G719X EGFR, 763insFQEA EGFR, 767insTLA EGFR, 769insASV EGFR, 769insGE EGFR, 770insSVD EGFR (or D770 _N771insSVD EGFR), 770insNPG EGFR (or D770_N771insNPG EGFR), 770insGT EGFR, 770insGF EGFR, 770insG EGFR, 771insH EGFR, 771insN EGFR, 772insNP EGFR, 773insNPH EGFR (or H773insNPH EGFR), 773insH EGFR, 773insPH EG FR, EGFRvii, EGFRviii, A767_dupASV EGFR, 773insAH EGFR, M766_A767insAI EGFR, and any combination thereof. In some embodiments, the EGFR mutation is del19 / T790M EGFR or L858R / T790M EGFR.
[0055] In another embodiment, a method of treating one or more cancer cells in a subject in need thereof, comprising: a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable amount thereof; Provided herein are methods comprising administering to the subject a salt or stereoisomer of the present invention.
[0056] In another embodiment, a method of treating cancer in a subject in need of treatment, comprising: administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, to said subject. Provided herein are such methods comprising administering to a patient.
[0057] In some embodiments, the cancer is bladder cancer, prostate cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, glioblastoma, head and neck cancer, lung cancer, or non-small cell lung cancer. It is. In some embodiments, the cancer is non-small cell lung cancer, prostate cancer, head and neck cancer, breast cancer, colorectal cancer, or glioblastoma.
[0058] In some embodiments, the cancer in the subject comprises an EGFR mutation. In some embodiments, the EGFR mutation comprises a substitution in exon 18, a deletion in exon 19, a substitution in exon 20, an insertion in exon 20, a mutation in the extracellular domain, or a substitution in exon 21. In some embodiments, the EGFR mutation is del19 / T790M EGFR, L858R / T790M EGFR, L858R EGFR, L861Q EGFR, G719X EGFR, 763insFQEA EGFR, 767insTLA EGFR, 769insASV EGFR, 769insGE EGFR, 770insSVD EGFR (or D770 _N771insSVD EGFR), 770insNPG EGFR (or D770_N771insNPG EGFR), 770insGT EGFR, 770insGF EGFR, 770insG EGFR, 771insH EGFR, 771insN EGFR, 772insNP EGFR, 773insNPH EGFR (or H773insNPH EGFR), 773insH EGFR, 773insPH EG FR, EGFRvii, EGFRviii, A767_dupASV EGFR, 773insAH EGFR, M766_A767insAI EGFR, and any combination thereof. In some embodiments, the EGFR mutation is del19 / T790M EGFR or L858R / T790M EGFR.
[0059] In another aspect, the disclosure provides a method of treating an inflammatory disease in a subject in need thereof, comprising: a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof; The method is provided comprising administering the stereoisomer to the subject.
[0060] In some embodiments, the inflammatory disease is psoriasis, eczema, or atherosclerosis.
[0061] In some embodiments, the inflammatory disease in the subject comprises an EGFR mutation. In some embodiments, the EGFR mutation comprises a substitution in exon 18, a deletion in exon 19, a substitution in exon 20, an insertion in exon 20, a mutation in the extracellular domain, or a substitution in exon 21. In some embodiments, the EGFR mutation is del19 / T790M EGFR, L858R / T790M EGFR, L858R EGFR, L861Q EGFR, G719X EGFR, 763insFQEA EGFR, 767insTLA EGFR, 769insASV EGFR, 769insGE EGFR, 770insSVD EGFR (or D770 _N771insSVD EGFR), 770insNPG EGFR (or D770_N771insNPG EGFR), 770insGT EGFR, 770insGF EGFR, 770insG EGFR, 771insH EGFR, 771insN EGFR, 772insNP EGFR, 773insNPH EGFR (or H773insNPH EGFR), 773insH EGFR, 773insPH EG FR, EGFRvii, EGFRviii, A767_dupASV EGFR, 773insAH EGFR, M766_A767insAI EGFR, and any combination thereof. In some embodiments, the EGFR mutation is del19 / T790M EGFR or L858R / T790M EGFR.
[0062] In another aspect, the disclosure provides a compound comprising: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0063] The present disclosure describes processes for preparing compounds of Formula I, or stereoisomers, tautomers, their pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates containing them. A pharmaceutical composition is disclosed.
[0064] Compounds of the present disclosure may be useful in treating, preventing, or suppressing diseases or disorders mediated by epidermal growth factor receptor (EGFR).
[0065] These and other features, aspects, and advantages of the present disclosure will be better understood with reference to the following description. This description is provided to introduce selected concepts in a simplified form. This description is not intended to identify key or essential features of the subject matter or to be used in limiting the scope of the subject matter.
[0066] Inclusion by reference All publications, patents, and patent applications mentioned herein are incorporated by reference as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. is incorporated herein by reference to this extent. [Form for carrying out the invention]
[0067] definition In the structural formulas provided herein and throughout this disclosure, the following terms have the meanings indicated unless otherwise indicated.
[0068] As used herein, the term "optionally substituted" means that the group in question is either unsubstituted or substituted with one or more substituents specified. means. In some embodiments where the group in question is substituted with more than one substituent, the substituents are the same. In some embodiments where the group in question is substituted with more than one substituent, the substituents are different. In some embodiments, the reference group is halogen, -CN, -NH 2 , -NH(alkyl), -N(alkyl) 2 , -OH, -CO 2 H, -CO 2 Alkyl, -C(=O)NH 2 , -C(=O)NH(alkyl), -C(=O)N(alkyl) 2 , -S(=O) 2 N.H. 2 , -S(=O) 2 NH (alkyl), -S (=O) 2 N (alkyl) 2 , alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, heterocycloalkyl, aryl, heteroaryl, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone individually and independently optionally substituted with one or more additional group(s) selected as In some other embodiments, optional substituents include halogen, -CN, -NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -OH, -CO 2 H, -CO 2 (C 1 ~C 4 alkyl), -C(=O)NH 2 , -C(=O)NH(C 1 ~C 4 alkyl), -C(=O)N(C 1 ~C 4 alkyl) 2 , -S(=O) 2 N.H. 2 , -S(=O) 2 NH(C 1 ~C 4 alkyl), -S(=O) 2 N(C 1 ~C 4 alkyl) 2 ,C 1 ~C 4 Alkyl, C 3 ~C 6 cycloalkyl, C 1 ~C 4 Fluoroalkyl, C 1 ~C 4 heteroalkyl, C 1 ~C 4 Alkoxy, C1~C4 fluoroalkoxy, -SC 1 ~C 4 Alkyl, -S(=O)C 1 ~C 4 Alkyl, and -S(=O) 2 C 1 ~C 4 independently selected from alkyl. In some embodiments, optional substituents include halogen, -CN, -NH 2 , -OH, -NH(CH 3 ), -N(CH 3 ) 2 ,-CH 3 ,-CH 2 CH 3 ,-CHF 2 ,-CF 3 ,-OCH 3 ,-OCHF 2 , and -OCF 3 independently selected from. In some embodiments, the substituted group is substituted with one or two of the aforementioned groups. In some embodiments, optional substituents on aliphatic carbon atoms (acyclic or cyclic) include oxo (=O).
[0069] As used herein, C 1 ~C x As, C 1 ~C 2 ,C 1 ~C 3 ...C 1 ~C x can be mentioned. Just as an example, 'C 1 ~C 6 '' means that a group containing from 1 to 6 carbon atoms, i.e., 1 carbon atom, 2 carbon atoms, 3 carbon atoms, or 4 carbon atoms is present in this moiety. Indicates that it exists. Therefore, simply by way of example, 'C 1 ~C 4 "Alkyl" means 1 to 4 carbon atoms are present in the alkyl group, i.e. the alkyl group is selected from methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and t-butyl. Indicates that the
[0070] The term "alkyl" refers to a branched or unbranched monoradical saturated hydrocarbon chain having 1, 2, 3, 4, 5, or 6 carbon atoms. This term is exemplified by radicals such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-hexyl, and the like.
[0071] The term "cycloalkyl", unless otherwise stated, refers to a carbocyclic group of 3 to 6 carbon atoms having a single ring or multiple fused or spiro rings or bridged rings. This definition includes rings that are saturated or partially unsaturated. Examples of such cycloalkyl groups include monocyclic structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, and cyclohexenyl.
[0072] "Halo" or "halogen", alone or in combination with any other term, means halogen, such as chloro (Cl), fluoro (F), bromo (Br), and iodo (I).
[0073] The term "aryl" refers to a radical derived from a hydrocarbon ring system containing hydrogen, 6 to 30 carbon atoms, and at least one aromatic ring. This definition includes monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, and fused or bridged ring systems. Aryl radicals include, but are not limited to, aceantrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, Included are aryl radicals derived from the hydrocarbon ring systems of phenalene, phenanthrene, preiadene, pyrene, and triphenylene. Unless explicitly stated otherwise herein, the term "aryl" or the prefix "ar-" (eg, in "aralkyl") is intended to encompass optionally substituted aryl radicals.
[0074] The term "phenyl" refers to an aromatic carbocyclic group of 6 carbon atoms having a single ring.
[0075] The term "phenylalkyl" means a branched or unbranched group having 1, 2, 3, 4, 5, or 6 carbon atoms substituted with an aromatic carbocyclic group of 6 carbon atoms having a single ring. Refers to a monoradical saturated hydrocarbon chain on a branch.
[0076] The term "heteroaryl" refers to an aromatic ring group having 5 or 6 carbon atoms and 1, 2, or 3 heteroatoms selected from oxygen, nitrogen, and sulfur in at least one ring. . "X-linked heteroaryl" refers to a heteroaryl that is linked to the remainder of the molecule through an X atom. for example, [ka] is N-linked imidazolyl, while [ka] is a C-linked imidazolyl.
[0077] The term "heterocycloalkyl", unless otherwise stated, refers to a monomer having 2 to 10 carbon atoms in the ring and 1 to 3 heteroatoms selected from nitrogen, sulfur, phosphorus, and / or oxygen. Refers to a saturated, partially unsaturated, or unsaturated group having a ring or multiple fused or spiro rings or bridged rings.
[0078] The term "alkenyl" refers to an unsaturated aliphatic group having at least one double bond.
[0079] The term "alkynyl" refers to an unsaturated aliphatic group having at least one triple bond.
[0080] The term "amino" refers to -NH 2 Refers to radicals.
[0081] The term "cyano" refers to the -CN radical.
[0082] The term "hydroxy" or "hydroxyl" refers to the -OH radical.
[0083] The term "heteroalkyl" refers to an alkyl radical as defined above in which one or more carbon atoms of the alkyl are replaced with an O, N, or S atom. Unless explicitly stated otherwise herein, a heteroalkyl group is optionally substituted as described below. Representative heteroalkyl groups include, but are not limited to, -OCH 2 CH 2 OMe, -OCH 2 CH 2 OCH 2 CH 2 N.H. 2 , and -OCH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 N(Me) 2 can be mentioned.
[0084] A "heterocycloalkyl" group refers to a cycloalkyl group containing at least one heteroatom selected from nitrogen, oxygen, and sulfur. In some embodiments, a heterocycloalkyl is fused to an aryl or heteroaryl. In some embodiments, heterocycloalkyl is oxazolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidin-2-onyl, pyrrolidine- 2,5-dithionyl, pyrrolidin-2,5-dionyl, pyrrolidinonyl, imidazolidinyl, imidazolidin-2-onyl, or thiazolidin-2-onyl. In one aspect, heterocycloalkyl is C 2 ~C 10 It is heterocycloalkyl. In another embodiment, heterocycloalkyl is C 4 ~C 10 It is heterocycloalkyl. In some embodiments, a heterocycloalkyl is monocyclic or bicyclic. In some embodiments, a heterocycloalkyl is monocyclic and has 3, 4, 5, 6, 7, or 8 members. In some embodiments, a heterocycloalkyl is monocyclic and has 3, 4, 5, or 6 members. In some embodiments, a heterocycloalkyl is monocyclic and has a 3- or 4-membered ring. In some embodiments, a heterocycloalkyl contains 0-2 N atoms in the ring. In some embodiments, the heterocycloalkyl contains 0-2 N atoms, 0-2 O atoms, and 0-1 S atoms in the ring.
[0085] The term "haloalkyl" refers to an alkyl radical as defined above in which one or more carbon atoms of the alkyl are replaced with a halogen atom. In some embodiments, haloalkyl groups are optionally substituted as described below. Representative haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, and trifluoroethyl.
[0086] The term "aminoalkyl" refers to an alkyl group substituted with an amino (NH2) group. In some embodiments, an aminoalkyl group is unsubstituted or substituted at the nitrogen atom with an alkyl.
[0087] The term "alkoxy" refers to the group R-O-, where R is optionally substituted alkyl, or optionally substituted cycloalkyl, or optionally substituted alkenyl, or optionally substituted alkynyl , or optionally substituted cycloalkenyl, where alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl are as defined herein. Representative examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2 -Dimethylbutoxy, trifluoromethoxy, etc.
[0088] The compounds described herein are characterized by the fact that one or more atoms are replaced with an atom having an atomic mass or mass number that differs from that normally found in nature. includes isotopically labeled compounds that are identical to those listed in the various formulas and structures shown in . In some embodiments, the compounds of the invention contain isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, chlorine, iodine, phosphorus, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 35 S, 18 F, 36 Cl, 123 I, 124 I, 125 I, 131 I, 32 P, and 33 Including P etc. In one aspect, an isotopically labeled compound described herein, e.g. 3 H and 14 Those incorporating radioactive isotopes such as C are useful in drug and / or substrate tissue distribution assays. In one aspect, substitution with isotopes such as deuterium may provide certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements. In some embodiments, compounds described herein exist as isotopic variants. In some embodiments, isotopic variants of the compounds described herein have one or more hydrogen atoms replaced with deuterium.
[0089] In some embodiments, the compounds described herein have one or more chiral centers and / or double bonds and are therefore stereoisomers, e.g., double bond isomers (i.e., geometric isomers), positional isomers, enantiomers, or diastereomers. Accordingly, the chemical structures depicted herein refer to stereomerically pure (e.g., geometrically pure, enantiomerically pure, diastereomerically pure) forms as well as enantiomeric mixtures and It encompasses all possible enantiomers and stereoisomers of the compound shown or identified, including stereoisomeric mixtures. In some embodiments, enantiomeric and stereoisomeric mixtures are separated into their enantiomeric or stereoisomeric components using separation techniques or chiral synthesis techniques well known to those skilled in the art. In some embodiments, compounds also exist in several tautomeric forms, including enol forms, keto forms, and mixtures thereof. Therefore, the chemical structures depicted herein encompass all possible tautomeric forms of the compound depicted or identified.
[0090] In some embodiments, the compounds disclosed herein are free bases, salts, hydrates, isomers, diastereomers, prodrugs (e.g., esters), metabolites, ion pair complexes, or chelates. It is a form. In some embodiments, the compound exists in solvated forms, including unsolvated forms and hydrated forms, and exists as an N-oxide. In some embodiments, the compound is hydrated, solvated, or an N-oxide. Homologs, analogs, hydrolysates, metabolites, and precursors or prodrugs of the compounds are also intended to be within the scope of this disclosure. Generally, unless stated otherwise, all physical forms are equivalent for uses contemplated herein and are intended to be within the scope of this disclosure.
[0091] "Pharmaceutically acceptable salts" include salts with pharmaceutically acceptable acids or bases. Pharmaceutically acceptable acids include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, diphosphoric acid, hydrobromic acid, hydroiodic acid, and nitric acid, and organic acids such as citric acid, fumaric acid. , maleic acid, malic acid, mandelic acid, ascorbic acid, oxalic acid, succinic acid, tartaric acid, benzoic acid, acetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, or p-toluenesulfonic acid. Pharmaceutically acceptable bases include alkali metal (e.g., sodium or potassium) and alkaline earth metal (e.g., calcium or magnesium) hydroxides, as well as organic bases such as alkylamines, arylalkylamines, and heterocyclics. Examples include amines. In some embodiments, the compound is a pharmaceutically acceptable salt derived from acids including, but not limited to: acetic acid, alginic acid, anthranilic acid, benzenesulfonic acid, benzoic acid. , camphorsulfonic acid, citric acid, ethanesulfonic acid, formic acid, fumaric acid, furoic acid, galacturonic acid, gluconic acid, glucuronic acid, glutamic acid, glycolic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, apple acids, mandelic acid, methane sulfate, mucilage acid, nitric acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, propionic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, sulfuric acid, tartaric acid or p-toluenesulfonic acid.
[0092] "Pharmaceutical composition" means one or more active ingredients and one or more inactive ingredients that constitute the carrier, and any two or more of the ingredients by combination, complexation, or aggregation, or by the combination, complexation, or aggregation of the ingredients. Refers to any product that results directly or indirectly by dissociation of one or more of the components or by other types of reactions or interactions of one or more of the components. Accordingly, pharmaceutical compositions of the present disclosure include any composition comprising a compound of the present disclosure and a pharmaceutically acceptable carrier.
[0093] "Carrier" refers to a diluent, adjuvant, excipient, or vehicle with which a therapeutic is administered. In some embodiments, such pharmaceutical carriers are sterile liquids, such as water, and petroleum, animal, vegetable or It is an oil that may be of synthetic origin. In some embodiments, water is a carrier when the pharmaceutical composition is administered orally. In some embodiments, when the pharmaceutical composition is administered intravenously, saline and aqueous dextrose are exemplary carriers. In some embodiments, saline and aqueous dextrose and glycerol solutions are used as liquid carriers for injections. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, wheat flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, skim milk powder, glycerol, propylene, Examples include glycol, water, and ethanol. In some embodiments, the composition includes small amounts of wetting or emulsifying agents or pH buffering agents. In some embodiments, these compositions take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained release formulations, and the like. In some embodiments, the composition is formulated as a suppository, containing traditional binders and carriers such as triglycerides. In some embodiments, oral formulations include carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions contain a therapeutically effective amount of the therapeutic agent, eg, in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation must be suitable for the mode of administration.
[0094] "Combined" or "in combination" or "combination" refers to scenarios in which the compounds are administered separately in different formulations, in different modes of administration (e.g., subcutaneously, intravenously, or orally), and at different points of administration. should be understood as a functional co-administration encompassing. In some embodiments, the individual compounds of such combinations are administered sequentially in separate pharmaceutical compositions. In some embodiments, the individual compounds of such combinations are administered simultaneously in a combined pharmaceutical composition.
[0095] Compound In one aspect, Formula I: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof, in which: X is -NH- or -O-; R 1 is -(C(R 4 ) 2 ) n R 5 and R 5 is 0 or 1 R 5’ has been replaced with n is 0, 1, 2, or 3; Each R 4 are independently hydrogen, alkyl, halo, haloalkyl, hydroxy, alkoxy, or heteroalkyl; R 5 is C 4~10 cycloalkyl, C-attached heterocycloalkyl, aryl, or heteroaryl; Each R 5’ are independently aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, oxo, halo, heteroalkyl, haloalkyl, cyano, hydroxy, amino, -NH 2 ,-NHR 6 , -N(R 6 ) 2 , -C(=O)NH 2 , -C(=O)NHR 6 , -C(=O)N(R 6 ) 2 ,-NR 6 C(=O)R 6 , -NHC(=O)R 6 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 N.H. 2 , -S(=O) 2 NHR 6 , -S(=O) 2 N(R 6 ) 2 , -S(=O) 2 heteroaryl, alkoxy, or haloalkoxy; Each R 6 are independently alkyl, cycloalkyl, aryl, or heteroaryl; R 2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, and the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl has at least one R 7 and 0, 1, or 2 R 8 has been replaced with Each R 7 is independently, [ka] and Y is -C(=O)-, -S(=O)-, or -S(=O) 2 and R 9 and R 9’ are independently hydrogen, halo, alkyl, haloalkyl, cycloalkyl, heteroalkyl, or (alkyl)heterocycloalkyl; R 10 is hydrogen, alkyl, haloalkyl, or cycloalkyl; Each R 8 are independently aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, halo, heteroalkyl, haloalkyl, cyano, hydroxy, amino, -N(R 11 ) 2 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 heteroaryl or alkoxy; Each R 11 are independently alkyl, cycloalkyl, aryl, or heteroaryl; R 3 is 0, 1, 2, or 3 R 12 is a heteroaryl substituted with Each R 12 are independently aryl, heteroaryl, alkyl, heteroalkyl, haloalkyl, halo, cyano, alkoxy, heterocycloalkyl, -N(R 13 ) 2 , -S(=O) 2 N.H. 2 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 heteroaryl, or cycloalkyl, where each aryl, heteroaryl, heterocycloalkyl, or cycloalkyl independently contains 0, 1, or 2 R 14 has been replaced with Each R 13 are independently alkyl, cycloalkyl, aryl, or heteroaryl; Each R 14 are independently aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, halo, heteroalkyl, haloalkyl, cyano, hydroxy, amino, -N(R 15 )2 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 heteroaryl or alkoxy; Each R 15 are independently alkyl, cycloalkyl, aryl, or heteroaryl; However, if X is -O-, then R 5 is not a C-attached heterocycloalkyl, or a pharmaceutically acceptable salt or stereoisomer thereof is provided herein.
[0096] In one aspect, Formula I: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof, in which: X is -NH- or -O-; R 1 is -(C(R 4 ) 2 ) n R 5 and R 5 is unsubstituted or one R 5’ has been replaced with n is 0, 1, 2, or 3; Each R 4 are independently hydrogen, alkyl, halo, haloalkyl, hydroxy, alkoxy, or heteroalkyl; R 5 is C 4~10 cycloalkyl, aryl, or heteroaryl; Each R 5’ are independently deuterium, aryl, heteroaryl, alkyl, C 3 ~C 6 Cycloalkyl, 3-8 membered heterocycloalkyl, oxo, halo, heteroalkyl, haloalkyl, cyano, hydroxy, amino, -NH 2 ,-NHR 6 , -N(CH 3 )R 6 , -N(R 6 ) 2 , -C(=O)NH 2 , -C(=O)NHR 6 , -C(=O)N(R 6 ) 2 ,-NR 6 C(=O)R 6 , -NHC(=O)R 6 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 N.H. 2 , -S(=O) 2 NHR 6 , -S(=O) 2 N(R 6 ) 2 , -S(=O) 2 heteroaryl, alkoxy, or haloalkoxy; Each R 6 is independently alkyl, aminoalkyl, cycloalkyl, aryl, or heteroaryl; R 2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, and the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl has at least one R 7 and 0, 1, or 2 R 8 has been replaced with Each R 7 is independently, [ka] and Y is -C(=O)-, -S(=O)-, or -S(=O) 2 and R 9 ,R 9’ , and R 9’’ are independently hydrogen, deuterium, halo, alkyl, haloalkyl, cycloalkyl, heteroalkyl, or (alkyl)heterocycloalkyl; R 10 is hydrogen, alkyl, haloalkyl, or cycloalkyl; Each R 8 are independently aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, halo, heteroalkyl, haloalkyl, cyano, hydroxy, amino, -N(R 11 ) 2 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 heteroaryl or alkoxy; Each R 11 are independently alkyl, cycloalkyl, aryl, or heteroaryl; R 3 is 0, 1, 2, or 3 R 12 is a heteroaryl substituted with Each R 12 are independently aryl, heteroaryl, alkyl, heteroalkyl, haloalkyl, halo, cyano, alkoxy, heterocycloalkyl, -N(R 13 ) 2 , -S(=O) 2 N.H. 2 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 heteroaryl, or cycloalkyl, in which each aryl, heteroaryl, heterocycloalkyl, or cycloalkyl is independently unsubstituted or has 0, 1, or 2 R 14 has been replaced with Each R 13 are independently hydrogen, alkyl, cycloalkyl, aryl, or heteroaryl; Each R 14 are independently deuterium, aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, halo, heteroalkyl, haloalkyl, cyano, hydroxy, amino, -N(R 15 ) 2 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 heteroaryl or alkoxy; Each R 15 is independently alkyl, cycloalkyl, aryl, or heteroaryl, or a pharmaceutically acceptable salt or stereoisomer thereof is provided herein.
[0097] For all embodiments, substituents are selected from a subset of the listed alternatives. For example, in some embodiments, X is -NH-. In some embodiments, X is -O-.
[0098] In some embodiments, n is 0, 1, 2, or 3. In some embodiments, n is 0, 1, or 2. In some embodiments, n is 0, 1, or 3. In some embodiments, n is 0, 2, or 3. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 0 or 1. In some embodiments, n is 1 or 2. In some embodiments, n is 2 or 3. In some embodiments, n is 0 or 2. In some embodiments, n is 0 or 3. In some embodiments, n is 1 or 3. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3.
[0099] In some embodiments, R 5 is phenyl, naphthyl, anthracenyl, phenanthrenyl, chrysenyl, pyrenyl, C-bonded pyridyl, C-bonded pyrimidinyl, C-bonded pyrazolyl, C-bonded imidazolyl, or C-bonded indolyl, where R 5 is 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is phenyl, naphthyl, anthracenyl, phenanthrenyl, C-bonded pyridyl, C-bonded pyrimidinyl, C-bonded pyrazolyl, or C-bonded imidazolyl, where R 5 is 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is phenyl, where the phenyl has 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is naphthyl, where the naphthyl has 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is an anthracenyl, where the anthracenyl has 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is phenanthrenyl, where the phenanthrenyl is 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is chrysenyl, where the chrysenyl has 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is pyrenyl, where the pyrenyl has 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is a C-bonded pyridyl, where the C-bonded pyridyl has 0 or 1 R 5’has been replaced with In some embodiments, R 5 is a C-attached pyrimidinyl, where the C-attached pyrimidinyl has 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is a C-bonded pyrazolyl, where the C-bonded pyrazolyl has 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is a C-bonded imidazolyl, where the C-bonded imidazolyl has 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is a C-bonded indolyl, where the C-bonded indolyl has 0 or 1 R 5’ has been replaced with
[0100] In some embodiments, R 5 is 0 or 1 R 5’ has been replaced with In some embodiments, R 5 is non-substituted. In some embodiments, R 5 is 1 R 5’ has been replaced with
[0101] In some embodiments, each R 4 are independently hydrogen, alkyl, halo, haloalkyl, hydroxy, alkoxy, or heteroalkyl. In some embodiments, each R 4 are independently hydrogen, alkyl, halo, haloalkyl, or alkoxy. In some embodiments, each R 4 are independently hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, fluoro, chloro, trifluoromethyl, trifluoroethyl, pentafluoroethyl, methoxy, Ethoxy or trifluoromethoxy. In some embodiments, each R 4 are independently hydrogen, methyl, fluoro, trifluoromethyl, methoxy, or trifluoromethoxy. In some embodiments, each R 4 is hydrogen. In some embodiments, each R 4 are independently alkyl. In some embodiments, each R 4 is independently a halo. In some embodiments, each R 4 are independently haloalkyl. In some embodiments, each R 4 is hydroxy. In some embodiments, each R 4 are independently alkoxy. In some embodiments, each R 4 are independently heteroalkyl. In some embodiments, each R 4 is methyl. In some embodiments, each R 4 is ethyl. In some embodiments, each R 4 is n-propyl. In some embodiments, each R 4 is isopropyl. In some embodiments, each R 4 is n-butyl. In some embodiments, each R 4 is isobutyl. In some embodiments, each R 4 is sec-butyl. In some embodiments, each R 4 is tert-butyl. In some embodiments, each R 4 is fluoro. In some embodiments, each R 4 is chloro. In some embodiments, each R 4 is trifluoromethyl. In some embodiments, each R 4 is trifluoroethyl. In some embodiments, each R 4 is pentafluoroethyl. In some embodiments, each R 4 is methoxy. In some embodiments, each R 4 is ethoxy. In some embodiments, each R 4 is trifluoromethoxy.
[0102] In some embodiments, each R 5’ are independently alkyl, haloalkyl, heterocycloalkyl, halo, cyano, hydroxy, -N(R 6 ) 2 , -C(=O)NHR 6 , -NHC(=O)R 6 , -S(=O) 2 N.H. 2 , alkoxy, or haloalkoxy. In some embodiments, each R 5’ are independently aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, halo, heteroalkyl, haloalkyl, cyano, hydroxy, amino, -N(R 6 ) 2 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 Heteroaryl or alkoxy. In some embodiments, each R 5’ are independently aryl, heteroaryl, alkyl, heterocycloalkyl, halo, cyano, hydroxy, -N(R 6 ) 2 , or alkoxy. In some embodiments, each R 5’ are independently aryl. In some embodiments, each R 5’ are independently heteroaryl. In some embodiments, each R 5’ are independently alkyl. In some embodiments, each R 5’ are independently cycloalkyl. In some embodiments, each R 5’ are independently heterocycloalkyl. In some embodiments, each R 5’ is independently a halo. In some embodiments, each R 5’ are independently heteroalkyl. In some embodiments, each R 5’ are independently haloalkyl. In some embodiments, each R 5’ is cyano. In some embodiments, each R 5’ is hydroxy. In some embodiments, each R 5’ is amino. In some embodiments, each R 5’ is independently -N(R 6 ) 2 It is. In some embodiments, each R 5’ is independently -S(=O) 2 It is an alkyl. In some embodiments, each R 5’ is independently -S(=O) 2 It is an aryl. In some embodiments, each R 5’ is independently -S(=O) 2 It is a heteroaryl. In some embodiments, each R 5’ are independently alkoxy. In some embodiments, each R 5’ is, independently, phenyl, naphthyl, anthracenyl, phenanthrenyl, chrysenyl, pyrenyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, indolyl, indazolyl, benzimidazolyl, azaindolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyridazinyl , pyrazinyl, triazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, naphthyridinyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, tetrahydrofura Nyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, fluoro, chloro, cyano, hydroxy, -N(R 6 ) 2 , methoxy, ethoxy, or trifluoromethoxy. In some embodiments, each R 5’ are independently phenyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, methyl, ethyl, tert-butyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, fluoro, chloro, cyano, hydroxy, -N (R 6 ) 2 , methoxy, ethoxy, or trifluoromethoxy. In some embodiments, each R 5’ are independently methyl, ethyl, tert-butyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, fluoro, chloro, cyano, hydroxy, -N(R 6 ) 2 , -C(=O)NHR 6 , -NHC(=O)R 6 , -S(=O) 2 N.H. 2 , methoxy, ethoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, or trifluoromethoxy. In some embodiments, each R 5’ are independently methyl, morpholinyl, fluoro, chloro, cyano, -C(=O)NHMe, -NHC(=O)Me, -S(=O) 2 N.H. 2 , methoxy, fluoromethyl, difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy. In some embodiments, each R 5’ are independently phenyl, imidazolyl, pyridinyl, methyl, tert-butyl, pyrrolidinyl, morpholinyl, fluoro, cyano, hydroxy, -N(R 6 ) 2 , or methoxy. In some embodiments, each R 5’ is phenyl. In some embodiments, each R 5’ is naphthyl. In some embodiments, each R 5’is anthracenyl. In some embodiments, each R 5’ is phenanthrenyl. In some embodiments, each R 5’ is chrysenyl. In some embodiments, each R 5’ is pyrenyl. In some embodiments, each R 5’ is pyrrolyl. In some embodiments, each R 5’ is imidazolyl. In some embodiments, each R 5’ is pyrazolyl. In some embodiments, each R 5’ is triazolyl. In some embodiments, each R 5’ is tetrazolyl. In some embodiments, each R 5’ is indolyl. In some embodiments, each R 5’ is indazolyl. In some embodiments, each R 5’ is benzimidazolyl. In some embodiments, each R 5’ is an azain drill. In some embodiments, each R 5’ is thiazolyl. In some embodiments, each R 5’ is isothiazolyl. In some embodiments, each R 5’ is oxazolyl. In some embodiments, each R 5’ is isoxazolyl. In some embodiments, each R 5’ is pyridinyl. In some embodiments, each R 5’ is pyrimidinyl. In some embodiments, each R 5’ is pyridazinyl. In some embodiments, each R 5’ is pyrazinyl. In some embodiments, each R 5’ is triazinyl. In some embodiments, each R 5’ is quinolinyl. In some embodiments, each R 5’ is isoquinolinyl. In some embodiments, each R 5’ is quinoxalinyl. In some embodiments, each R 5’ is quinazolinyl. In some embodiments, each R 5’ is cinnolinyl. In some embodiments, each R 5’ is naphthyridinyl. In some embodiments, each R 5’ is methyl. In some embodiments, each R 5’ is ethyl. In some embodiments, each R 5’ is n-propyl. In some embodiments, each R 5’ is isopropyl. In some embodiments, each R 5’ is n-butyl. In some embodiments, each R 5’ is isobutyl. In some embodiments, each R 5’ is sec-butyl. In some embodiments, each R 5’ is tert-butyl. In some embodiments, each R 5’ is azetidinyl. In some embodiments, each R 5’ is oxetanil. In some embodiments, each R 5’ is pyrrolidinyl. In some embodiments, each R 5’ is imidazolidinyl. In some embodiments, each R 5’ is tetrahydrofuranyl. In some embodiments, each R 5’ is piperidinyl. In some embodiments, each R 5’ is piperazinyl. In some embodiments, each R 5’ is tetrahydropyranyl. In some embodiments, each R 5’ is morpholinyl. In some embodiments, each R 5’ is fluoro. In some embodiments, each R 5’ is chloro. In some embodiments, each R 5’ is methoxy. In some embodiments, each R 5’ is ethoxy. In some embodiments, each R 5’ is trifluoromethoxy. In some embodiments, each R 5’ is -C(=O)NHMe. In some embodiments, each R 5’ is -NHC(=O)Me. In some embodiments, each R 5’ is -S(=O) 2 N.H. 2 It is. In some embodiments, each R 5’ is difluoromethoxy.
[0103] In some embodiments, each R 6 are independently alkyl, cycloalkyl, aryl, or heteroaryl. In some embodiments, each R 6 are independently alkyl or aryl. In some embodiments, each R 6 are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, phenyl, naphthyl, anthracenyl, phenanthrenyl, chrysenyl, or pyrenyl. In some embodiments, each R 6 are independently methyl, ethyl, isopropyl, tert-butyl, phenyl, or naphthyl. In some embodiments, each R 6 are independently methyl or phenyl. In some embodiments, each R 6 is methyl. In some embodiments, each R 6 is ethyl. In some embodiments, each R 6 is n-propyl. In some embodiments, each R 6 is isopropyl. In some embodiments, each R 6 is n-butyl. In some embodiments, each R 6 is isobutyl. In some embodiments, each R 6 is sec-butyl. In some embodiments, each R 6 is tert-butyl. In some embodiments, each R 6 is phenyl. In some embodiments, each R 6 is naphthyl. In some embodiments, each R 6 is anthracenyl. In some embodiments, each R 6 is phenanthrenyl. In some embodiments, each R 6 is chrysenyl. In some embodiments, each R 6 is pyrenyl.
[0104] In some embodiments, R 2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is an aryl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is a heteroaryl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is cycloalkyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is heterocycloalkyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is monocyclic. In some embodiments, R 2 R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is phenyl, cyclohexyl, or pyrrolyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is phenyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is cyclopropyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is cyclobutyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is cyclopentyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8has been replaced with In some embodiments, R 2 is cyclohexyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is pyrrolyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is imidazolyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is pyrazolyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is triazolyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is tetrazolyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is thiazolyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is isothiazolyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is oxazolyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is isoxazolyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is pyridinyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is pyrimidinyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is pyridazinyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is pyrazinyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is triazinyl, where R 2 is at least one R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R2 is at least one R 7 and R 8 is not replaced by . In some embodiments, R2 is at least one R 7 and one R 8 has been replaced with In some embodiments, R2 is at least 2 R 7 and one R 8 has been replaced with
[0105] In some embodiments, R 2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is an aryl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is a heteroaryl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is cycloalkyl, where R 2 is 1 piece R7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is heterocycloalkyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is monocyclic. In some embodiments, R 2 R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is phenyl, cyclohexyl, or pyrrolyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is phenyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is cyclopropyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is cyclobutyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is cyclopentyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is cyclohexyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is pyrrolyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is imidazolyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is pyrazolyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is triazolyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is tetrazolyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is thiazolyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is isothiazolyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is oxazolyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is isoxazolyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2is pyridinyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is pyrimidinyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is pyridazinyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is pyrazinyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R 2 is triazinyl, where R 2 is 1 R 7 and 0, 1, or 2 R 8 has been replaced with In some embodiments, R2 is 1 R 7 and R 8 is not replaced by . In some embodiments, R2 is 1 R 7 and one R 8 has been replaced with In some embodiments, R2 is 1 R 7 and two R 8 has been replaced with
[0106] In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is.
[0107] In some embodiments, Y is -C(=O)-. In some embodiments, Y is -S(=O)-. In some embodiments, Y is -S(=O) 2 -is.
[0108] In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is. In some embodiments, R 7 teeth, [ka] It is.
[0109] In some embodiments, R 9 and R 9’ are independently hydrogen, halo, alkyl, heteroalkyl, haloalkyl, or (alkyl)heterocycloalkyl. In some embodiments, R 9 is hydrogen, halo, alkyl, cycloalkyl, or heteroalkyl. In some embodiments, R 9 is hydrogen, halo, or heteroalkyl. In some embodiments, R 9 and R 9’ are independently hydrogen, fluoro, chloro, methyl, hydroxyethyl, methoxyethyl, methoxymethyl, dimethylaminomethyl, 1-piperidinylmethyl, 1-morpholinylmethyl, or fluoromethyl. In some embodiments, R 9 is hydrogen, fluoro, chloro, hydroxyethyl, or methoxyethyl. In some embodiments, R 9 is hydrogen. In some embodiments, R 9 is fluoro. In some embodiments, R 9 is chloro. In some embodiments, R 9 is hydroxyethyl. In some embodiments, R 9 is methoxyethyl. In some embodiments, R 9 is methyl. In some embodiments, R 9 is methoxymethyl. In some embodiments, R9 is dimethylaminomethyl. In some embodiments, R 9 is 1-piperidinylmethyl. In some embodiments, R 9 is 1-morpholinomethyl. In some embodiments, R 9 is fluoromethyl. In some embodiments, R 9’ is hydrogen. In some embodiments, R 9’ is fluoro. In some embodiments, R 9’ is chloro. In some embodiments, R 9’ is hydroxyethyl. In some embodiments, R 9’ is methoxyethyl. In some embodiments, R 9’ is methyl. In some embodiments, R 9’ is methoxymethyl. In some embodiments, R 9’ is dimethylaminomethyl. In some embodiments, R 9’ is 1-piperidinylmethyl. In some embodiments, R 9’ is 1-morpholinomethyl. In some embodiments, R 9’ is fluoromethyl.
[0110] In some embodiments, R 10 is hydrogen or alkyl. In some embodiments, R 10 is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl. In some embodiments, R 10 is hydrogen. In some embodiments, R 10 is methyl. In some embodiments, R 10 is ethyl. In some embodiments, R 10 is n-propyl. In some embodiments, R 10 is isopropyl. In some embodiments, R 10 is n-butyl. In some embodiments, R 10 is isobutyl. In some embodiments, R 10 is sec-butyl. In some embodiments, R 10 is tert-butyl.
[0111] In some embodiments, R 2 is R 8 is not replaced by . In some embodiments, R 2 is 1 or 2 R 8 has been replaced with In some embodiments, R 2 is 1 R 8 has been replaced with In some embodiments, R 2 is two R 8 has been replaced with
[0112] In some embodiments, each R 8 are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, fluoro, chloro, heteroalkyl, cyano, hydroxy, amino, -N(R 11 ) 2 , methoxy, ethoxy, or trifluoromethoxy. In some embodiments, each R 8 are independently methyl, ethyl, isopropyl, tert-butyl, fluoro, chloro, -N(R 11 ) 2 , hydroxyethyl, methoxyethyl, or cyano. In some embodiments, each R 8 is methyl. In some embodiments, each R 8 is ethyl. In some embodiments, each R 8 is n-propyl. In some embodiments, each R 8 is isopropyl. In some embodiments, each R 8 is n-butyl. In some embodiments, each R 8 is isobutyl. In some embodiments, each R 8 is sec-butyl. In some embodiments, each R 8 is tert-butyl. In some embodiments, each R 8 is fluoro. In some embodiments, each R 8 is chloro. In some embodiments, each R 8 is independently -N(R 11 ) 2 It is. In some embodiments, each R 8 is hydroxyethyl. In some embodiments, each R 8 is methoxyethyl. In some embodiments, each R 8 is cyano.
[0113] In some embodiments, each R 11 are independently alkyl, cycloalkyl, aryl, or heteroaryl. In some embodiments, each R 11 are independently alkyl or aryl. In some embodiments, each R 11 are independently alkyl. In some embodiments, each R 11 are independently cycloalkyl. In some embodiments, each R 11 are independently aryl. In some embodiments, each R 11 are independently heteroaryl. In some embodiments, each R 11 are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, phenyl, naphthyl, anthracenyl, phenanthrenyl, chrysenyl, or pyrenyl. In some embodiments, each R 11 are independently methyl, ethyl, isopropyl, tert-butyl, phenyl, or naphthyl. In some embodiments, each R 11 are independently methyl or phenyl. In some embodiments, each R 11 is methyl. In some embodiments, each R 11 is ethyl. In some embodiments, each R 11 is n-propyl. In some embodiments, each R 11 is isopropyl. In some embodiments, each R 11 is n-butyl. In some embodiments, each R 11 is isobutyl. In some embodiments, each R 11 is sec-butyl. In some embodiments, each R 11 is tert-butyl. In some embodiments, each R 11 is phenyl. In some embodiments, each R 11 is naphthyl. In some embodiments, each R 11 is anthracenyl. In some embodiments, each R 11 is phenanthrenyl. In some embodiments, each R 11 is chrysenyl. In some embodiments, each R 11 is pyrenyl.
[0114] In some embodiments, R 3 is pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, indolyl, indazolyl, benzimidazolyl, azaindolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, or naphthyridinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is imidazolyl, pyrazolyl, triazolyl, indolyl, indazolyl, thiazolyl, isothiazolyl, or pyridinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is pyrrolyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is imidazolyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is pyrazolyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is triazolyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is tetrazolyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is indolyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is indazolyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is benzimidazolyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is an azain drill, where R3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is thiazolyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is isothiazolyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is oxazolyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is isoxazolyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is pyridinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is pyrimidinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is pyridazinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is pyrazinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is triazinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is quinolinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is isoquinolinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is quinoxalinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is quinazolinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is cinnolinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with In some embodiments, R 3 is naphthyridinyl, where R 3 is 0, 1, 2, or 3 R 12 has been replaced with
[0115] In some embodiments, R 3 is non-substituted. In some embodiments, R 3 is at least one R 12 has been replaced with In some embodiments, R 3 is at least 2 R 12 has been replaced with In some embodiments, R 3 is 1 R 12 has been replaced with In some embodiments, R 3 is two R 12 has been replaced with In some embodiments, R 3 is 3 R 12 has been replaced with
[0116] In some embodiments, R 3 teeth, [ka] , where R 3 is 0 to 3 R 12 has been replaced with In some embodiments, R 3 teeth, [ka] , where R 3 is 1 or 2 R 12 has been replaced with
[0117] In some embodiments, R 3 teeth, [ka] [ka] It is.
[0118] In some embodiments, R 3 teeth, [ka] It is.
[0119] In some embodiments, R 3 teeth, [ka] It is.
[0120] In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is. In some embodiments, R 3 teeth, [ka] It is.
[0121] In some embodiments, each R 12 are independently aryl, heteroaryl, alkyl, heteroalkyl, haloalkyl, halo, cyano, alkoxy, heterocycloalkyl, -N(R 13 ) 2 , -S(=O) 2 N.H. 2 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 Heteroaryl or cycloalkyl. In some embodiments, each R 12 are independently alkyl, heteroalkyl, haloalkyl, halo, cyano, heterocycloalkyl, -N(R 13 ) 2 , or cycloalkyl. In some embodiments, each R 12 are independently aryl. In some embodiments, each R 12 are independently heteroaryl. In some embodiments, each R 12 are independently alkyl. In some embodiments, each R 12 are independently heteroalkyl. In some embodiments, each R 12 are independently haloalkyl. In some embodiments, each R 12 is independently a halo. In some embodiments, each R 12 is cyano. In some embodiments, each R 12 are independently alkoxy. In some embodiments, each R 12 are independently heterocycloalkyl. In some embodiments, each R 12 is independently -N(R 13 ) 2 It is. In some embodiments, each R 12 is independently -S(=O) 2 N.H. 2 It is. In some embodiments, each R 12 is independently -S(=O) 2 It is an alkyl. In some embodiments, each R 12 is independently -S(=O) 2 It is an aryl. In some embodiments, each R 12 is independently -S(=O) 2 It is a heteroaryl. In some embodiments, each R 12are independently cycloalkyl. In some embodiments, each R 12 are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, hydroxyethyl, methoxyethyl, trifluoromethyl, trifluoroethyl, pentafluoroethyl, fluoro, Chloro, cyano, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, -N(R 13 ) 2 , cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, each R 12 are independently methyl, isopropyl, tert-butyl, hydroxyethyl, methoxyethyl, trifluoromethyl, trifluoroethyl, chloro, cyano, morpholinyl, or cyclopropyl. In some embodiments, each R 12 are independently methyl, hydroxyethyl, methoxyethyl, trifluoroethyl, or chloro. In some embodiments, each R 12 are independently methyl or chloro. In some embodiments, each R 12 is methyl. In some embodiments, each R 12 is ethyl. In some embodiments, each R 12 is n-propyl. In some embodiments, each R 12 is isopropyl. In some embodiments, each R 12 is n-butyl. In some embodiments, each R 12 is isobutyl. In some embodiments, each R 12 is sec-butyl. In some embodiments, each R 12 is tert-butyl. In some embodiments, each R 12 is hydroxyethyl. In some embodiments, each R 12 is methoxyethyl. In some embodiments, each R 12 is trifluoromethyl. In some embodiments, each R 12 is trifluoroethyl. In some embodiments, each R 12 is pentafluoroethyl. In some embodiments, each R 12 is fluoro. In some embodiments, each R 12 is chloro. In some embodiments, each R 12 is azetidinyl. In some embodiments, each R 12 is oxetanil. In some embodiments, each R 12 is pyrrolidinyl. In some embodiments, each R 12 is imidazolidinyl. In some embodiments, each R 12 is tetrahydrofuranyl. In some embodiments, each R 12 is piperidinyl. In some embodiments, each R 12 is piperazinyl. In some embodiments, each R 12 is tetrahydropyranyl. In some embodiments, each R 12 is morpholinyl. In some embodiments, each R 12 is cyclopropyl. In some embodiments, each R 12 is cyclobutyl. In some embodiments, each R 12 is cyclopentyl. In some embodiments, each R 12 is cyclohexyl.
[0122] In some embodiments, each R 13 are independently alkyl, cycloalkyl, aryl, or heteroaryl. In some embodiments, each R 13 are independently alkyl or cycloalkyl. In some embodiments, each R 13 are independently alkyl. In some embodiments, each R 13 are independently cycloalkyl. In some embodiments, each R 13 are independently aryl. In some embodiments, each R 13 are independently heteroaryl. In some embodiments, each R 13 are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, each R 13 are independently methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, or cyclohexyl. In some embodiments, each R 13 are independently methyl, cyclopropyl, or cyclohexyl. In some embodiments, each R 13 is methyl. In some embodiments, each R 13 is ethyl. In some embodiments, each R 13 is n-propyl. In some embodiments, each R 13 is isopropyl. In some embodiments, each R 13 is n-butyl. In some embodiments, each R 13 is isobutyl. In some embodiments, each R 13 is sec-butyl. In some embodiments, each R 13 is tert-butyl. In some embodiments, each R 13 is cyclopropyl. In some embodiments, each R 13 is cyclobutyl. In some embodiments, each R 13 is cyclopentyl. In some embodiments, each R 13 is cyclohexyl.
[0123] In some embodiments, R 12 aryl, heteroaryl, heterocycloalkyl, or cycloalkyl is unsubstituted. In some embodiments, R 12 aryl, heteroaryl, heterocycloalkyl, or cycloalkyl contains 1 or 2 R 14 has been replaced with In some embodiments, R 12 aryl, heteroaryl, heterocycloalkyl, or cycloalkyl contains one R 14 has been replaced with In some embodiments, R 12 aryl, heteroaryl, heterocycloalkyl, or cycloalkyl of two R 14 has been replaced with
[0124] In some embodiments, each R 14 are independently aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, halo, heteroalkyl, haloalkyl, cyano, hydroxy, amino, -N(R 15 ) 2 , -S(=O) 2 Alkyl, -S(=O) 2 Aryl, -S(=O) 2 Heteroaryl or alkoxy. In some embodiments, each R 14 are independently alkyl, cycloalkyl, heterocycloalkyl, halo, cyano, -N(R 15 ) 2 , or alkoxy. In some embodiments, each R 14 are independently aryl. In some embodiments, each R 14 are independently heteroaryl. In some embodiments, each R 14 are independently alkyl. In some embodiments, each R 14 are independently cycloalkyl. In some embodiments, each R 14 are independently heterocycloalkyl. In some embodiments, each R 14 is independently a halo. In some embodiments, each R 14 are independently heteroalkyl. In some embodiments, each R 14 are independently haloalkyl. In some embodiments, each R 14 is cyano. In some embodiments, each R 14 is hydroxy. In some embodiments, each R 14 is amino. In some embodiments, each R 14 is independently -N(R 15 ) 2 It is. In some embodiments, each R 14 is independently -S(=O) 2 It is an alkyl. In some embodiments, each R 14 is independently -S(=O) 2 It is an aryl. In some embodiments, each R 14 is independently -S(=O) 2 It is a heteroaryl. In some embodiments, each R 14 are independently alkoxy. In some embodiments, each R 14 are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, fluoro, chloro, cyano, -N(R 15 ) 2 , methoxy, ethoxy, or trifluoromethoxy. In some embodiments, each R 14 are independently methyl, ethyl, isopropyl, tert-butyl, pyrrolidinyl, piperidinyl, morpholinyl, fluoro, chloro, -N(R 15) 2 , or methoxy. In some embodiments, each R 14 is methyl. In some embodiments, each R 14 is ethyl. In some embodiments, each R 14 is n-propyl. In some embodiments, each R 14 is isopropyl. In some embodiments, each R 14 is n-butyl. In some embodiments, each R 14 is isobutyl. In some embodiments, each R 14 is sec-butyl. In some embodiments, each R 14 is tert-butyl. In some embodiments, each R 14 is cyclopropyl. In some embodiments, each R 14 is cyclobutyl. In some embodiments, each R 14 is cyclopentyl. In some embodiments, each R 14 is cyclohexyl. In some embodiments, each R 14 is azetidinyl. In some embodiments, each R 14 is oxetanil. In some embodiments, each R 14 is pyrrolidinyl. In some embodiments, each R 14 is imidazolidinyl. In some embodiments, each R 14 is tetrahydrofuranyl. In some embodiments, each R 14 is piperidinyl. In some embodiments, each R 14 is piperazinyl. In some embodiments, each R 14 is tetrahydropyranyl. In some embodiments, each R 14 is morpholinyl. In some embodiments, each R 14 is fluoro. In some embodiments, each R 14 is chloro. In some embodiments, each R 14 is methoxy. In some embodiments, each R 14 is ethoxy. In some embodiments, each R 14 is trifluoromethoxy.
[0125] In some embodiments, each R 15 are independently alkyl, cycloalkyl, aryl, or heteroaryl. In some embodiments, each R 15 are independently alkyl or cycloalkyl. In some embodiments, each R 15 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, each R 15 is methyl. In some embodiments, each R 15 is ethyl. In some embodiments, each R 15 is n-propyl. In some embodiments, each R 15 is isopropyl. In some embodiments, each R 15 is n-butyl. In some embodiments, each R 15 is isobutyl. In some embodiments, each R 15 is sec-butyl. In some embodiments, each R 15 is tert-butyl. In some embodiments, each R 15 is cyclopropyl. In some embodiments, each R 15 is cyclobutyl. In some embodiments, each R 15 is cyclopentyl. In some embodiments, each R 15 is cyclohexyl.
[0126] In some embodiments, X is -NH- or -O-; n is 0, R 5 is 0 or 1 R 5’ phenyl substituted with R 2 is at least one R 7 and 0, 1, or 2 R 8 phenyl substituted with R 3 is 0, 1, 2, or 3 R 12 pyrazolyl substituted with
[0127] In some embodiments, R 2 is 1 R 7 and 0, 1, or 2 R 8 phenyl substituted with
[0128] In some embodiments, X is -NH-.
[0129] In some embodiments, R 5’ is fluoromethyl, difluoromethyl, or trifluoromethyl.
[0130] In some embodiments, R 7 teeth, [ka] and R 8 is a halo.
[0131] In some embodiments, R 8 is fluoro, Y is -C(=O)-, R 9 and R 9’ is hydrogen, R 10 is hydrogen.
[0132] In some embodiments, R 12 is alkyl.
[0133] In some embodiments, R 12 is methyl.
[0134] In some embodiments, the compound has Formula I-A, Formula I-B, Formula I-C, Formula I-D, Formula I-E, Formula I-F, or Formula I-G: [ka] [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0135] In some embodiments, the compound has formula I-A: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the compound has formula I-A: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0136] In some embodiments, the compound has formula I-B: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments of compounds of formula I-B, R 1 is R 5 It is. In some embodiments of compounds of formula I-B, R 5 is 0 or 1 R 5’で has been replaced. In some embodiments of compounds of formula I-B, R 5 is non-substituted. In some embodiments of compounds of formula I-B, R 5 is 1 R 5’ has been replaced with
[0137] In some embodiments, the compound has formula I-C: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments of compounds of formula I-B, R 1 is R 5 It is. In some embodiments of compounds of formula I-C, R 5 is 0 or 1 R 5’ has been replaced with In some embodiments of compounds of formula I-C, R 5 is non-substituted. In some embodiments of compounds of formula I-C, R 5 is 1 R 5’ has been replaced with
[0138] In some embodiments, the compound has formula I-D: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the compound has formula I-D: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0139] In some embodiments, the compound has formula I-E: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the compound has formula I-E: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0140] In some embodiments, the compound has formula I-F: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the compound has formula I-F: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0141] In some embodiments, the compound has formula I-G: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments of compounds of formula I-G, R 1 is R 5 It is. In some embodiments of compounds of formula I-G, R 5 is 0 or 1 R 5’ has been replaced with In some embodiments of compounds of formula I-G, R 5 is non-substituted. In some embodiments of compounds of formula I-G, R 5 is 1 R 5’ has been replaced with
[0142] In some embodiments, the compound of formula (I) is [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof.
[0143] In another aspect, the disclosure provides a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier.
[0144] Certain embodiments of this disclosure provide compounds of formula I selected from the group consisting of: or stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates thereof , and is a hydrate: N-(3-((5-chloro-2-((1-(4-hydroxycyclohexyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide( Compound 1), N-(3-((5-chloro-2-((6-oxo-1,6-dihydropyridin-3-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 2) , N-(3-((2-(4-amino-2-oxopyridin-1(2H)-yl)-5-chloropyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 3), (E)-N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-4- (dimethylamino)but-2-enamide (compound 4), (E)-N-(3-((5-chloro-2-((1-(4-hydroxycyclohexyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)-4-(dimethylamino)but-2-enamide (compound 5), (E)-N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-4- Methoxybut-2-enamide (compound 6), (E)-N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-4- fluorobuta-2-enamide (compound 7), N-(4-chloro-3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 8), (E)-N-(4-chloro-3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)-4- (dimethylamino)but-2-enamide (compound 9), N-(4-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-3-fluorophenyl)acrylamide (compound 10), (E)-N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)buta-2 -enamide (compound 11), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)methacrylamide (compound 12), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-methoxyphenyl)acrylamide (compound 13), N-(3-((5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)acrylamide (compound 14), N-(3-((5-chloro-2-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide( Compound 15), (E)-N-(3-((5-chloro-2-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)-4-(dimethylamino)but-2-enamide (compound 16), (E)-4-(dimethylamino)-N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((phenylamino)methyl)pyrimidine-4- yl)amino)phenyl)but-2-enamide (compound 17), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((N-phenylacetamido)methyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 18), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((N-(1-phenylethyl)acetamido)methyl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 19), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)(phenyl)amino)-4-fluorophenyl)acrylamide (compound 20 ), N-(3-((5-chloro-2-((5-(methoxymethyl)-1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl) acrylamide (compound 21), N-(3-((5-chloro-2-((6-methoxypyridin-3-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 22), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-2-fluoroacrylamide (compound twenty three), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)cyclohexyl)-2-fluoroacrylamide (compound 24), 1-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)piperidin-1-yl)-2-fluoroprop-2 -en-1-one (compound 25), N-(3-((5-chloro-2-((1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)acrylamide (compound 26), (E)-N-(3-((5-chloro-2-((3-methylisothiazol-5-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-4-(dimethyl amino)but-2-enamide (compound 27), N-(4-((3-acrylamidophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)benzamide (compound 28), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(phenylsulfonamido)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 29), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 30), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 31), N-(3-((5-(benzylamino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 32), (E)-N-(3-((5-(benzylamino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)-4-( dimethylamino)but-2-enamide (compound 33), 4-((3-acrylamidophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)-N-(1-phenylethyl)pyrimidine-5-carboxamide (compound 34), (E)-4-((3-(4-(dimethylamino)but-2-enamido)phenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)-N-( 1-phenylethyl)pyrimidine-5-carboxamide (compound 35), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 36), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 37), N-(4-fluoro-3-((2-((2-fluoropyridin-3-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 38), N-(4-fluoro-3-((2-((2-methoxyphenyl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide trifluoroacetate (compound 39), N-(3-((2-((2-chlorophenyl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide trifluoroacetate ( Compound 40), N-(3-((2-((5-chlorothiophen-3-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide trifluoroacetate (compound 41), N-(4-fluoro-3-((2-((1-methylpiperidin-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide trifluoroacetate (compound 42), N-(3-((2-((2-(dimethylamino)ethyl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamidetri fluoroacetate (compound 43), N-(3-((2-((4-(dimethylamino)phenyl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamidetri fluoroacetate (compound 44), N-(3-((2-((4-((dimethylamino)methyl)phenyl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-4-fluorophenyl ) acrylamide trifluoroacetate (compound 45), N-(4-fluoro-3-((2-(thiophen-3-ylamino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide trifluoroacetate (compound 46), N-(3-((5-(1-(N-benzylacetamido)ethyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 47), N-(3-((5-((N-benzylacetamido)methyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 48), 4-((5-acrylamido-2-fluorophenyl)amino)-N-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)-N-phenylpyrimidine-5-carboxamide (compound 49 ), N-(4-((5-acrylamido-2-fluorophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)benzamide (compound 50), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(phenylsulfonamido)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 51), (E)-4-((3-(4-(dimethylamino)but-2-enamido)phenyl)amino)-2-((2-methoxy-4-(piperidin-1-yl)phenyl)amino)- N-methyl-N-phenylpyrimidine-5-carboxamide (compound 52), (E)-N-(3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine-4- yl)amino)phenyl)-4-(dimethylamino)but-2-enamide (compound 53), (E)-N-(3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl )-4-(dimethylamino)but-2-enamide (compound 54), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(6-morpholinopyridin-3-yl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 55), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(5-(trifluoromethyl)pyridin-3-yl)pyrimidine-4- yl)amino)phenyl)acrylamide (compound 56), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(6-(trifluoromethyl)pyridin-3-yl)pyrimidine-4- yl)amino)phenyl)acrylamide (compound 57), N-(3-((5-(4-acetamidophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide( Compound 58), N-(3-((5-(3-acetamidophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide( Compound 59), 3-(4-((5-acrylamido-2-fluorophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)-N-methylbenzamide (compound 60), N-(3-((5-(4-chlorophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 61), N-(3-((5-(4-cyanophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide( Compound 62), N-(4-fluoro-3-((5-(4-fluorophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide( Compound 63), 4-(4-((5-acrylamido-2-fluorophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)-N-methylbenzamide (compound 64), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(2-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 65), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(6-methylpyridin-3-yl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 66), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(5-methylpyridin-3-yl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 67), N-(4-fluoro-3-((5-(2-methoxypyridin-4-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 68), N-(4-fluoro-3-((5-(5-fluoropyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 69), N-(3-((5-(6-(difluoromethoxy)pyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)- 4-fluorophenyl)acrylamide (compound 70), N-(3-((5-(2-(difluoromethoxy)pyridin-4-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)- 4-fluorophenyl)acrylamide (compound 71), N-(3-((2-((1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine-4- yl)amino)-4-fluorophenyl)acrylamide trifluoroacetate (compound 72), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(6-(trifluoromethyl)pyridin-3-yl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 73), N-(3-((5-(6-fluoropyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide( Compound 74), N-(3-((5-(4-bromophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamidetri fluoroacetate (compound 75), N-(3-((5-(4-(tert-butyl)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)acrylamide trifluoroacetate (compound 76), N-(4-fluoro-3-((5-(1-methyl-1H-indol-5-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl )amino)phenyl)acrylamide trifluoroacetate (compound 77), N-(4-fluoro-3-((2-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine-4 -yl)amino)phenyl)acrylamide (compound 78), N-(4-fluoro-3-((5-(2-methoxypyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 79), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(2-methylpyridin-4-yl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 80), N-(1-(2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)-1H-indole-4- yl) acrylamide (compound 81), N-(4-fluoro-3-((5-(2-fluoropyridin-4-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 82), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(2-(trifluoromethyl)pyridin-4-yl)pyrimidine-4- yl)amino)phenyl)acrylamide (compound 83), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(pyridin-3-yl)pyrimidin-4-yl)amino)phenyl)acrylamide (Compound 84), N-(4-fluoro-3-((2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl )pyrimidin-4-yl)amino)phenyl)acrylamide (compound 85), N-(4-fluoro-3-((5-(6-methoxypyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 86), N-(4-fluoro-3-((2-((3-fluoro-1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine-4- yl)amino)phenyl)acrylamide (compound 87), N-(4-fluoro-3-((5-(3-fluorophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide( Compound 88), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(3-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 89), N-(4-fluoro-3-((5-(2-fluorophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide( Compound 90), N-(4-fluoro-3-((5-(4-methoxyphenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide( Compound 91), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethoxy)phenyl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 92), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-phenylpyrimidin-4-yl)amino)phenyl)acrylamide (compound 93), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-morpholinophenyl)pyrimidin-4-yl)amino)phenyl)acrylamide( Compound 94), N-(3-((5-(5-(difluoromethoxy)pyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)- 4-fluorophenyl)acrylamide (compound 95), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(3-(trifluoromethoxy)phenyl)pyrimidin-4-yl)amino) phenyl)acrylamide trifluoroacetate (compound 96), N-(3-((5-(1H-indol-5-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) acrylamide (compound 97), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(1H-pyrazol-4-yl)pyrimidin-4-yl)amino)phenyl ) acrylamide (compound 98), N-(3-((5-(4-(difluoromethyl)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) acrylamide (compound 99), N-(4-fluoro-3-((5-(6-fluoropyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 100), N-(3-((5-(6-chloropyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)acrylamide (compound 101), N-(3-((5-(5-chloropyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)acrylamide (compound 102), N-(3-((5-(4-(dimethylamino)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) acrylamide (compound 103), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(5-(trifluoromethyl)pyridin-3-yl)pyrimidin-4-yl)oxy) phenyl)acrylamide (compound 104), N-(3-((5-(4-(difluoromethyl)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)phenyl)acrylamide (compound 105), N-(3-((5-(6-(difluoromethyl)pyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)- 4-fluorophenyl)acrylamide (compound 106), N-(3-((5-(6-(dimethylamino)pyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)- 4-fluorophenyl)acrylamide (compound 107), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(6-(trifluoromethyl)pyridin-3-yl)pyrimidin-4-yl)oxy) phenyl)acrylamide (compound 108), N-(3-((5-(6-fluoropyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)phenyl)acrylamide( Compound 109), N-(3-((5-(5-(difluoromethyl)pyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)- 4-fluorophenyl)acrylamide (compound 110), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide( Compound 111), N-(3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) -4-fluorophenyl)acrylamide trifluoroacetate (compound 112), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-3-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)acrylamide trifluoroacetate (compound 113), N-(4-fluoro-3-((5-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-((1-methyl-1H-pyrazol-4-yl) amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 114), N-(3-((5-(3-fluorophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide trifluoroacetate ( Compound 115), N-(3-((5-(5-(dimethylamino)pyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)- 4-fluorophenyl)acrylamide trifluoroacetate (compound 116), N-(3-((5-(2-chloropyridin-4-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)acrylamide (compound 117), N-(3-((5-(6-methoxypyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamidetri fluoroacetate (compound 118), N-(4-(dimethylamino)-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl )amino)phenyl)acrylamide trifluoroacetate (compound 119), N-(3-((5-cyclopropyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide trifluoroacetate ( compound 120), N-(4-fluoro-3-((2-(phenylamino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 121), N-(4-fluoro-3-((2-((4-fluorophenyl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide trifluoroacetate (compound 122), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-2'-(trifluoromethyl)-[5,5'-bipyrimidine]-4- yl)amino)phenyl)acrylamide (compound 123), N-(3-((5-(3,6-dihydro-2H-pyran-4-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino )-4-fluorophenyl)acrylamide (compound 124), N-(3-((5-(3-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidine- 4-yl)amino)-4-fluorophenyl)acrylamide (compound 125), N-(4-fluoro-3-((5-(4-isopropylphenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamidetri fluoroacetate (compound 126), N-(3-((5-([1,1'-biphenyl]-4-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) -4-fluorophenyl)acrylamide (compound 127), N-(3-((5-(4-cyclopropylphenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide trifluoroacetate (compound 128), N-(3-((5-(2-chlorophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide trifluoro acetate (compound 129), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(2,2,2-trifluoroethyl)phenyl)pyrimidine- 4-yl)amino)phenyl)acrylamide trifluoroacetate (compound 130), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(quinolin-7-yl)pyrimidin-4-yl)amino)phenyl)acrylamide (Compound 131), N-(4-fluoro-3-((5-(imidazo[1,2-a]pyridin-7-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidine-4 -yl)amino)phenyl)acrylamide (compound 132), N-(4-fluoro-3-((5-(imidazo[1,2-a]pyridin-6-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidine-4 -yl)amino)phenyl)acrylamide trifluoroacetate (compound 133), N-(3-((5-(3-((dimethylamino)methyl)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4 -fluorophenyl)acrylamide (compound 134), N-(3-((2-((1,3-dimethyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-4 -fluorophenyl)acrylamide trifluoroacetate (compound 135), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(naphthalen-1-yl)pyrimidin-4-yl)amino)phenyl)acrylamide trifluoroacetate (compound 136), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(pyridin-4-yl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 137), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-sulfamoylphenyl)pyrimidin-4-yl)amino)phenyl) acrylamide (compound 138), N-(4-fluoro-3-((2-((1-(oxetan-3-yl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine- 4-yl)amino)phenyl)acrylamide (compound 139), N-(3-((5-(4-(difluoromethoxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) acrylamide (compound 140), N-(4-fluoro-3-((5-(5-methoxypyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 141), N-(3-((5-(4-(difluoromethoxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide trifluoro acetate (compound 142), N-(3-((5-(3-(difluoromethoxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) acrylamide trifluoroacetate (compound 143), N-(3-((5-(5-(difluoromethyl)pyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl ) acrylamide trifluoroacetate (compound 144), N-(3-((5-(3-(dimethylamino)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) acrylamide (compound 145), N-(4-fluoro-3-((2-((1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl) pyrimidin-4-yl)amino)phenyl)acrylamide trifluoroacetate (compound 146), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-[5,5'-bipyrimidin]-4-yl)amino)phenyl)acrylamide trifluoro acetate (compound 147), N-(2-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)acrylamide trifluoroacetate (compound 148), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(naphthalen-2-yl)pyrimidin-4-yl)amino)phenyl)acrylamide trifluoroacetate (compound 149), N-(3-((5-(2-chlorophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide 2, 2,2-trifluoroacetate (compound 150), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide( Compound 151), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)oxy) phenyl)acrylamide (compound 152), N-(3-((3-chloro-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)amino)-4-fluorophenyl)acrylamide (compound 153), N-(3-((3-chloro-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)oxy)phenyl)acrylamide (compound 154), N-(3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)amino)-4-fluorophenyl) acrylamide (compound 155), N-(3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)amino)phenyl)acrylamide (compound 156 ), N-(3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)oxy)phenyl)acrylamide (compound 157 ), N-(3-((3-methyl-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)oxy)phenyl)acrylamide (compound 158), N-(3-(5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-4-fluorophenyl)acrylamide (compound 159), (E)-N-(3-(5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-4-fluorophenyl)-4-(dimethylamino ) but-2-enamide (compound 160), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(phenylethynyl)pyrimidin-4-yl)amino)phenyl)acrylamide (Compound 161 ), (E)-4-(dimethylamino)-N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(phenylethynyl)pyrimidine-4 -yl)amino)phenyl)but-2-enamide (compound 162), 4-acrylamido-2-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-N-phenylbenzamide (compound 163), 4-acrylamido-2-((2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-N-phenylbenzamide (compound 164), N-(4-chloro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 165), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)-4-fluorophenyl)acrylamide (compound 166), N-(3-((5-chloro-2-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)-4-fluorophenyl)acrylamide( Compound 167), N-(3-((5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)-4-fluoro phenyl)acrylamide (compound 168), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)-4-(trifluoromethyl)phenyl)acrylamide (compound 169), N-(3-((5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)-4-methoxy phenyl)acrylamide (compound 170), N-(3-((5-chloro-2-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)-4-methoxyphenyl)acrylamide( Compound 171), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)-4-methoxyphenyl)acrylamide (compound 172), N-(2-(((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)methyl)-3-fluorophenyl)acrylamide (Compound 173 ), (E)-N-(2-(((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)methyl)-3-fluorophenyl) -4-(dimethylamino)but-2-enamide (compound 174), N-(2-((2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-[1,1'-biphenyl]-4-yl)acrylamide (compound 175), (E)-4-(dimethylamino)-N-(2-((2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-[1,1' -biphenyl]-4-yl)but-2-enamide (compound 176), N-(2-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-[1,1'-biphenyl]-4-yl ) acrylamide (compound 177), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-(phenylethynyl)phenyl)acrylamide (Compound 178 ), (E)-N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-(phenylethynyl)phenyl) -4-(dimethylamino)but-2-enamide (compound 179), N-(3-((2-(cyclopropylamino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 180), N-(3-((2-(cyclobutylamino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 181), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyridin-4-yl)oxy)phenyl)acrylamide( Compound 182), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(5-methylpyridin-3-yl)pyrimidin-4-yl)oxy)phenyl)acrylamide( Compound 183), N-(3-((5-(5-fluoropyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)phenyl)acrylamide( Compound 184), N-(3-((5-(6-chloropyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)phenyl)acrylamide( Compound 185), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(6-methylpyridin-3-yl)pyrimidin-4-yl)oxy)phenyl)acrylamide( Compound 186), N-(3-((5-(6-(difluoromethyl)pyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)phenyl ) acrylamide (compound 187), N-(3-((5-(6-(difluoromethoxy)pyridin-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy)phenyl ) acrylamide (compound 188), N-(3-((2-((2-chlorophenyl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide (compound 189), N-(3-((5-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidine- 4-yl)oxy)phenyl)acrylamide (compound 190), N-(3-((2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl) oxy)phenyl)acrylamide (compound 191), N-(3-((5-(3,6-dihydro-2H-pyran-4-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)oxy ) phenyl) acrylamide (compound 192), N-(3-((2-((2-methoxyphenyl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide (compound 193), N-(3-((2-(cyclopropylamino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide (compound 194), N-(5-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)pyridine-3- yl) acrylamide (compound 195), N-(2-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)pyridine-4- yl) acrylamide (compound 196), N-(6-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)pyridine-2- yl) acrylamide (compound 197), N-(5-fluoro-4-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) pyridin-2-yl)acrylamide (compound 198), N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-( trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 199), N-(4-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)pyridine-2- yl) acrylamide (compound 200), N-(3-((5-(3-bromophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide( compound 201), N-(3-((5-(4-bromophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-2-fluorophenyl)acrylamide( compound 202), N-(3-((5-(4-bromophenyl)-2-((1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) -4-fluorophenyl)acrylamide (compound 203), N-(3-((5-(4-bromophenyl)-2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)acrylamide (compound 204), N-(3-((5-(4-bromophenyl)-2-((1-(oxetan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4 -fluorophenyl)acrylamide (compound 205), N-(3-((5-(4-bromophenyl)-2-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4- fluorophenyl)acrylamide (compound 206), N-(3-((5-(4-bromophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-5-fluorophenyl)acrylamide( compound 207), N-(3-((5-(4-bromophenyl)-2-((3-chloro-1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)amino)pyrimidine-4- yl)amino)-4-fluorophenyl)acrylamide (compound 208), N-(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-7-(trifluoromethyl)-9H-pyrimido[4,5-b]indol-9-yl)phenyl ) acrylamide (compound 209), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyridin-4-yl)amino) phenyl)acrylamide (compound 210), N-(4-fluoro-3-((2-((3-methylisothiazol-5-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl) acrylamide (compound 211), N-(4-fluoro-3-((2-((5-methylisothiazol-3-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl) acrylamide (compound 212), N-(4-fluoro-3-((2-((4-methylthiazol-2-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide (Compound 213), N-(4-fluoro-3-((2-((1-methyl-1H-imidazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 214), N-(4-fluoro-3-((2-(thiazol-2-ylamino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 215), N-(3-((2-((1-(3-(dimethylamino)propyl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine-4- yl)amino)-4-fluorophenyl)acrylamide (compound 216), N-(4-fluoro-3-((2-((5-methylthiophen-3-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 217), N-(3-((2-((3-((dimethylamino)methyl)phenyl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-4-fluorophenyl ) acrylamide (compound 218), N-(4-fluoro-3-((2-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine-4 -yl)amino)phenyl)acrylamide (compound 219), N-(4-fluoro-3-((2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl) phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 220), N-(3-((2-((3-chloro-1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl) pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 221), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-morpholinopyrimidin-4-yl)amino)phenyl)acrylamide (compound 222), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-methylpiperazin-1-yl)pyrimidin-4-yl)oxy)phenyl)acrylamide( Compound 223), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-6-(methylamino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl )amino)phenyl)acrylamide (compound 224), N-(4-fluoro-3-((2-(isoxazol-4-ylamino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 225), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(1-methyl-2,5-dihydro-1H-pyrrol-3-yl )pyrimidin-4-yl)amino)phenyl)acrylamide (compound 226), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(1-methylpyrrolidin-3-yl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 227), N-(4-fluoro-3-(methyl(2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino ) phenyl) acrylamide (compound 228), N-(3-(methyl(2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide (Compound 229), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(thiazol-5-yl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 230), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-6-(trifluoromethyl)quinazolin-4-yl)amino)phenyl)acrylamide (compound 231), N-(4-fluoro-3-((2-(pyridin-3-ylamino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 232), N-(3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)oxy) phenyl)acrylamide (compound 233), N-(3-((2-((4-((dimethylamino)methyl)phenyl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide (compound 234), N-(3-((2-((1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine-4- yl)oxy)phenyl)acrylamide (compound 235), N-(3-((2-((2-(dimethylamino)ethyl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)oxy)phenyl)acrylamide (compound 236), N-(3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(3,6-dihydro-2H-pyran-4-yl)pyrimidine-4 -yl)amino)-4-fluorophenyl)acrylamide (compound 237), N-(2-fluoro-5-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 238), N-(3-fluoro-5-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 239), N-(4-fluoro-3-((2-((1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl )pyrimidin-4-yl)amino)phenyl)acrylamide (compound 240), N-(3-((2-((3-chloro-1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine-4 -yl)amino)-4-fluorophenyl)acrylamide (compound 241), N-(4-fluoro-3-((2-((1-(methyl-d 3 )-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 242), N-(4-fluoro-3-((2-((1-(methyl- 13 C-d 3 )-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 243), N-(3-((5-(cyclopropylethynyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 244), N-(3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) -5-fluorophenyl)acrylamide (compound 245), N-(3-((2-((1-(2-cyanopropan-2-yl)-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine-4 -yl)amino)-4-fluorophenyl)acrylamide (compound 246), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)acrylamide-3,3-d 2 (Compound 247), N-(4-fluoro-3-((2-((1-(methyl-d 3 )-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)acrylamide-3,3-d 2 (compound 248), N-(3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) -4-fluorophenyl)acrylamide-3,3-d 2 (compound 249), N-(3-((5-(4-bromophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide- 3,3-d 2 (compound 250), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)but-2,3-dienamide (compound 251), 2-chloro-N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine-4- yl)amino)phenyl)acetamide (compound 252), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)ethenesulfonamide (compound 253), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)propiolamide (compound 254), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-yl)amino ) phenyl) acrylamide (compound 255), N-(3-((5-bromo-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 256), N 4 -(5-amino-2-fluorophenyl)-N 2 -(1-methyl-1H-pyrazol-4-yl)-5-(4-(trifluoromethyl)phenyl)pyrimidine-2,4-diamine (compound 257), N-(4-fluoro-3-((5-(2-isopropylphenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide( compound 258), N-(4-fluoro-3-((5-(2-methoxyphenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide( Compound 259), N-(4-fluoro-3-((5-(1-methyl-1H-indol-4-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl )amino)phenyl)acrylamide (compound 260), N-(3-((5-(2,5-dihydrofuran-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4 -fluorophenyl)acrylamide (compound 261), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(quinolin-5-yl)pyrimidin-4-yl)amino)phenyl)acrylamide (Compound 262), N-(3-((5-([1,1'-biphenyl]-2-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) -4-fluorophenyl)acrylamide (compound 263), N-(3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(2-fluorophenyl)pyrimidin-4-yl)amino)-4-fluoro phenyl)acrylamide (compound 264), N-(3-((5-(1H-indol-7-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) acrylamide (compound 265), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(tetrahydrofuran-3-yl)pyrimidin-4-yl)amino)phenyl)acrylamide (Compound 266), N-(3-((5-(2-(dimethylamino)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) acrylamide (compound 267), N-(4-fluoro-3-((5-(isoquinolin-8-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 268), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(piperidin-1-yl)pyrimidin-4-yl)amino)phenyl)acrylamide (Compound 269), N-(4-fluoro-3-((5-(1-methyl-1H-indazol-5-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl )amino)phenyl)acrylamide (compound 270), N-(3-((5-bromo-2-((1-(2-cyanopropan-2-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)acrylamide (compound 271), N-(3-((2-((1-(2-cyanopropan-2-yl)-1H-pyrazol-4-yl)amino)-5-(2,5-dihydrofuran-3-yl)pyrimidine -4-yl)amino)-4-fluorophenyl)acrylamide (compound 272), N-(3-((5-bromo-2-((1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)acrylamide (compound 273), N-(3-((5-(4-bromophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 274), N-(3-((5-chloro-4-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 275), N-(4-fluoro-3-((5-(4-((3-fluorobenzyl)oxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidine-4- yl)amino)phenyl)acrylamide (compound 276), N-(3-((5-(1H-indazol-5-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) acrylamide (compound 277), N-(3-((5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino) pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 278), N-(3-((5-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino) pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 279), N-(3-((5-fluoro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 280), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(phenyl-4-d)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 281), N-(3-bromo-5-((5-(4-(difluoromethoxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl ) acrylamide (compound 282), N-(3-bromo-5-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 283), N-(3-((5-chloro-2-((1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) acrylamide (compound 284), N-(4-fluoro-3-((5-fluoro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 285), N-(3-((5-chloro-2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 286), N-(3-((5-chloro-2-((4-((dimethylamino)methyl)phenyl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 287), N-(3-((5-chloro-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl) acrylamide (compound 288), N-(3-((5-(4-bromophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-5-(trifluoromethyl) phenyl)acrylamide (compound 289), N-(3-bromo-5-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 290), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-5-(trifluoromethyl)phenyl)acrylamide (compound 291), N-(3-((5-(4-bromophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-chlorophenyl)acrylamide (compound 292), N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(2,2,2-trifluoroethyl)phenyl)pyrimidin-4-yl) amino)phenyl)acrylamide (compound 293), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(1-(trifluoromethyl)cyclopropyl)phenyl)pyrimidine- 4-yl)amino)phenyl)acrylamide (compound 294), N-(3-Fluoro-5-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(2,2,2-trifluoroethyl)phenyl)pyrimidine- 4-yl)amino)phenyl)acrylamide (compound 295), N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(perfluoroethyl)phenyl)pyrimidin-4-yl)amino)phenyl ) acrylamide (compound 296), N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)naphthalen-1-yl)acrylamide (compound 297), N-(3-((5-(5-chlorothiophen-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)acrylamide (compound 298), N-(3-((5-(benzofuran-6-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 299), N-(4-fluoro-3-((5-(4-(3fluorophenoxy)phenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) phenyl)acrylamide (compound 300), (E)-4-(dimethylamino)-N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(2,2 ,2-trifluoroethyl)phenyl)pyrimidin-4-yl)amino)phenyl)but-2-enamide (compound 301), N-(3-bromo-5-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(2,2,2-trifluoroethyl)phenyl)pyrimidine- 4-yl)amino)phenyl)acrylamide (compound 302), (E)-4-Fluoro-N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(2,2,2- trifluoroethyl)phenyl)pyrimidin-4-yl)amino)phenyl)but-2-enamide (compound 303), (E)-N-(3-((5-(4-bromophenyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluoro phenyl)-4-(dimethylamino)but-2-enamide (compound 304), and N-(4-fluoro-3-((5-(3-fluoro-5-methoxyphenyl)-2-(methyl(1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino ) phenyl) acrylamide (compound 305).
[0145] Embodiments of the present disclosure provide compounds of formula I, or stereoisomers, tautomers thereof, pharmaceutically acceptable Regarding salts, stereoisomers, solvates, and hydrates.
[0146] Another embodiment of the present disclosure provides compounds of formula I, or stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates thereof, for treating cancer. and regarding hydrates.
[0147] Another embodiment of the disclosure provides a compound of formula I, or a stereoisomer thereof, for treating a disease or condition associated with non-small cell lung cancer or small cell lung cancer or prostate cancer or head and neck cancer or breast cancer or colorectal cancer. tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof.
[0148] The present disclosure relates to a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, together with a pharmaceutically acceptable carrier, and one or more other pharmaceutical compositions. The present invention relates to such pharmaceutical compositions, optionally combined.
[0149] The present disclosure further relates to processes for preparing compounds of Formula I, or stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof.
[0150] In another aspect, the present disclosure provides: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0151] Purpose Some embodiments provided herein describe classes of compounds that are useful as epidermal growth factor receptor (EGFR) family kinase inhibitors. Some embodiments provided herein describe classes of compounds that are useful as EGFR inhibitors. Some embodiments provided herein describe classes of compounds that are useful as del19 / T790M EGFR inhibitors. Some embodiments provided herein describe classes of compounds that are useful as L858R / T790M EGFR inhibitors. In some embodiments, the compounds described herein have improved potency and / or beneficial activity profiles and / or beneficial selectivity profiles and / or increased efficacy and / or improved safety. have a sexual profile (eg, reduced side effects) and / or improved pharmacokinetic properties. In some embodiments, the compounds described herein are selective inhibitors of del19 / T790M EGFR over WT EGFR. In some embodiments, the compounds described herein are selective inhibitors of L858R / T790M EGFR over WT EGFR.
[0152] In some embodiments, the compounds described herein are selective inhibitors of EGFR over HER2.
[0153] In some embodiments, the compounds described herein have an improved safety profile. In some embodiments, the compounds described herein have an improved toxicity profile. In some embodiments, the compounds described herein have an improved therapeutic index.
[0154] In some embodiments, the compounds described herein are useful for treating, preventing, or ameliorating a disease or condition exhibiting drug resistance associated with del19 / T790M EGFR activation. be. In some embodiments, the compounds described herein are useful for treating, preventing, or ameliorating a disease or condition exhibiting drug resistance associated with L858R / T790M EGFR activation. be.
[0155] In some embodiments, EGFR family kinase variants are detected using commercially available test kits. In some embodiments, EGFR family kinase variants are detected by reverse transcription polymerase chain reaction (RT-PCR) based methods. In some embodiments, EGFR family kinase variants are detected by sequencing-based methods. In some embodiments, EGFR family kinase variants are detected by mass spectrometry genotyping-based methods. In some embodiments, EGFR family kinase variants are detected by immunohistochemistry-based methods. In some embodiments, EGFR family kinase variants are detected by a molecular diagnostic panel. In some embodiments, the EGFR family kinase variant is detected from the tumor sample. In some embodiments, EGFR family kinase variants are detected from circulating DNA. In some embodiments, EGFR family kinase variants are detected from tumor cells.
[0156] In one aspect, a method of inhibiting an epidermal growth factor receptor (EGFR) family kinase variant in a subject in need of inhibiting an epidermal growth factor receptor (EGFR) family kinase variant, the method comprising: Provided herein is a method comprising administering to the subject a compound of I, or a pharmaceutically acceptable salt or stereoisomer thereof.
[0157] In another aspect, a method of inhibiting a human epidermal growth factor receptor 2 (HER2) variant in a subject in need of inhibiting a human epidermal growth factor receptor 2 (HER2) variant, the method comprising: Provided herein are methods comprising administering to the subject a compound of Formula I, or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the HER2 variant comprises an insertion in exon 20, an in-frame deletion and insertion in exon 20, a substitution in the extracellular domain, an extracellular truncation, or a substitution in exon 30. In some embodiments, the HER2 variant is A775_G776insYVMA, A775_G776insSVMA, A775_G776insVVMA, G776del insVC, G776del insLC, G776del insAV, G776del insAVGC, S310F, S310Y, p95, V842I, P780_Y781 insGSP, and any combination thereof. . In some embodiments, the HER2 variant is A775_G776insYVMA. In some embodiments, the HER2 variant is A775_G776insSVMA. In some embodiments, the HER2 variant is A775_G776insVVMA. In some embodiments, the HER2 variant is G776del insVC. In some embodiments, the HER2 variant is G776del insLC. In some embodiments, the HER2 variant is G776del insAV. In some embodiments, the HER2 variant is G776del insAVGC. In some embodiments, the HER2 variant is S310F. In some embodiments, the HER2 variant is S310Y. In some embodiments, the HER2 variant is p95. In some embodiments, the HER2 variant is V842I. In some embodiments, the HER2 variant is P780_Y781insGSP.
[0158] In another embodiment, a method of inhibiting an epidermal growth factor receptor (EGFR) variant in a subject in need of inhibiting an epidermal growth factor receptor (EGFR) variant, the method comprising: a therapeutically effective amount of a compound of formula I; or a pharmaceutically acceptable salt or stereoisomer thereof to the subject.
[0159] In another aspect, a method of inhibiting a drug-resistant epidermal growth factor receptor (EGFR) variant in a subject in need of inhibiting the drug-resistant epidermal growth factor receptor (EGFR) variant, the method comprising: Provided herein are methods comprising administering to the subject an amount of a compound of Formula I, or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the drug-resistant EGFR variant is del19 / T790M EGFR or L858R / T790M EGFR.
[0160] In another embodiment, a method of inhibiting human epidermal growth factor receptor 2 (HER2) in a subject in need of inhibiting human epidermal growth factor receptor 2 (HER2), the method comprising: a therapeutically effective amount of a compound of formula I; or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound exhibits stronger inhibition of the HER2 variant compared to wild-type EGFR. Provided in In some embodiments, the HER2 variant comprises an insertion in exon 20, an in-frame deletion and insertion in exon 20, a substitution in the extracellular domain, an extracellular truncation, or a substitution in exon 30. In some embodiments, the HER2 variant is A775_G776insYVMA, A775_G776insSVMA, A775_G776insVVMA, G776del insVC, G776del insLC, G776del insAV, G776del insAVGC, S310F, S310Y, p95, V842I, P780_Y781 insGSP, and any combination thereof. . In some embodiments, the HER2 variant is A775_G776insYVMA. In some embodiments, the HER2 variant is A775_G776insSVMA. In some embodiments, the HER2 variant is A775_G776insVVMA. In some embodiments, the HER2 variant is G776del insVC. In some embodiments, the HER2 variant is G776del insLC. In some embodiments, the HER2 variant is G776del insAV. In some embodiments, the HER2 variant is G776del insAVGC. In some embodiments, the HER2 variant is S310F. In some embodiments, the HER2 variant is S310Y. In some embodiments, the HER2 variant is p95. In some embodiments, the HER2 variant is V842I. In some embodiments, the HER2 variant is P780_Y781insGSP.
[0161] In another embodiment, a method of inhibiting epidermal growth factor receptor (EGFR) in a subject in need of inhibiting epidermal growth factor receptor (EGFR), comprising: a therapeutically effective amount of a compound of Formula I or a pharmaceutically thereof; provided herein is a method comprising administering to the subject a salt or stereoisomer that is acceptable for .
[0162] In some embodiments, the EGFR variant comprises a substitution in exon 18, a deletion in exon 19, a substitution in exon 20, an insertion in exon 20, a mutation in the extracellular domain, or a substitution in exon 21. In some embodiments, the EGFR variant is del19 / T790M EGFR, L858R / T790M EGFR, L858R EGFR, L861Q EGFR, G719X EGFR, 763insFQEA EGFR, 767insTLA EGFR, 769insASV EGFR, 769insGE EGFR, 770insSVD EGFR (or D77 0_N771insSVD EGFR) , 770insNPG EGFR (or D770_N771insNPG EGFR), 770insGT EGFR, 770insGF EGFR, 770insG EGFR, 771insH EGFR, 771insN EGFR, 772insNP EGFR, 773insNPH EGFR (or H773insNPH EGFR), 773insH EGFR, 773insPH EGFR, EGFRvii, EGFRviii, A767_dupASV EGFR, 773insAH EGFR , M766_A767insAI EGFR, and any combination thereof. In some embodiments, the EGFR variant is del19 / T790M EGFR or L858R / T790M EGFR. In some embodiments, the EGFR variant is del19 / T790M EGFR. In some embodiments, the EGFR variant is L858R / T790M EGFR.
[0163] In another aspect, a method of treating a disease or disorder associated with epidermal growth factor receptor (EGFR) in a subject in need of treatment, comprising: treating a disease or disorder associated with epidermal growth factor receptor (EGFR); Provided herein are methods comprising administering to the subject an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or stereoisomer thereof.
[0164] In some embodiments, the disease or disorder in the subject comprises a HER2 mutation. In some embodiments, the HER2 mutation comprises an insertion in exon 20, an in-frame deletion and insertion in exon 20, a substitution in the extracellular domain, an extracellular truncation, or a substitution in exon 30. In some embodiments, the HER2 mutation is A775_G776insYVMA, A775_G776insSVMA, A775_G776insVVMA, G776del insVC, G776del insLC, G776del insAV, G776del insAVGC, S310F, S310Y, p95, V842I, P780_Y781ins GSP, and combinations thereof. In some embodiments, the HER2 mutation is A775_G776insYVMA. In some embodiments, the HER2 mutation is A775_G776insSVMA. In some embodiments, the HER2 mutation is A775_G776insVVMA. In some embodiments, the HER2 mutation is G776del insVC. In some embodiments, the HER2 mutation is G776del insLC. In some embodiments, the HER2 mutation is G776del insAV. In some embodiments, the HER2 mutation is G776del insAVGC. In some embodiments, the HER2 mutation is S310F. In some embodiments, the HER2 mutation is S310Y. In some embodiments, the HER2 mutation is p95. In some embodiments, the HER2 mutation is V842I. In some embodiments, the HER2 mutation is P780_Y781insGSP.
[0165] In some embodiments, the disease or disorder in the subject comprises an EGFR mutation. In some embodiments, the EGFR mutation comprises a substitution in exon 18, a deletion in exon 19, a substitution in exon 20, an insertion in exon 20, a mutation in the extracellular domain, or a substitution in exon 21. In some embodiments, the EGFR mutation is del19 / T790M EGFR, L858R / T790M EGFR, L858R EGFR, L861Q EGFR, G719X EGFR, 763insFQEA EGFR, 767insTLA EGFR, 769insASV EGFR, 769insGE EGFR, 770insSVD EGFR (or D770 _N771insSVD EGFR), 770insNPG EGFR (or D770_N771insNPG EGFR), 770insGT EGFR, 770insGF EGFR, 770insG EGFR, 771insH EGFR, 771insN EGFR, 772insNP EGFR, 773insNPH EGFR (or H773insNPH EGFR), 773insH EGFR, 773insPH EG FR, EGFRvii, EGFRviii, A767_dupASV EGFR, 773insAH EGFR, M766_A767insAI EGFR, and any combination thereof. In some embodiments, the EGFR mutation is del19 / T790M EGFR or L858R / T790M EGFR. In some embodiments, the EGFR mutation is del19 / T790M EGFR. In some embodiments, the EGFR mutation is L858R / T790M EGFR.
[0166] In another embodiment, a method of treating cancer in a subject in need of treatment, comprising: administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, to said subject. Provided herein are such methods comprising administering to a patient. In some embodiments, the cancer exhibits drug resistance associated with del19 / T790M EGFR activation. In some embodiments, the cancer exhibits drug resistance associated with L858R / T790M EGFR activation. Other embodiments provided herein describe the use of the compounds described herein to treat cancer.
[0167] In some embodiments, the cancer is bladder cancer, prostate cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, glioblastoma, head and neck cancer, lung cancer, or non-small cell lung cancer. It is. In some embodiments, the cancer is non-small cell lung cancer, prostate cancer, head and neck cancer, breast cancer, colorectal cancer, or glioblastoma. In some embodiments, the cancer is non-small cell lung cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is head and neck cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is colorectal cancer. In some embodiments, the cancer is glioblastoma.
[0168] In some embodiments, the cancer in the subject comprises a HER2 mutation. In some embodiments, the HER2 mutation comprises an insertion in exon 20, an in-frame deletion and insertion in exon 20, a substitution in the extracellular domain, an extracellular truncation, or a substitution in exon 30. In some embodiments, the HER2 mutation is A775_G776insYVMA, A775_G776insSVMA, A775_G776insVVMA, G776del insVC, G776del insLC, G776del insAV, G776del insAVGC, S310F, S310Y, p95, V842I, P780_Y781ins GSP, and combinations thereof. In some embodiments, the HER2 mutation is A775_G776insYVMA. In some embodiments, the HER2 mutation is A775_G776insSVMA. In some embodiments, the HER2 mutation is A775_G776insVVMA. In some embodiments, the HER2 mutation is G776del insVC. In some embodiments, the HER2 mutation is G776del insLC. In some embodiments, the HER2 mutation is G776del insAV. In some embodiments, the HER2 mutation is G776del insAVGC. In some embodiments, the HER2 mutation is S310F. In some embodiments, the HER2 mutation is S310Y. In some embodiments, the HER2 mutation is p95. In some embodiments, the HER2 mutation is V842I. In some embodiments, the HER2 mutation is P780_Y781insGSP.
[0169] In some embodiments, the cancer in the subject comprises an EGFR mutation. In some embodiments, the EGFR mutation comprises a substitution in exon 18, a deletion in exon 19, a substitution in exon 20, an insertion in exon 20, a mutation in the extracellular domain, or a substitution in exon 21. In some embodiments, the EGFR mutation is del19 / T790M EGFR, L858R / T790M EGFR, L858R EGFR, L861Q EGFR, G719X EGFR, 763insFQEA EGFR, 767insTLA EGFR, 769insASV EGFR, 769insGE EGFR, 770insSVD EGFR (or D770 _N771insSVD EGFR), 770insNPG EGFR (or D770_N771insNPG EGFR), 770insGT EGFR, 770insGF EGFR, 770insG EGFR, 771insH EGFR, 771insN EGFR, 772insNP EGFR, 773insNPH EGFR (or H773insNPH EGFR), 773insH EGFR, 773insPH EG FR, EGFRvii, EGFRviii, A767_dupASV EGFR, 773insAH EGFR, M766_A767insAI EGFR, and any combination thereof. In some embodiments, the EGFR mutation is del19 / T790M EGFR or L858R / T790M EGFR. In some embodiments, the EGFR mutation is del19 / T790M EGFR. In some embodiments, the EGFR mutation is L858R / T790M EGFR.
[0170] In another embodiment, a method of treating an inflammatory disease in a subject in need thereof, comprising: administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or stereoisomer thereof. Provided herein are such methods comprising administering to the subject. Also described herein is the use of the compounds described herein to treat inflammatory diseases associated with del19 / T790M EGFR activation. Also described herein is the use of the compounds described herein to treat inflammatory diseases associated with L858R / T790M EGFR activation.
[0171] In some embodiments, the inflammatory disease is psoriasis, eczema, or atherosclerosis. In some embodiments, the inflammatory disease is psoriasis. In some embodiments, the inflammatory disease is eczema. In some embodiments, the inflammatory disease is atherosclerosis.
[0172] In some embodiments, the inflammatory disease in the subject comprises a HER2 mutation. In some embodiments, the HER2 mutation comprises an insertion in exon 20, an in-frame deletion and insertion in exon 20, a substitution in the extracellular domain, an extracellular truncation, or a substitution in exon 30. In some embodiments, the HER2 mutation is A775_G776insYVMA, A775_G776insSVMA, A775_G776insVVMA, G776del insVC, G776del insLC, G776del insAV, G776del insAVGC, S310F, S310Y, p95, V842I, P780_Y781ins GSP, and any combination thereof. In some embodiments, the HER2 mutation is A775_G776insYVMA. In some embodiments, the HER2 mutation is A775_G776insSVMA. In some embodiments, the HER2 mutation is A775_G776insVVMA. In some embodiments, the HER2 mutation is G776del insVC. In some embodiments, the HER2 mutation is G776del insLC. In some embodiments, the HER2 mutation is G776del insAV. In some embodiments, the HER2 mutation is G776del insAVGC. In some embodiments, the HER2 mutation is S310F. In some embodiments, the HER2 mutation is S310Y. In some embodiments, the HER2 mutation is p95. In some embodiments, the HER2 mutation is V842I. In some embodiments, the HER2 mutation is P780_Y781insGSP.
[0173] In some embodiments, the inflammatory disease in the subject comprises an EGFR mutation. In some embodiments, the EGFR mutation comprises a substitution in exon 18, a deletion in exon 19, a substitution in exon 20, an insertion in exon 20, a mutation in the extracellular domain, or a substitution in exon 21. In some embodiments, the EGFR mutation is del19 / T790M EGFR, L858R / T790M EGFR, L858R EGFR, L861Q EGFR, G719X EGFR, 763insFQEA EGFR, 767insTLA EGFR, 769insASV EGFR, 769insGE EGFR, 770insSVD EGFR (or D770 _N771insSVD EGFR), 770insNPG EGFR (or D770_N771insNPG EGFR), 770insGT EGFR, 770insGF EGFR, 770insG EGFR, 771insH EGFR, 771insN EGFR, 772insNP EGFR, 773insNPH EGFR (or H773insNPH EGFR), 773insH EGFR, 773insPH EG FR, EGFRvii, EGFRviii, A767_dupASV EGFR, 773insAH EGFR, M766_A767insAI EGFR, and any combination thereof. In some embodiments, the EGFR mutation is del19 / T790M EGFR or L858R / T790M EGFR. In some embodiments, the EGFR mutation is del19 / T790M EGFR. In some embodiments, the EGFR mutation is L858R / T790M EGFR.
[0174] Administration and pharmaceutical compositions In certain embodiments, the EGFR inhibitory compounds described herein are administered as pure chemicals. In other embodiments, the EGFR inhibitory compounds described herein are administered by a selected route of administration and, for example, Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA). A pharmaceutically suitable or pharmaceutically acceptable carrier (herein referred to as a pharmaceutically suitable (or acceptable) carrier selected based on standard pharmaceutical techniques such as those described in (also referred to as excipients, physiologically suitable (or acceptable) excipients, or physiologically suitable (or acceptable) carriers).
[0175] A pharmaceutical composition comprising at least one EGFR inhibitor compound as described herein, or a stereoisomer, pharmaceutically acceptable salt, or N-oxide thereof, together with one or more pharmaceutically acceptable carriers. provided herein. Carrier(s) (or excipient(s)) are acceptable if the carrier is compatible with the other ingredients of the composition and is not deleterious to the recipient (i.e., subject or patient) of the composition. or suitable.
[0176] One embodiment provides a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a pharmaceutically acceptable excipient. provide something.
[0177] In certain embodiments, the EGFR inhibitory compounds disclosed herein contain less than about 5%, or less than about 1%, or less than about 0.1% of other small organic molecules, e.g., of the steps of a synthetic method. Substantially pure in that it contains unreacted intermediates or synthetic by-products produced in one or more of the following:
[0178] Suitable oral dosage forms include, for example, tablets, pills, sachets, or soft or hard gelatin capsules, methylcellulose capsules, or capsules of another suitable material that is easily dissolved in the gastrointestinal tract. In some embodiments, suitable non-toxic solid carriers are used, including, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like. Ru. (See, e.g., Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)).
[0179] The dosage of a composition comprising at least one EGFR inhibitory compound described herein will vary depending on the condition of the patient, ie, stage of disease, health status, age, and other factors.
[0180] Pharmaceutical compositions are administered in a manner appropriate to the disease being treated (or prevented). The appropriate dosage, as well as the suitable duration and frequency of administration, will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration. Generally, an appropriate dosage and treatment regimen will include an amount of the composition(s) sufficient to produce a therapeutic and / or prophylactic effect (e.g., improved clinical outcome), or a reduction in symptom severity. provide. Optimal doses are usually determined using experimental models and / or clinical trials. The optimal dose depends on the patient's size, weight, or blood volume.
[0181] Oral doses usually range from about 1.0 mg to about 1000 mg one to four times a day or more.
Example
[0182] Example 1: Synthesis procedure Yields reported herein are for purified products (unless stated) and are not optimized. TLC analysis on Merck aluminum-backed silica gel 60 F 254 Performed on plate. Compounds were visualized by ultraviolet light and / or stained with either iodine, potassium permanganate, or ninhydrin solution. Flash column chromatography was performed on silica gel (100-200M) or flash chromatography. 1 H-NMR spectra were recorded on a Bruker Avance-400MHz spectrometer equipped with BBO (Broad Band Observe) and BBFO (Broad Band Fluorine Observe) probes. Chemical shifts (δ) are expressed in parts per million (ppm) downfield with respect to tetramethylsilane (TMS) as an internal standard. The splitting patterns are expressed as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and bs (broad singlet). Coupling constants (J) are shown in Hertz (Hz). LC-MS analysis was performed on an Acquity BEH C-18 column (2.10 × 100 mm, 1.70 μm) or an Acquity HSS-T3 column (2.10 × 100 mm, 1.80 μm) using electrospray ionization (ESI) technique.
[0183] The following solvents, reagents, or scientific terms may be referred to by their abbreviations. TLC thin layer chromatography DCM dichloromethane THF Tetrahydrofuran MeOH methanol EtOH ethanol IPA Isopropyl alcohol EtOAc ethyl acetate Et 2 O diethyl ether DMA N,N-dimethylacetamide DMF N,N-dimethylformamide TEA / Et 3 N-triethylamine DMSO dimethyl sulfoxide DIPEA Diisopropylethylamine (Hunig base) MeI Methyl iodide NBS N-bromosuccinimide TBAB Tetrabutylammonium bromide TBAI Tetrabutylammonium iodide DIBAL-H Diisobutylaluminum hydride TFA trifluoroacetic acid AcOH Acetic acid Boc tert-butoxycarbonyl Cat catalyst mL milliliter mmol mmol h hour or hours min minute or minutes g gram mg milligram μl microliter eq equivalent rt or RT Room temperature, ambient temperature, approximately 27°C MS mass spectrometry Boc tert-butyloxycarbonyl m-CPBA metachloroperbenzoic acid T3P Propanephosphonic anhydride BH 3 -DMS Borane dimethyl sulfide complex LiBH 4 lithium aluminum hydride NaBH 4 sodium borohydride H 2 hydrogen Pd / C palladium carbon 1,2-DCE 1,2-dichloroethane
[0184] General procedure A: To an ice-cold solution of the arylamine (1.0 eq.) in tetrahydrofuran was added sodium hydride (60% dispersion in mineral oil, 3.0 eq.) in portions. The resulting reaction mixture was stirred at room temperature for 30 minutes, followed by the addition of 2,4,5-trichloropyrimidine or 2,4-dichloro-5-bromopyrimidine (1.0 eq.). The resulting reaction mixture was heated at 60°C for 16 hours. After completion (TLC monitoring), quench with ice and extract with ethyl acetate (3x). The combined organic layers were washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was triturated with diethyl ether, filtered and dried under reduced pressure to yield the desired product.
[0185] General procedure B: To a solution of arylhalo (1.0 eq.) in 1,4-dioxane or toluene was added cesium carbonate (3.0 eq.) and arylamine (1.2 eq.). The resulting reaction mixture was degassed under nitrogen for 15 min, followed by addition of 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos, 0.1 eq.) and tris(dibenzylideneacetone)di Palladium(0) (0.1 eq.) was added under nitrogen atmosphere. The resulting reaction mixture was again degassed for 15 minutes and then heated at 100° C. for 16 hours. After completion of the reaction (monitoring by TLC), the reaction mixture was cooled, diluted with water and extracted with dichloromethane (3 times). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography using 4-8% methanol in dichloromethane as eluent and the desired fractions were concentrated under reduced pressure to yield the desired product.
[0186] General procedure C: To an ice-cold solution of primary or secondary arylamine (1.0 eq.) in dichloromethane was added triethylamine (3.0 eq.) and acetyl chloride (1.2 eq.) dropwise. The resulting reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction (monitoring by TLC), the reaction mixture was diluted with water and extracted with dichloromethane (3 times). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash, eluting with 4-5% methanol in dichloromethane, and the desired fractions were concentrated under reduced pressure to yield the desired product.
[0187] General procedure D: To a solution of the aldehyde (1.0 eq.) in methanol was added the corresponding amine (3.0 eq.) and sodium acetate (5.0 eq.). The resulting reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was poured into ice-cold water and the resulting solid was filtered. The solid was dried under reduced pressure to yield the desired product.
[0188] General procedure E: To a solution of the product obtained by General Procedure D (1.0 eq.) in methanol (2.5 vol.) was added acetic acid (1.0 vol.) followed by sodium borohydride (1.0 eq.). The resulting reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (monitoring by TLC), the reaction mixture was quenched with ice-cold water and the resulting solid was filtered and washed with water. The solid was dried under reduced pressure to yield the desired product.
[0189] General procedure F: To an ice-cold solution of the product obtained by general procedure E (1.0 eq.) in tetrahydrofuran was added diisopropylethylamine (4.0 eq.) followed by triphosgene (0.4 eq.). The resulting reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (monitoring by TLC), saturated sodium bicarbonate solution was added and extracted with dichloromethane (3 times). The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was triturated with diethyl ether to give the desired product.
[0190] General procedure G: To an ice-cold solution of the product obtained by general procedure F (1.0 eq.) in dichloromethane was added m-chloroperbenzoic acid (2.0 eq.). The resulting reaction mixture was stirred at room temperature for 4 hours. After the completion of the reaction (monitoring by TLC), saturated sodium bicarbonate solution was added to the reaction mixture and extracted with dichloromethane (3 times). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was triturated with diethyl ether to give the desired product.
[0191] General procedure H: To an ice-cold solution of the product obtained by general procedure G (1.0 eq.) in isopropanol was added the corresponding amine (1.2 eq.) and trifluoroacetic acid (2.0 eq.). The reaction mixture was heated at 110°C for 16 hours. After completion of the reaction (monitoring by TLC), the reaction mixture was concentrated under reduced pressure, saturated sodium bicarbonate solution was added and extracted with dichloromethane (3 times). The combined organic layers were washed with brine solution, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude residue was triturated with diethyl ether to give the desired product, which was used directly in the next step.
[0192] General procedure I: An ice-cold solution of the product obtained by general procedure H (1.0 eq.) in 20% trifluoroacetic acid in dichloromethane was stirred at room temperature for 3-16 hours. After completion of the reaction (monitoring by TLC), the solvent was evaporated. The reaction mass was diluted with saturated sodium bicarbonate solution and extracted with 5% methanol in dichloromethane (3 times). The combined organic layers were washed with brine solution, dried over sodium sulfate and evaporated under reduced pressure. The crude product was triturated with ether or purified by CombiFlash, eluting with 5-10% methanol in dichloromethane to give the desired product.
[0193] General procedure J: To an ice-cold solution of the product obtained by general procedure I (1.0 eq.) in dichloromethane was added triethylamine (3-5 eq.) and the corresponding acid (1.1 eq.), followed by propylphosphonic anhydride (T 3 P, 50% in ethyl acetate, 2.5 eq.) was added. The resulting reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (monitored by TLC), the reaction mass was diluted with saturated sodium bicarbonate solution and extracted with 5% methanol in dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash or preparative TLC or preparative HPLC purification to give the final compound.
[0194] General procedure K: A solution of the product obtained according to General Procedure I (1.0 eq.) in dichloromethane:tetrahydrofuran (1:1) was cooled to -40°C, followed by triethylamine (3-5 eq.) and acryloyl chloride (1.0 eq.). was added. The mixture was stirred at the same temperature for 2 hours. After completion of the reaction (monitored by TLC), water was added and extracted with dichloromethane (3x). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by preparative HPLC purification to give the final compound.
[0195] General procedure K 1 : To a solution of the product obtained by general procedure I (1.0 eq.) in tetrahydrofuran and water (3:1) was added triethylamine (5 eq.) and acryloyl chloride (1.0 eq.) at -0.degree. The reaction mixture was stirred at the same temperature for 2 hours. After completion of the reaction (monitored by TLC), water was added and extracted with ethyl acetate (3x). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by preparative HPLC purification to give the final compound.
[0196] General procedure K 2 : To a solution of the product obtained according to general procedure I (1.0 eq.) in tetrahydrofuran and water (3:1) was added triethylamine (5 eq.) and 3-chloropropionyl chloride (1.2-1.5 eq.) at -0 °C. did. The reaction mixture was stirred at the same temperature for 20 minutes to 1 hour. After completion of the reaction (monitored by LCMS), water was added and extracted with ethyl acetate (3x). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by preparative HPLC purification to give the final compound.
[0197] General procedure L: To an ice-cold solution of the nitro derivative (1.0 eq.) in methanol:tetrahydrofuran:water (2:2:1) was added zinc or iron powder (5 eq.) and ammonium chloride (5 eq.). The resulting reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction (monitored by TLC), the reaction mixture was passed through a bed of Celite and washed with 5% methanol in dichloromethane. The filtrate was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated to dryness to give the amino derivative.
[0198] General procedure L 1 : To a solution of the nitro derivative (1.0 equivalent) in methanol or ethanol (10 volumes) was added 10% palladium on carbon (20% w / w). The reaction mixture was stirred under hydrogen atmosphere for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was filtered through a bed of Celite and washed with methanol. The combined filtrates were concentrated under reduced pressure to obtain the amino derivative.
[0199] General procedure M 1 :(Suzuki coupling): To a solution of the halo derivative (1.0 eq.) in acetonitrile was added the corresponding boronate acid / boronate ester derivative (1.0 eq.) followed by an aqueous solution of potassium carbonate (2.0 eq.) under an argon purge. The resulting reaction mixture was degassed for 15 min, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane complex (0.1 eq.) and the reaction mixture heated to 80°C. It was heated for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with ice water and extracted with ethyl acetate (3 times). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by CombiFlash, eluting with 40-60% ethyl acetate in hexane, and the desired fractions were concentrated under reduced pressure to yield the desired product.
[0200] General procedure M 2 : A solution of the halo derivative (1.0 eq.) and the corresponding boronic acid (1.1 eq.) in toluene:ethanol (1:1) or dimethylformamide or dimethoxyethane and water (4:1) was added with potassium carbonate (2.0 eq.) or carbonic acid. Sodium hydrogen (2.0 eq.) was added. The resulting reaction mixture was degassed with argon for 15 minutes, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (0.05 eq.). The resulting reaction mixture was heated at 90°C for 5 to 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, water was added and extracted with ethyl acetate (3 times). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash, eluting with 30-50% ethyl acetate in hexane, and the desired fractions were concentrated under reduced pressure to yield the desired product.
[0201] General procedure M 3 : A solution of the halo derivative (1.0 eq.) and the corresponding boronate acid / boronic acid ester derivative (1.1 eq.) in N,N-dimethylformamide:water (4:1) was added with sodium carbonate or sodium bicarbonate (2.0 eq. equivalent amount) was added. The resulting reaction mixture was degassed under an argon atmosphere for 15 minutes, followed by the addition of tetrakis(triphenylphosphine)palladium(0) (0.1 eq.). The resulting reaction mixture was heated at 90° C. for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature, water was added and extracted with ethyl acetate (3 times). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by using CombiFlash and the desired fractions were concentrated under reduced pressure to obtain the desired product.
[0202] General procedure N: To an ice-cold solution of N-(3-(2-chloro-6-fluoroquinazolin-8-yl)phenyl)acrylamide (1.0 eq.) in dimethylformamide was added sodium hydride (60% dispersion in mineral oil, 10 eq. ) was added in portions and stirred for 30 minutes at room temperature, followed by the addition of the corresponding amine (1.2 eq.). The resulting reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (according to TLC monitoring), the reaction mixture was diluted with ice-cold water and extracted with 5% methanol / dichloromethane (3 times). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash or preparative HPLC purification to give the desired product.
[0203] General steps: To a solution of primary or secondary alcohol (1.0 eq.) in dichloromethane was added activated manganese dioxide (10 eq.) under nitrogen atmosphere at room temperature. The resulting reaction mixture was stirred at the same temperature for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was filtered through a bed of Celite and washed with dichloromethane (3 times). The combined filtrates were dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield the desired product.
[0204] Scheme 1: tert-butyl (3-(7-chloro-2-oxo-3-phenyl-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)carbamate ( 8) Synthesis: [ka] Step 1: Synthesis of 5-(hydroxymethyl)pyrimidine-2,4(1H,3H)-dione (2): An ice-cold solution of pyrimidine-2,4(1H,3H)-dione (1) (10 g, 89.21 mmol) and paraformaldehyde (9.63 g, 107.05 mmol) in aqueous potassium hydroxide solution (132 mL, 0.5 M, 66.74 mmol) The solution was heated at 55°C for 14 hours. After completion of starting material (TLC), the reaction mixture was cooled to 0 °C, the pH was adjusted to 6 with 12N hydrochloric acid, and the resulting white precipitate was filtered through a sintered funnel and washed with diethyl ether. , 2 was obtained as a white solid (6.3 g, yield: 50%), which was used directly in the next step. 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.98 (bs, 1H), 10.64 (bs, 1H), 7.24 (s, 1H), 4.78 (m, 1H), 4.12 (d, J = 12.8 Hz, 2H). LCMS: [M+H] + 143.04.
[0205] Step 2: Synthesis of 2,4-dichloro-5-(chloromethyl)pyrimidine (3): To an ice-cold solution of 5-(hydroxymethyl)pyrimidine-2,4(1H,3H)-dione (2) (10 g, 70.36 mmol) in toluene (25 mL) was added phosphoryl chloride (14 mL, 140.72 mmol), then N,N-diisopropylethylamine (37 mL, 211 mmol) was added. The reaction mixture was heated at 120°C for 16 hours. After complete disappearance of starting material on TLC, the reaction mixture was slowly quenched with sodium bicarbonate solution and extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to give 3 as a brown solid (12 g, yield: 86%), which was carried directly into the next step. used. 1 H NMR (400 MHz, CDCl 3 ): δ 8.66 (s, 1H), 4.64 (s, 2H). MS: [M+H] + 197.0.
[0206] Step 3: Synthesis of 2,4-dichloro-5-(iodomethyl)pyrimidine (4): To a solution of 2,4-dichloro-5-(chloromethyl)pyrimidine (3) (8.0 g, 40.51 mmol) in acetone (40 mL) was added sodium iodide (9.71 g, 64.82 mmol). The reaction mixture was stirred at room temperature for 30 minutes and heated to reflux for 2 hours. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature. The resulting white precipitate was filtered through a sintered funnel and washed with acetone. The filtrate was concentrated under reduced pressure to give 4 as a brown solid (10 g, yield: 85%), which was used directly in the next step. 1 H-NMR (400 MHz, CDCl 3 ): δ 8.60 (s, 1H), 4.39 (s, 2H).
[0207] Step 4: Synthesis of N-((2,4-dichloropyrimidin-5-yl)methyl)aniline (6): To an ice-cold solution of 2,4-dichloro-5-(iodomethyl)pyrimidine (4) (5.0 g, 17.30 mmol) in acetone (50 mL) was added potassium carbonate (5.26 g, 38.06 mmol) and aniline (5) (1.93 g, 20.76 mmol) was added. The resulting reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (according to TLC monitoring), the resulting white precipitate was filtered through a sintered funnel and washed with acetone. The filtrate was concentrated under reduced pressure and the crude product was purified by silica gel column chromatography (100-200 mesh) using 15% ethyl acetate / hexane as eluent to give 6 as a brown solid (2.5 g, yield: 57%). 1 H-NMR (400 MHz, CDCl 3 ): δ 8.61 (s, 1H), 7.07 (t, J = 7.6 Hz, 2H), 6.58 (m, 3H), 6.30 (bs, 1H), 4.33 (m, 2H). LCMS: [M+H] + 254.03.
[0208] Step 5: tert-butyl(3-(7-chloro-2-oxo-3-phenyl-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)carbamate( 8) Synthesis: To an ice-cold solution of N-((2,4-dichloropyrimidin-5-yl)methyl)aniline (6) (500 mg, 1.96 mmol) in isopropanol (5 mL) was added N,N-diisopropylethylamine (1.47 mL, 8.42 mmol) and tert-butyl (3-aminophenyl)carbamate (7) (409 mg, 1.96 mmol) were added. The resulting reaction mixture was heated at 100° C. for 16 hours in a sealed tube. After the completion of the reaction (monitored by TLC), the solvent was then evaporated under reduced pressure and the resulting crude product was subjected to silica gel column chromatography (100-200 mesh) using 30% ethyl acetate in hexane as eluent. Purification to give 8 as a brown solid (500 mg, yield: 60%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 9.41 (s, 1H), 8.96 (s, 1H), 8.10 (s, 1H), 7.73 (s, 1H), 7.25 (m, 2H), 7.12 (m, 3H), 6.61 (m, 3H ), 6.14 (t, J = 7.2 Hz, 1H), 4.26 (m, 2H), 1.53 (s, 9H). LCMS: [M+H] + 426.14.
[0209] Scheme 2: Synthesis of 2-(4-amino-1H-pyrazol-1-yl)ethane-1-ol (11): [ka] Step 1: Synthesis of 2-(4-nitro-1H-pyrazol-1-yl)ethane-1-ol (10) To a stirred solution of 4-nitro-1H-pyrazole (9) (2.00 g, 17.7 mmol) in acetonitrile (20.0 mL) was added 2-bromoethane-1-ol (1.38 mL, 19.5 mmol), potassium carbonate (2.93 g, 21.2 mmol) was added and the reaction mixture was heated at 80° C. for 15 hours. The reaction mixture was cooled to room temperature, diluted with water (50 mL), and extracted with ethyl acetate (30 mL x 4). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate and evaporated. The crude product was purified by column chromatography using a CombiFlash purifier, eluting with 45% ethyl acetate in hexanes to give the title compound (10) as a white solid (2.5 g, 90%). LCMS: [M+H] + 158.0.
[0210] Step 2: Synthesis of 2-(4-amino-1H-pyrazol-1-yl)ethan-1-ol (11) A stirred solution of 2-(4-nitro-1H-pyrazol-1-yl)ethan-1-ol (10) (2.50 g, 15.9 mmol) in ethanol (20 mL) was purged with nitrogen for 5 min and treated with palladium on carbon. (0.25g, 10% w / w) was added and the reaction mixture was hydrogenated for 15 hours. The reaction mixture was filtered through Celite and the filtrate was evaporated to give the title compound (11) as a brown liquid (2.0 g, crude product). 1 H NMR (400 MHz, DMSO-d 6 ): δ 7.00 (s, 1H), 6.87 (s, 1H), 4.78 (t, J = 4.8 Hz, 1H), 3.92 (t, J = 6.0 Hz, 2H), 3.73 (bs, 2H), 3.63- 3.59 (m, 2H).
[0211] Scheme 3: N-(3-((5-chloro-2-((1-(4-hydroxycyclohexyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) Synthesis of acrylamide (compound 1): [ka] Step 1: Synthesis of 2,5-dichloro-N-(2-fluoro-5-nitrophenyl)pyrimidin-4-amine (14): The title compound was prepared in a manner substantially similar to that described in General Procedure A. The crude product was triturated with diethyl ether, filtered, and dried under reduced pressure to yield 2,5-dichloro-N-(2-fluoro-5-nitrophenyl)pyrimidin-4-amine (14) as a pale yellow solid. (10.0 g, yield: 34%). 1 H-NMR (400 MHz, CDCl 3 ): δ 9.87 (s, 1H), 8.48 (s, 1H), 8.40-8.43 (m, 1H), 8.22-8.26 (m, 1H), 7.65 (t, J = 9.2 Hz, 1H).
[0212] Step 2: 4-(4-((5-chloro-4-((2-fluoro-5-nitrophenyl)amino)pyrimidin-2-yl)amino)-1H-pyrazol-1-yl)cyclohexane-1- Synthesis of all (16): The title compound was prepared in a manner substantially similar to that described in General Procedure H to afford the desired product (16) as a pale yellow solid (0.75 g, yield: 84.7%). MS: [M+H] + 448.21.
[0213] Step 3: 4-(4-((4-((5-amino-2-fluorophenyl)amino)-5-chloropyrimidin-2-yl)amino)-1H-pyrazol-1-yl)cyclohexane-1- Synthesis of all (17): The title compound was prepared in a manner substantially similar to that described in General Procedure L to afford the desired product (17) as a brown solid (0.55 g, yield: 78.57%). MS: [M+H] + 418.18.
[0214] Step 4: N-(3-((5-chloro-2-((1-(4-hydroxycyclohexyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) Synthesis of acrylamide (compound 1): The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by preparative HPLC purification to obtain compound 1 (45 mg, yield: 13.27%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.32 (bs, 1H), 9.26 (bs, 1H), 8.86 (bs, 1H), 8.05 (s, 1H), 7.78-7.79 (m, 1H), 7.70 (s, 1H), 7.65 (bs , 1H), 7.31-7.34 (m, 1H), 7.08-7.13 (m, 2H), 6.38-6.45 (m, 1H), 6.24 (d, J = 17.2 Hz, 1H), 5.75 (d, J = 10.4 Hz, 1H), 4.62 (d, J = 4.4 Hz, 1H), 3.60-3.62 (m, 1H), 1.83 (d, J = 11.2 Hz, 2H), 1.23-1.63 (m, 6H). LCMS: [M+H] + 472.22.
[0215] Table 1: The following compounds were prepared using the procedure described above. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6]
[0216] Scheme 4: N-(3-((5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)- 4-fluorophenyl)acrylamide (compound 14): [ka] Step 1: 5-chloro-N4-(2-fluoro-5-nitrophenyl)-N2-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)pyrimidine-2,4- Diamine(20) The title compound was prepared in a manner substantially similar to that described in General Procedure H to afford the desired product (20) as a pale yellow solid (0.2 g, yield: 23%). LCMS: [M+H] + 447.2.
[0217] Step 2: N4-(5-amino-2-fluorophenyl)-5-chloro-N2-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)pyrimidine-2,4- Diamine(21) 5-chloro-N4-(2-fluoro-5-nitrophenyl)-N2-[1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl]pyrimidine-2 in methanol (30 mL) To a stirred solution of ,4-diamine (20) (0.2 g, 0.44 mmol) was added Raney nickel (0.07 g, 1.34 mmol) and allowed to stir at room temperature under a hydrogen atmosphere for 16 hours. The reaction mixture was filtered through a bed of celite and distilled to give the title compound (21) as a yellow solid (0.16 g, 85%). LCMS [M+H] + 417.1.
[0218] Step 3: N-(3-((5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)- 4-fluorophenyl)acrylamide (compound 14) The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by preparative HPLC purification to give compound 14 (17 mg, yield: 14%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.26 (s, 1H), 9.23 (s, 1H), 8.85 (s, 1H), 8.02 (s, 1H), 7.71 (d, J = 6.4 Hz, 2H), 7.30 (s, 1H), 7.10 (t, J = 15.2 Hz, 2H), 6.35-6.42 (m, 1H), 6.23 (d, J = 17.2 Hz, 1H), 5.74 (d, J = 10.0 Hz, 1H), 3.57 (s, 1H) ), 2.75 (d, J = 10.0 Hz, 2H), 2.16 (s, 3H). 1.93 (s, 2H), 1.63 (s, 4H). LCMS: [M+H] + 471.0.
[0219] Table 2: The following compounds were prepared using the procedure described above. [Table 2]
[0220] Scheme 5: (E)-4-(dimethylamino)-N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((phenylamino)methyl)pyrimidine Synthesis of -4-yl)amino)phenyl)but-2-enamide (compound 17): [ka] Step 1: (3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((phenylamino)methyl)pyrimidin-4-yl)amino)phenyl)carbamic acid tert- Synthesis of butyl(23): The title compound was prepared in a manner substantially similar to that described in General Procedure B. The crude product was purified by CombiFlash chromatography using 5% methanol in dichloromethane as eluent and the desired fractions were concentrated under reduced pressure to give (3-((2-((1-methyl-1H- tert-butyl pyrazol-4-yl)amino)-5-((phenylamino)methyl)pyrimidin-4-yl)amino)phenyl)carbamate (23) as a light brown solid (500 mg; yield: 87%) Obtained. MS: [M+H] + 487.25.
[0221] Step 2: Synthesis of N4-(3-aminophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)-5-((phenylamino)methyl)pyrimidine-2,4-diamine (24): The title compound was prepared in a manner substantially similar to that described in General Procedure I. The crude product was triturated with diethyl ether to give N4-(3-aminophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)-5-((phenylamino)methyl)pyrimidine as the TFA salt. -2,4-diamine (24) was obtained as a brown solid (0.50 g, yield: 84%). MS: [M+H] + 387.25.
[0222] Step 3: (E)-4-(dimethylamino)-N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((phenylamino)methyl)pyrimidine Synthesis of -4-yl)amino)phenyl)but-2-enamide (compound 17) The title compound was prepared in a manner substantially similar to that described in General Procedure J. The resulting crude product was purified by CombiFlash, eluting with 8% methanol in dichloromethane. The title compound was further purified by preparative HPLC to give (E)-N-(3-((5-chloro-2-((1-(4-hydroxycyclohexyl)-1H-pyrazol-4-yl)amino) Pyrimidin-4-yl)amino)-4-fluorophenyl)-4-(dimethylamino)but-2-enamide (compound 17) was obtained as a white solid (66 mg; yield: 20.52%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.06 (bs, 1H), 8.91 (bs, 1H), 8.43 (s, 1H), 7.98 (s, 1H), 7.79 (s, 1H), 7.58-7.30 (m, 4H), 7.11-7.07 (m, 2H), 6.75-6.66 (m, 4H), 6.57 (t, J = 7.2 Hz, 1H), 6.27 (d, J = 15.2 Hz, 1H), 5.99-5.97 (m, 1H), 4.17 ( d, J = 4.0 Hz, 2H), 3.62 (s, 3H), 3.05 (d, J = 5.2 Hz, 2H), 2.16 (s, 6H). LCMS: [M+H] + 498.38(96.05%).
[0223] Scheme 6: (E)-4-(dimethylamino)-N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((N-phenylacetamido)methyl ) Synthesis of pyrimidin-4-yl)amino)phenyl)but-2-enamide (compound 18): [ka] Step 1: Synthesis of tert-butyl (3-((2-chloro-5-((N-phenylacetamido)methyl)pyrimidin-4-yl)amino)phenyl)carbamate (26): The title compound was prepared in a manner substantially similar to that described in General Procedure C. The crude product was purified through silica gel (100-200 mesh) eluting with 3-5% methanol in dichloromethane and the desired fractions were concentrated to dryness to give (3-((2-chloro-5-( Tert-butyl (N-phenylacetamido)methyl)pyrimidin-4-yl)amino)phenyl)carbamate (26) was obtained as a light brown solid (300 mg, yield: 54.84%). MS: [M+H] + 468.06.
[0224] Step 2: (3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((N-phenylacetamido)methyl)pyrimidin-4-yl)amino)phenyl)carbamic acid Synthesis of tert-butyl (27): The title compound was prepared in a manner substantially similar to that described in General Procedure H. The crude product was purified through silica gel (100-200 mesh) eluting with 6-8% methanol in dichloromethane and the desired fractions were concentrated under reduced pressure to give (3-((2-((1- Tert-butyl methyl-1H-pyrazol-4-yl)amino)-5-((N-phenylacetamido)methyl)pyrimidin-4-yl)amino)phenyl)carbamate (27) was dissolved as a light brown solid (290 mg, rate: 85.5%). MS: [M+H] + 529.14.
[0225] Step 3: N-((4-((3-aminophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)methyl)-N-phenylacetamide Synthesis of (28): The title compound was prepared in a manner substantially similar to that described in General Procedure I. The crude product was triturated with diethyl ether to give N-((4-((3-aminophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidine as the TFA salt. -5-yl)methyl)-N-phenylacetamide (28) was obtained as a brown solid (130 mg, yield: 55.3%). MS: [M+H] + 429.25.
[0226] Step 4: N-(3-((5-chloro-2-((1-(4-hydroxycyclohexyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl ) Synthesis of acrylamide (compound 18): The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by preparative HPLC purification to give N-(3-((5-chloro-2-((1-(4-hydroxycyclohexyl)-1H-pyrazol-4-yl)amino)pyrimidine-4 -yl)amino)-4-fluorophenyl)acrylamide (compound 18) was obtained as a white solid (22 mg; yield: 15.0%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.27 (s, 1H), 9.30 (s, 1H), 8.98 (s, 1H), 8.00-7.60 (m, 3H), 7.54 (d, J = 7.6 Hz, 1H), 7.47-7.32 (m , 6H), 7.20 (d, J = 7.6 Hz, 2H), 6.51-6.44 (q, J = 10.0 Hz, 1H), 6.28-6.23 (m, 1H), 5.77-5.74 (m, 1H), 4.74 ( s, 2H), 3.66 (s, 3H), 1.84 (s, 3H). LCMS: [M+H] + 483.33.
[0227] Scheme 7: N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((N-(1-phenylethyl)acetamido)methyl)pyrimidin-4-yl ) Synthesis of amino)phenyl)acrylamide (compound 19): [ka] Step 1: tert-butyl (E)-(3-((2-(methylthio)-5-(((1-phenylethyl)imino)methyl)pyrimidin-4-yl)amino)phenyl)carbamate (31) Synthesis of: The title compound was prepared in a manner substantially similar to that described in General Procedure D to give (E)-(3-((2-(methylthio)-5-(((1-phenylethyl)imino) Tert-butyl (methyl)pyrimidin-4-yl)amino)phenyl)carbamate (31) was obtained as a light brown solid (1.20 g, yield: 93.70%). MS: [M+H] + 464.31.
[0228] Step 2: Synthesis of tert-butyl (3-((2-(methylthio)-5-(((1-phenylethyl)amino)methyl)pyrimidin-4-yl)amino)phenyl)carbamate (32): The title compound was prepared in a manner substantially similar to that described in General Procedure E to give (3-((2-(methylthio)-5-(((1-phenylethyl)amino)methyl)pyrimidine- Tert-butyl 4-yl)amino)phenyl)carbamate (32) was obtained as a pale yellow solid (1.0 g, yield: 83%). MS: [M+H] + 466.25.
[0229] Step 3: Synthesis of tert-butyl (3-((2-(methylthio)-5-((N-(1-phenylethyl)acetamido)methyl)pyrimidin-4-yl)amino)phenyl)carbamate (33) : The title compound was prepared in a manner substantially similar to that described in General Procedure C. The resulting crude product was purified through silica gel (100-200 mesh), eluting with 4-5% methanol in dichloromethane, and the desired fractions were concentrated under reduced pressure to give (3-((2-chloro tert-Butyl -5-((N-phenylacetamido)methyl)pyrimidin-4-yl)amino)phenyl)carbamate (33) was obtained as a light brown solid (500 mg; yield: 41.66%). MS: [M+H] + 508.25.
[0230] Step 4: tert-butyl(3-((2-(methylsulfonyl)-5-((N-(1-phenylethyl)acetamido)methyl)pyrimidin-4-yl)amino)phenyl)carbamate (34) Synthesis: The title compound was prepared in a manner substantially similar to that described in General Procedure G to give (3-((2-(methylsulfonyl)-5-((N-(1-phenylethyl)acetamido)methyl tert-Butyl)pyrimidin-4-yl)amino)phenyl)carbamate (34) was obtained as an off-white solid (400 mg; yield: 75%). MS: [M+H] + 540.15.
[0231] Step 5: (3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((N-(1-phenylethyl)acetamido)methyl)pyrimidin-4-yl)amino Synthesis of tert-butyl)phenyl)carbamate (35): The title compound was prepared in a manner substantially similar to that described in General Procedure H to give (3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-( Tert-butyl (N-(1-phenylethyl)acetamido)methyl)pyrimidin-4-yl)amino)phenyl)carbamate (35) was obtained as a light brown solid (200 mg; yield: 48.54%). LCMS: [M+H] + 557.31.
[0232] Step 6: N-((4-((3-aminophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)methyl)-N-(1 Synthesis of -phenylethyl)acetamide (36): The title compound was prepared in a manner substantially similar to that described in General Procedure I to give N-((4-((3-aminophenyl)amino)-2-((1-methyl -1H-pyrazol-4-yl)amino)pyrimidin-5-yl)methyl)-N-(1-phenylethyl)acetamide (36) was obtained as a brown solid (150 mg; yield: 91.64%). MS: [M+H] + 457.25.
[0233] Step 7: N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((N-(1-phenylethyl)acetamido)methyl)pyrimidin-4-yl ) Synthesis of amino)phenyl)acrylamide (compound 19): The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by preparative HPLC to give N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((N-(1-phenylethyl) Acetamido)methyl)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 19) was obtained as a white solid (30 mg; yield: 15.0%). 1 H NMR (400 MHz, DMSO d 6 ): δ 10.20 (s, 1H), 9.48 (s, 1H), 8.89 (s, 1H), 7.89 (s, 1H), 7.74-7.25 (m, 11H), 6.49-6.42 (m, 1H), 6.27 -6.23 (m, 1H), 5-76-5.73 (m, 1H), 5.25-5.23 (m, 1H), 4.53-4.41 (m, 1H), 4.25-4.15 (m, 1H), 3.64 (bs, 3H), 2.15 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H). LCMS: [M+H] + 511.37.
[0234] Scheme 8: N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)(phenyl)amino)-4-fluorophenyl)acrylamide Synthesis of (compound 20): [ka] Step 1: Synthesis of 2-fluoro-5-nitro-N-phenylaniline (38): The title compound was prepared in a manner substantially similar to that described in General Procedure B. The crude product was purified by CombiFlash chromatography using 10-20% ethyl acetate in hexane as eluent and the desired fractions were concentrated under reduced pressure to give 2-fluoro-5-nitro-N-phenylaniline. (38) was obtained as a light brown solid (4.0 g; yield: 54.0%). MS: [M-H] - 230.96.
[0235] Step 2: Synthesis of 2,5-dichloro-N-(2-fluoro-5-nitrophenyl)-N-phenylpyrimidine-4-amine (39): A solution of 2,5-dichloro-N-(2-fluoro-5-nitrophenyl)pyrimidin-4-amine (38) (2.00 g, 8.61 mmol) in N,N-dimethylformamide (20 mL) was added with potassium carbonate ( 2.40 g, 17.22 mmol) and 2,4,5-trichloropyrimidine (13) (1.60 g, 8.61 mmol) were added. The resulting reaction mixture was heated at 100°C for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was cooled, diluted with ice-cold water, and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography using 5-10% ethyl acetate in hexane as eluent, and the desired fractions were concentrated under reduced pressure to give 2,5-dichloro-N-(2-fluoro -5-nitrophenyl)-N-phenylpyrimidine-4-amine (39) was obtained as a light brown solid (1.40 g; yield: 42.9%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 8.48 (s, 1H), 7.97-7.94 (m, 1H), 7.72-7.68 (m, 1H), 7.49-7.42 (m, 1H), 7.38-7.29 (m, 2H), 7.19-7.17 ( m, 2H), 7.14-7.03 (m, 1H).
[0236] Step 3: 5-chloro-N4-(2-fluoro-5-nitrophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)-N4-phenylpyrimidine-2,4-diamine (40) Synthesis: The title compound was prepared in a manner substantially similar to that described in General Procedure H to give 5-chloro-N4-(2-fluoro-5-nitrophenyl)-N2-(1-methyl-1H-pyrazole. -4-yl)-N4-phenylpyrimidine-2,4-diamine (40) was obtained as a light brown solid (550 mg; yield: 94.8%). MS: [M+H] + 440.17.
[0237] Step 4: N4-(5-amino-2-fluorophenyl)-5-chloro-N2-(1-methyl-1H-pyrazol-4-yl)-N4-phenylpyrimidine-2,4-diamine (41) Synthesis: The title compound was prepared in a manner substantially similar to that described in General Procedure L to give N4-(5-amino-2-fluorophenyl)-5-chloro-N2-(1-methyl-1H-pyrazole -4-yl)-N4-phenylpyrimidine-2,4-diamine (41) was obtained as a brown solid (450 mg; yield: 88%). MS: [M+H] + 410.01.
[0238] Step 5: N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)(phenyl)amino)-4-fluorophenyl)acrylamide Synthesis of (compound 20): The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by preparative HPLC purification to give N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)(phenyl )Amino)-4-fluorophenyl)acrylamide (compound 20) was obtained as a white solid (95 mg, yield: 33.56%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.25 (s, 1H), 9.58 (s, 1H), 8.19 (s, 1H), 7.69-7.05 (m, 9H), 6.62 (bs, 1H), 6.36-6.18 (m, 2H), 5.74 -5.71 (m, 1H), 3.47 (s, 3H). LCMS: [M+H] + 464.18.
[0239] Scheme 9: N-(3-((5-chloro-2-((5-(methoxymethyl)-1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)amino)-4- Synthesis of fluorophenyl)acrylamide (compound 21): [ka] Step 1: 5-chloro-N4-(2-fluoro-5-nitrophenyl)-N2-(5-(methoxymethyl)-1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine ( Synthesis of 43) The title compound was prepared in a manner substantially similar to that described in General Procedure H to give 5-chloro-N4-(2-fluoro-5-nitrophenyl)-N2-(5-(methoxymethyl)- 1-Methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (43) was obtained as a light brown solid (500 mg; yield: 62.11%). LCMS: [M+H] + 407.97.
[0240] Step 2: N4-(5-amino-2-fluorophenyl)-5-chloro-N2-(1-methyl-1H-pyrazol-4-yl)-N4-phenylpyrimidine-2,4-diamine (44) Synthesis: 5-chloro-N4-(2-fluoro-5-nitrophenyl)-N2-(5-(methoxymethyl)-1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (43)( To a solution of 250 mg, 0.61 mmol) in methanol (15 mL) was added Raney nickel (100 mg). The resulting reaction mixture was stirred at room temperature under hydrogen atmosphere for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was filtered through a bed of Celite and washed with 10% methanol in dichloromethane (3 x 5 mL). The combined organic components were concentrated under reduced pressure to give N4-(5-amino-2-fluorophenyl)-5-chloro-N2-(5-(methoxymethyl)-1-methyl-1H-pyrazol-3-yl ) Pyrimidine-2,4-diamine (44) was obtained as a light brown solid (200 mg, yield: 86.58%). MS: [M+H] + 378.20.
[0241] Step 3: N-(3-((5-chloro-2-((5-(methoxymethyl)-1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)amino)-4- Synthesis of fluorophenyl)acrylamide (compound 21): The title compound was prepared in a manner substantially similar to that described in General Procedure K. N4-(5-amino-2-fluorophenyl)-5-chloro-N2-(5-(methoxymethyl)-1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (44) and Acryloyl chloride (18) gives N-(3-((5-chloro-2-((5-(methoxymethyl)-1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)amino )-4-fluorophenyl)acrylamide (compound 21) was obtained as a white solid (45 mg, yield: 19.77%). 1 H NMR (400 MHz, DMSO-d 6 ): δ 10.26 (s, 1H), 9.46 (s, 1H), 8.89 (s, 1H), 8.06 (s, 1H), 7.76-7.68 (m, 2H), 7.28 (t, J = 9.4 Hz, 1H ), 6.45-6.23 (m, 2H), 5.86-5.75 (m, 2H), 4.14 (s, 2H), 3.57 (s, 3H), 3.12 (s, 3H). LCMS: [M+H] + 432.17.
[0242] Scheme 10: Synthesis of N-(3-((5-chloro-2-((6-methoxypyridin-3-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 22) : [ka] Step 1: Synthesis of N1-(2,5-dichloropyrimidin-4-yl)-6-fluorobenzene-1,3-diamine (46) The title compound was prepared in a manner substantially similar to that described in General Procedure I to give N1-(2,5-dichloropyrimidin-4-yl)-6-fluorobenzene-1,3 as the TFA salt. -diamine (46) was obtained as an off-white solid (2.0 g; yield: 62.11%). LCMS: [M+H] + 272.88.
[0243] Step 2: Synthesis of N-(3-((2,5-dichloropyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (47): The title compound was prepared in a manner substantially similar to that described in General Procedure K. The resulting crude product was purified by silica gel (100-200 mesh), eluting with 3-5% methanol in dichloromethane, and the desired fractions were concentrated under reduced pressure to give N-(3-((2 ,5-dichloropyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (47) was obtained as an off-white solid (800 mg, yield: 94.2%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.39 (s, 1H), 8.40 (s, 1H), 7.80-7.83 (m, 1H), 7.53-7.57 (m, 2H), 7.27-7.32 (m, 1H), 6.39-6.46 (m, 1H), 6.22-6.29 (m, 2H).
[0244] Step 3: Synthesis of N-(3-((5-chloro-2-((6-methoxypyridin-3-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (compound 22) : The title compound was prepared in a manner substantially similar to that described in General Procedure H. The crude product was purified through silica gel (100-200 mesh) eluting with 4-6% methanol in dichloromethane and the desired fractions were concentrated under reduced pressure. The resulting solid was purified again by preparative HPLC purification to give N-(3-((5-chloro-2-((6-methoxypyridin-3-yl)amino)pyrimidin-4-yl)amino)- 4-Fluorophenyl)acrylamide (compound 22) was obtained as an off-white solid (30 mg, yield: 19.77%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.22 (s, 1H), 9.21 (s, 1H), 8.94 (s, 1H), 8.12-8.09 (m, 2H), 7.81-7.77 (m, 2H), 7.58-7.54 (m, 1H) , 7.28 (t, J = 9.1 Hz, 1H), 6.50-6.37 (m, 2H), 6.27-6.22 (m, 1H), 5.77-5.54 (m, 1H), 3.73 (s, 3H). LCMS: [M+H] + 414.80.
[0245] Scheme 11: N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-2-fluoro Synthesis of acrylamide (compound 23): [ka] Step 1: Synthesis of N-(3-((2,5-dichloropyrimidin-4-yl)amino)-4-fluorophenyl)-2-fluoroacrylamide (50): The title compound was prepared in a manner substantially similar to that described in General Procedure J. The resulting crude product was purified by CombiFlash, eluting with 10% methanol in dichloromethane, and the desired fractions were concentrated under reduced pressure to give N-(3-((2,5-dichloropyrimidine-4- yl)amino)-4-fluorophenyl)-2-fluoroacrylamide (50) was obtained as an off-white solid (350 mg; yield: 34%). MS: [M+H] + 345.18.
[0246] Step 2: N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-2-fluoro Synthesis of acrylamide (compound 23): The title compound was prepared in a manner substantially similar to that described in General Procedure H. The crude product was further purified by preparative HPLC purification to give N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino )-4-fluorophenyl)-2-fluoroacrylamide (compound 23) was obtained as an off-white solid (55 mg, yield: 31.42%). 1 H NMR (400 MHz, DMSO-d 6 ): δ 10.46 (s, 1H), 9.25 (s, 1H), 8.95 (s, 1H), 8.05 (s, 1H), 7.85-7.74 (m, 2H), 7.37 (s, 1H), 7.11 (m , 1H), 6.98 (m, 1H), 5.78-5.65 (m, 1H), 5.47-5.42 (m, 1H), 3.52 (s, 3H). LCMS: [M+H] + 405.82.
[0247] Scheme 12: N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)cyclohexyl)-2-fluoroacrylamide (compound 24 ) composition: [ka] Step 1: Synthesis of tert-butyl (3-aminocyclohexyl)carbamate (52): To an ice-cold solution of cyclohexane-1,3-diamine (51) (15.0 g, 131.57 mmol) in chloroform (300 mL) was added di-tert-butyl dicarbonate (14.93 mL, 65.78 mmol) dropwise. The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (monitored by TLC), water was added and extracted with dichloromethane (3 x 200 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude product was purified through silica gel (100-200 mesh), eluting with 3-5% methanol in dichloromethane, and the desired fractions were concentrated under reduced pressure to obtain (3-aminocyclohexyl)carbamic acid. Tert-butyl (52) was obtained as a white solid (21.0 g; yield: 75%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 8.29 (s, 2H), 5.74 (s, 1H), 3.72 -3.76 (m, 2H), 3.01-3.20 (m, 4H), 1.40-1.84 (m, 4H), 1.36 (s, 9H) .
[0248] Step 2: Synthesis of tert-butyl (3-((2,5-dichloropyrimidin-4-yl)amino)cyclohexyl)carbamate (53): To an ice-cold solution of tert-butyl (3-aminocyclohexyl)carbamate (52) (2.33 g, 10.9 mmol) in ethanol (20 mL) was added N,N-diisopropylethylamine (9.5 mL, 54.51 mmol) and 2,4 ,5-Trichloropyrimidine (13) (2.0g, 10.9mmol) was added. The resulting reaction mixture was heated at 90°C for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with ethyl acetate (3 x 100 mL). The combined organic components were washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified using flash chromatography using 30-50% ethyl acetate in hexane as eluent and the desired fractions were concentrated under reduced pressure to give (3-((2,5- Tert-butyl dichloropyrimidin-4-yl)amino)cyclohexyl)carbamate (53) was obtained as a light brown solid (1.20 g; yield: 30.4%). MS: [M+H] + 360.97.
[0249] Step 3: Synthesis of tert-butyl (3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)cyclohexyl)carbamate (54) : The title compound was prepared in a manner substantially similar to that described in General Procedure H. The crude product was purified by silica gel (100-200 mesh), eluting with 2-4% methanol in dichloromethane, and the desired fractions were concentrated under reduced pressure to give (3-((5-chloro-2- Tert-butyl ((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)cyclohexyl)carbamate (54) was obtained as a light brown solid (600 mg, yield: 85.83%) . MS: [M+H] + 422.38.
[0250] Step 4: Synthesis of N4-(3-aminocyclohexyl)-5-chloro-N2-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (55): The title compound was prepared in a manner substantially similar to that described in General Procedure I to give N4-(3-aminocyclohexyl)-5-chloro-N2-(1-methyl-1H-pyrazole) as the TFA salt. -4-yl)pyrimidine-2,4-diamine (55) was obtained as a light brown solid (400 mg; yield: 88%). MS: [M+H] + 322.25.
[0251] Step 5: N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)(phenyl)amino)-4-fluorophenyl)acrylamide Synthesis of (compound 24): The title compound was prepared in a manner substantially similar to that described in General Procedure J. The crude product was purified by preparative HPLC purification to give N-(3-((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)(phenyl )Amino)-4-fluorophenyl)acrylamide (compound 24) was obtained as a white solid (35 mg; yield: 10%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 9.05 (s, 1H), 8.47 (d, J = 8.0 Hz, 1H), 7.90-7.75 (m, 2H), 7.36 (s, 1H), 6.78-6.76 (m, 1H), 5.57-5.73 (m, 1H), 5.25-5.20 (m, 1H), 4.03 (s, 1H), 3.83-3.76 (m, 4H), 2.01-1.23 (m, 8H). LCMS: [M+H] + 394.14.
[0252] Table 3: The following compounds were prepared using the procedure described above. [Table 3]
[0253] Scheme 13: (E)-N-(3-((5-chloro-2-((3-methylisothiazol-5-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-4 Synthesis of -(dimethylamino)but-2-enamide (compound 27): [ka] Step 1: Synthesis of 5-chloro-N4-(2-fluoro-5-nitrophenyl)-N2-(3-methylisothiazol-5-yl)pyrimidine-2,4-diamine (57): The title compound was prepared in a manner substantially similar to that described in General Procedure B. The crude product was purified by silica gel (100-200 mesh), eluting with 3-5% methanol in dichloromethane, and the desired fractions were concentrated to dryness to give 5-chloro-N4-(2-fluoro-5 -Nitrophenyl)-N2-(3-methylisothiazol-5-yl)pyrimidine-2,4-diamine (57) was obtained as a light brown solid (500 mg; yield: 79.74%). MS: [M+H] + 381.13.
[0254] Step 2: Synthesis of N4-(5-amino-2-fluorophenyl)-5-chloro-N2-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (58): The title compound was prepared in a manner substantially similar to that described in General Procedure L to give N4-(5-amino-2-fluorophenyl)-5-chloro-N2-(1-methyl-1H-pyrazole -4-yl)pyrimidine-2,4-diamine (58) was obtained as a brown solid (300 mg; yield: 65%). MS: [M+H] + 350.94.
[0255] Step 3: (E)-N-(3-((5-chloro-2-((3-methylisothiazol-5-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-4 Synthesis of -(dimethylamino)but-2-enamide (compound 27): The title compound was prepared in a manner substantially similar to that described in General Procedure J. The crude product was purified by CombiFlash, eluting with 8% methanol in dichloromethane, and the desired fractions were concentrated under reduced pressure and purified again using preparative HPLC to give (E)-N-(3 -((5-chloro-2-((3-methylisothiazol-5-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-4-(dimethylamino)but-2-enamide( Compound 27) was obtained as a white solid (20 mg, yield: 5.06%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 11.05 (bs, 1H), 10.19 (bs 1H), 9.22 (bs, 1H), 8.24 (s, 1H), 7.79 (s, 1H), 7.59 (s, 1H), 7.27 (t, J = 9.4 Hz, 1H), 6.69-6.76 (m, 1H), 6.49 (s, 1H), 6.25 (d, J = 15.4 Hz, 1H), 3.04-3.05 (m, 2H), 2.17 (m, 9H). LCMS: [M+H] + 462.13.
[0256] Scheme 14: Synthesis of N-(4-((3-acrylamidophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)benzamide (compound 28): [ka] Step 1: Synthesis of tert-butyl (3-((2-chloro-5-nitropyridin-4-yl)amino)phenyl)carbamate (60): To an ice-cold solution of tert-butyl (3-aminophenyl)carbamate (7) (5.0 g, 26.04 mmol) in tetrahydrofuran (45 mL) was added N,N-diisopropylethylamine (9.3 mL, 52.082 mmol) and 2,4 -Dichloro-5-nitropyrimidine (59) (5.0g, 26.04mmol) was added. The resulting reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction (monitored by TLC), ice-cold water was added and the resulting solid precipitate was filtered and dried under reduced pressure to give the desired product (60) as a pale yellow solid (8.1 g , yield: 85.23%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.25 (s, 1H), 9.16 (s, 1H), 9.03 (s, 1H), 7.95 (s, 1H), 7.23 (d, J = 15.2 Hz, 2H), 7.13 (s, 1H), 1.47 (s, 9H). LCMS: [M+H] + 366.09.
[0257] Step 2: Synthesis of tert-butyl (3-((5-amino-2-chloropyrimidin-4-yl)amino)phenyl)carbamate (61): The title compound was prepared in a manner substantially similar to that described in General Procedure L to afford the desired product (61) as a brown solid (6.4 g, yield: 85%). LCMS: [M+H] + 336.11.
[0258] Step 3: Synthesis of tert-butyl (3-((5-benzamido-2-chloropyrimidin-4-yl)amino)phenyl)carbamate (63): An ice-cold solution of tert-butyl (3-((5-amino-2-chloropyrimidin-4-yl)amino)phenyl)carbamate (61) (1.0 g, 2.9 mmol) in tetrahydrofuran (20 mL) was added with pyridine. (0.9 mL, 11.9 mmol) and benzoyl chloride (62) (417.12 mg, 2.9 mmol) were added under nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for 30 minutes. After completion of the reaction mixture (monitored by TLC), the reaction mixture was quenched with water (100 mL) and extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash eluting with 20% ethyl acetate in hexane to give the desired product (63) as a brown solid (1.1 g, yield: 84%). LCMS: [M+H] + 440.14.
[0259] Step 4: Synthesis of tert-butyl (3-((5-benzamido-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)carbamate (64) : The title compound was prepared in a manner substantially similar to that described in General Procedure H. The crude product was purified by CombiFlash chromatography eluting with 4% methanol in dichloromethane to give the desired product (64) as a brown solid (720 mg; yield: 57%). LCMS: [M+H] + 501.23.
[0260] Step 5: Synthesis of N-(4-((3-aminophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)benzamide (65). The title compound was prepared in a manner substantially similar to that described in General Procedure I to afford the desired product (65) as a brown solid (510 mg, yield: 91.01%). MS: [M+H] + 401.21.
[0261] Step 6: Synthesis of N-(4-((3-acrylamidophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)benzamide (compound 28). The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by preparative HPLC to obtain the desired product, compound 28, as an off-white color (65 mg, yield: 19.12%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.15 (bs, 1H), 9.59 (bs, 1H), 7.07 (bs, 1H), 8.72 (bs, 1H), 8.03-8.06 (m, 2H), 7.94 (s, 1H), 7.83 (s , 1H), 7.51-7.59 (m, 4H), 7.31-7.43 (m, 4H), 6.40-6.47 (m, 1H), 6.21-6.26 (m, 1H), 5.73 (dd, J = 2.0 & 10.4 Hz , 1H), 3.64 (s, 3H). LCMS: [M+H] + 455.28.
[0262] Scheme 15: N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(phenylsulfonamido)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 29 ) composition: [ka] Step 1: Synthesis of tert-butyl (3-((2-chloro-5-(phenylsulfonamido)pyrimidin-4-yl)amino)phenyl)carbamate (67): An ice-cold solution of tert-butyl (3-((5-amino-2-chloropyrimidin-4-yl)amino)phenyl)carbamate (61) (1.0 g, 2.98 mmol) in dichloromethane (15 mL) was added with pyridine. (0.69 mL, 11.98 mmol) and benzenesulfonyl chloride (66) (525 mg, 2.98 mmol) were added at the same temperature under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction mixture (monitored by TLC), the reaction was diluted with water and extracted with dichloromethane (3 times). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the desired product (67) as a semi-solid (700 mg, yield: 50%). LCMS: [M+H] + 476.11.
[0263] Step 2: Synthesis of N-(4-((3-aminophenyl)amino)-2-chloropyrimidin-5-yl)benzenesulfonamide (68): The title compound was prepared in a manner substantially similar to that described in General Procedure I to afford the desired product (68) as a brown solid (480 mg, yield: 96%). LCMS: [M+H] + 376.11.
[0264] Step 3: Synthesis of N-(3-((2-chloro-5-(phenylsulfonamido)pyrimidin-4-yl)amino)phenyl)acrylamide (69). The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by CombiFlash, eluting with 4% methanol in dichloromethane to give the desired product (69) as a brown solid (340 mg, yield: 67%). MS: [M+H] + 430.07.
[0265] Step 4: N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(phenylsulfonamido)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 29 ) composition: The title compound was prepared in a manner substantially similar to that described in General Procedure H. The crude product was purified by preparative HPLC purification to give the desired product, compound 29, as an off-white solid (10 mg, yield: 9%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.13 (bs, 1H), 9.25 (bs, 1H), 8.23 (bs, 1H), 7.73-7.75 (m, 2H), 7.65 (s, 1H), 7.53-7.57 (m, 4H), 7.44 -7.51 (m, 3H), 7.25 (s, 2H), 7.00-7.02 (m, 1H), 6.41-6.48 (m, 1H), 6.24 (d, J = 15.2 Hz, 1H), 5.74 (dd, J = 10.4 and 2.0 Hz, 1H), 3.59 (s, 3H). LCMS: [M+H] + 491.26.
[0266] Table 4: The following compounds were prepared using the procedure described above. [Table 4]
[0267] Scheme 16: N-(3-((5-(benzylamino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 32) Synthesis of: [ka] Step 1: Synthesis of tert-butyl (3-((5-(benzylamino)-2-chloropyrimidin-4-yl)amino)phenyl)carbamate (71): To an ice-cold solution of tert-butyl (3-((5-amino-2-chloropyrimidin-4-yl)amino)phenyl)carbamate (61) (1.5 g, 4.477 mmol) in dichloroethane (15 ml) was added benzaldehyde. (70) (570 mg, 5.37 mmol) and sodium triacetoxyborohydride (2.8 g, 13.431 mmol) were added at the same temperature under nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction, the reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified on a CombiFlash purifier, eluting with 40% ethyl acetate in hexanes to give the desired product (71) as a brown solid (1.1 g, yield: 57%). MS: [M+H] + 426.17.
[0268] Step 2: Synthesis of N-(3-aminophenyl)-N5-benzyl-2-chloropyrimidine-4,5-diamine (72): The title compound was prepared in a manner substantially similar to that described in General Procedure I to afford the desired product (72) as an off-white solid (820 mg, yield: 97%). MS: [M+H] + 326.17.
[0269] Step 3: Synthesis of N-(3-((5-(benzylamino)-2-chloropyrimidin-4-yl)amino)phenyl)acrylamide (73). The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by CombiFlash eluting with 2% methanol in dichloromethane to give the desired product (73) as an off-white solid (260 mg; yield: 55.7%). MS: [M+H] + 380.13.
[0270] Step 4: N-(3-((5-(benzylamino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (compound 32) synthesis of The title compound was prepared in a manner substantially similar to that described in General Procedure H. The crude product was purified by preparative HPLC purification to obtain the desired product, compound 32, as a white solid (40 mg; yield: 14%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.12 (bs, 1H), 8.39 (bs, 2H), 7.91 (s, 1H), 7.67 (s, 1H), 7.53-7.54 (m, 1H), 7.43-7.44 (m, 3H), 7.34 -7.37 (m, 3H), 7.24-7.27 (m, 3H), 6.42-6.49 (m, 1H), 6.23-6.27 (m, 1H), 5.74 (dd, J = 10.0 Hz and 1.6 Hz, 1H), 5.05-5.07 (m, 1H), 4.25 (d, J = 6.0 Hz, 2H), 3.65 (s, 3H). LCMS: [M+H] + 441.28.
[0271] Scheme 17: (E)-N-(3-((5-(benzylamino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)- Synthesis of 4-(dimethylamino)but-2-enamide (compound 33): [ka] Step 1: (E)-N-(3-((5-(benzylamino)-2-chloropyrimidin-4-yl)amino)phenyl)-4-(dimethylamino)but-2-enamide (74) synthesis The title compound was prepared in a manner substantially similar to that described in General Procedure J to afford the desired product (74) as an off-white solid (210 mg; yield: 40%). MS: [M+H] + 437.17.
[0272] Step 2: (E)-N-(3-((5-(benzylamino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)- 4-(dimethylamino)but-2-enamide (compound 33) The title compound was prepared in a manner substantially similar to that described in General Procedure H. The crude product was purified by preparative HPLC purification to give the desired product, compound 33, as an off-white solid (35 mg; yield: 16%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.02 (bs, 1H), 8.40 (bs, 2H), 7.90 (s, 1H), 7.67 (s, 1H), 7.51-7.52 (m, 1H), 7.43-7.44 (m, 3H), 7.33 -7.37 (m, 3H), 7.24-7.27 (m, 3H), 6.69-6.76 (m, 1H), 6.26 (d, J = 15.4 Hz, 1H), 5.04-5.06 (m, 1H), 4.25 (d , J = 5.6 Hz, 2H), 3.65 (s, 3H), 3.04 (d, J = 5.2 Hz, 2H), 2.17 (s, 6H). LCMS: [M+H] + 498.30.
[0273] Scheme 18: 4-((3-acrylamidophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)-N-(1-phenylethyl)pyrimidine-5-carboxamide (compound 34 ) composition: [ka] Step 1: Synthesis of ethyl 4-((3-((tert-butoxycarbonyl)amino)phenyl)amino)-2-chloropyrimidine-5-carboxylate (76): A solution of ethyl 2,4-dichloropyrimidine-5-carboxylate (75) (3.0 g, 13.56 mmol) in tetrahydrofuran (30 mL) was added with N,N-diisopropylethylamine (4.82 mL, 27.02 mmol) and (3-aminophenyl ) tert-Butyl carbamate (7) (2.82 g, 13.56 mmol) was added at room temperature. The resulting reaction mixture was heated at 100°C for 4 hours. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the desired product (76) (4.5 g, yield: 84.42%). LCMS: [M+H] + 392.98.
[0274] Step 2: Synthesis of 4-((3-((tert-butoxycarbonyl)amino)phenyl)amino)-2-chloropyrimidine-5-carboxylic acid (77): Ice-cold solution of ethyl 4-((3-((tert-butoxycarbonyl)amino)phenyl)amino)-2-chloropyrimidine-5-carboxylate (76) (4.5 g, 4.82 mmol) in tetrahydrofuran (50 mL). To this, sodium hydroxide (386 mg, 9.65 mmol) in water (10 mL) was added. The resulting reaction mixture was heated at 50°C for 8 hours. After completion of the reaction (monitored by TLC), the mixture was concentrated under reduced pressure. The crude product was diluted with ice-cold water (25 mL) and acidified with 1N hydrochloric acid (adjusted to pH ~5). The resulting precipitate was filtered and dried under reduced pressure to obtain the desired product (77) as an off-white solid (2.6 g; yield: 63.14%). LCMS: [M+H] + 364.94.
[0275] Step 3: Synthesis of tert-butyl (3-((2-chloro-5-((1-phenylethyl)carbamoyl)pyrimidin-4-yl)amino)phenyl)carbamate (78): The title compound was prepared in a manner substantially similar to that described in General Procedure J to afford the desired product (78) as an off-white solid (800 mg; Yield: 66.62%). MS: [M+H] + 468.17.
[0276] Step 4: (3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-((1-phenylethyl)carbamoyl)pyrimidin-4-yl)amino)phenyl)carbamic acid Synthesis of tert-butyl (79): The title compound was prepared in a manner substantially similar to that described in General Procedure H. The crude product was purified by CombiFlash eluting with 2% methanol in dichloromethane to give the desired product (79) as a semi-solid (600 mg; yield: 61.32%). LCMS: [M+H] + 529.16.
[0277] Step 5: 4-((3-aminophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)-N-(1-phenylethyl)pyrimidine-5-carboxamide (80) Synthesis of: The title compound was prepared in a manner substantially similar to that described in General Procedure I to afford the desired product (80) as an off-white solid (430 mg, yield: 88.21%). LCMS: [M+H] + 429.21.
[0278] Step 6: 4-((3-acrylamidophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)-N-(1-phenylethyl)pyrimidine-5-carboxamide (compound 34 ) composition: The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by preparative HPLC purification to obtain the desired product, compound 34, as an off-white solid (40 mg; yield: 14.21%). 1 H NMR (400 MHz, DMSO-d 6 ): δ 11.15 (bs, 1H), 10.19 (bs, 1H), 9.68 (bs, 1H), 8.73-8.84 (m, 2H), 7.47-7.93 (m, 4H), 7.39-7.41 (m, 2H) , 7.29-7.35 (m, 3H), 7.21-7.24 (m, 2H), 6.39-6.46 (m, 1H), 6.22-6.26 (m, 1H), 5.74 (dd, J = 10.4 and 2.0 Hz, 1H) , 5.12-5.19 (m, 1H) 3.61 (s, 3H), 1.47 (d, J = 2.2 Hz, 3H). LCMS: [M+H] + 483.28.
[0279] Scheme 19: (E)-4-((3-(4-(dimethylamino)but-2-enamido)phenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)- Synthesis of N-(1-phenylethyl)pyrimidine-5-carboxamide (compound 35): [ka] The title compound was prepared in a manner substantially similar to that described in General Procedure J. The crude product was purified by preparative HPLC purification to give the desired product, compound 35, as an off-white solid (48 mg; yield: 15.23%). 1 H-NMR (400 MHz, DMSO-d 6): δ 11.14 (bs, 1H), 10.13 (bs, 1H), 9.67 (bs, 1H), 8.77-8.79 (m, 2H), 7.86-7.92 (m, 1H), 7.58-7.79 (m, 2H) , 7.21-7.41 (m, 8H), 6.72 (s, 1H), 6.26 (s, 1H), 5.14-5.19 (m, 1H) 3.62 (s, 3H), 3.11-3.13 (m, 2H), 2.02 ( s, 6H), 1.47 (d, J = 2.2 Hz, 3H). LCMS: [M+H] + 540.40.
[0280] Scheme 20: N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl) Synthesis of acrylamide (compound 36): [ka] Step 1: Synthesis of tert-butyl (4-fluoro-3-nitrophenyl)carbamate (82): To a solution of 4-fluoro-3-nitroaniline (81) (10 g, 64.102 mmol) in tert-butanol (50 mL) was added Boc anhydride (13.99 g, 64.102 mmol) at room temperature. The resulting reaction mass was heated at 80°C for 16 hours. After the completion of the reaction (according to TLC monitoring), the mixture was concentrated under reduced pressure. The residue was washed with hexane and dried under reduced pressure to obtain the desired product (82) as a pale yellow solid (14 g; yield: 85.32%). 1 H NMR (400 MHz, DMSO-d 6 ): δ 9.9 (s, 1H), 8.36 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.49-7.54 (m, 1H),1.49 (s, 9H).
[0281] Step 2: Synthesis of tert-butyl (3-amino-4-fluorophenyl)carbamate (83): To a solution of tert-butyl (4-fluoro-3-nitrophenyl)carbamate (82) (14 g, 54.68 mmol) in ethanol (50 mL) was added 10% palladium on carbon (1.4 g, 10% w / w). did. The resulting reaction was stirred at room temperature under hydrogen atmosphere for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was filtered and washed with ethyl acetate (200 mL). The combined filtrates were concentrated under reduced pressure to obtain the desired product (83) as an off-white solid (11 g; yield: 89.21%). 1 H NMR (400 MHz, DMSO-d 6 ): δ 9.01 (bs, 1H), 6.60-7.20 (m, 3H), 5.21 (s, 2H), 1.49 (s, 9H). LCMS: [M+1H] + 227.24.
[0282] Step 3: Synthesis of tert-butyl (3-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)amino)-4-fluorophenyl)carbamate (85): The title compound was prepared in a manner substantially similar to that described in General Procedure A. The crude product was purified by CombiFlash eluting with 70% ethyl acetate in hexane to give the desired product (85) (600 mg; yield: 21.42%). MS: [M+H] + 407.08.
[0283] Step 4: (4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)carbamic acid Synthesis of tert-butyl (86): The title compound was prepared in a manner substantially similar to that described in General Procedure H. The crude product was purified by CombiFlash, eluting with 1% methanol in dichloromethane to give (86) (300 mg; yield: 43.47%). MS: [M+H] + 468.17.
[0284] Step 5: N4-(5-amino-2-fluorophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine (87) Synthesis: The title compound was prepared in a manner substantially similar to that described in General Procedure I to afford the desired product (87) (150 mg; yield: 63.24%). MS: [M+H] + 368.15.
[0285] Step 6: N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl) Acrylamide (compound 36): The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by preparative HPLC purification to give compound 36 as an off-white solid (20 mg; yield: 12.62%). 1 H NMR (400 MHz, DMSO-d 6 ): δ 10.30 (bs, 1H), 9.71 (bs, 1H), 8.82 (bs, 1H), 8.35 (s, 1H), 7.70-7.77 (m, 2H), 7.28-7.42 (m, 1H), 7.10 (s, 1H), 6.89 (s, 1H), 6.37-6.44 (m, 1H), 6.23-6.28 (m, 1H), 5.76 (d, J = 8.0 Hz, 1H), 3.50 (s, 3H). LCMS: [M+H] + 422.23.
[0286] Scheme 21: N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl Synthesis of )amino)phenyl)acrylamide (compound 37): [ka] Step 1: Synthesis of 5-bromo-2-chloro-N-(2-fluoro-5-nitrophenyl)pyrimidin-4-amine (89): The title compound was prepared in a manner substantially similar to that described in General Procedure A. The crude product was purified by CombiFlash, eluting with 40% ethyl acetate in hexanes to give (89) as a pale yellow solid (1.3 g, yield: 44.24%). MS: [M+H] + 346.97.
[0287] Step 2: Synthesis of 2-chloro-N-(2-fluoro-5-nitrophenyl)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-amine (91): The title compound was prepared using general procedure M. 3 It was prepared in a manner substantially similar to the procedure described in . The crude product was purified by CombiFlash, eluting with 35% ethyl acetate in hexane to give the desired product (91) as a pale yellow solid (700 mg; yield: 50.12%). MS: [M+H] + 413.10.
[0288] Step 3: N4-(2-fluoro-5-nitrophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)-5-(4-(trifluoromethyl)phenyl)pyrimidine-2,4- Synthesis of diamine (92): The title compound was prepared in a manner substantially similar to that described in General Procedure H. The crude product was purified by CombiFlash, eluting with 1% methanol in dichloromethane to give the desired product (92) as a pale yellow solid (500 mg; yield: 70.24%). MS: [M+H] + 474.09.
[0289] Step 4: N4-(5-amino-2-fluorophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)-5-(4-(trifluoromethyl)phenyl)pyrimidine-2,4- Synthesis of diamine (93): The title compound was prepared in a manner substantially similar to that described in General Procedure L to provide (93) as a semi-solid (350 mg; yield: 74.78%). MS: [M+H] + 444.11.
[0290] Step 5: N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl Synthesis of )amino)phenyl)acrylamide (compound 37): The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by preparative HPLC to give compound 37 as an off-white solid (30 mg, yield: 13.33%). 1 H NMR (400 MHz, DMSO-d 6 ): δ 10.21 (bs, 1H), 9.24 (bs, 1H), 8.53 (bs, 1H), 7.99 (s, 1H), 7.71-7.81 (m, 5H), 7.57 (s, 1H), 7.08-7.16 (m, 3H), 6.37-6.44 (m, 1H), 6.21-6.26 (m, 1H), 5.74 (d, J = 8.4 Hz, 1H), 3.54 (s, 3H). LCMS: [M+H] + 498.35.
[0291] Table 5: The following compounds were prepared using the procedure described above. [Table 5-1] [Table 5-2] [Table 5-3]
[0292] Scheme 22: N-(3-((5-(1-(N-benzylacetamido)ethyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) Synthesis of phenyl)acrylamide (compound 47): [ka] Step 1: Preparation of tert-butyl (3-((5-(1-hydroxyethyl)-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (94) A solution of tert-butyl (3-((5-formyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (29) (8.0 g, 22.22 mmol) in tetrahydrofuran (150 mL) at -78 °C followed by the addition of methylmagnesium bromide (3.0 M in diethyl ether, 22.22 mL, 66.66 mmol). The resulting reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with saturated ammonium chloride solution (100 mL) and extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified through silica gel (100-200 mesh), eluting with 40-50% ethyl acetate in hexane, and the desired fractions were concentrated to dryness to give (3-((5-(1-hydroxy) Tert-butyl ethyl)-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (94) was obtained as an off-white solid (4.0 g; yield: 48%). MS: [M+H] + 377.43.
[0293] Step 2: Synthesis of tert-butyl (3-((5-acetyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (95): The title compound was prepared in a manner substantially similar to that described in General Procedure O to give (3-((5-acetyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamic acid tert. -Butyl (95) was obtained as a light brown solid (1.5 g; yield: 60%). MS: [M+H] + 375.42.
[0294] Step 3: Preparation of tert-butyl (E)-(3-((5-(1-(benzylimino)ethyl)-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (97): The title compound was prepared in a manner substantially similar to that described in General Procedure D to afford the desired product (97) as an off-white solid (1.0 g; yield: 58%). MS: [M+H] + 464.25.
[0295] Step 4: Synthesis of tert-butyl (3-((5-(1-(benzylamino)ethyl)-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (98): The title compound was prepared in a manner substantially similar to that described in General Procedure E. The resulting crude product was purified through silica gel (100-200 mesh) eluting with 4-5% methanol in dichloromethane and the desired fractions were concentrated under reduced pressure to give (3-((5-( Tert-butyl 1-(benzylamino)ethyl)-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (98) was obtained as a pale yellow solid (400 mg; yield: 40%). MS: [M+H] + 466.30.
[0296] Step 5: Synthesis of tert-butyl (3-((5-(1-(N-benzylacetamido)ethyl)-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (99): The title compound was prepared in a manner substantially similar to that described in General Procedure C. The crude product was purified through silica gel (100-200 mesh) eluting with 3% methanol in dichloromethane and the desired fractions were concentrated under reduced pressure to give (3-((5-(1-(N tert-Butyl-benzylacetamido)ethyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (99) was obtained as a light brown solid (220 mg; yield: 50.45%). MS: [M+H] + 508.27.
[0297] Step 6: Synthesis of tert-butyl (3-((5-(1-(N-benzylacetamido)ethyl)-2-(methylsulfonyl)pyrimidin-4-yl)amino)phenyl)carbamate (100): The title compound was prepared in a manner substantially similar to that described in General Procedure G to afford the desired product (100) as an off-white solid (130 mg; yield: 61%). MS: [M+H] + 540.06.
[0298] Step 7: (3-((5-(1-(N-benzylacetamido)ethyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl) Synthesis of tert-butyl carbamate (101): The title compound was prepared in a manner substantially similar to that described in General Procedure H to give (3-((5-(1-(N-benzylacetamido)ethyl)-2-((1-methyl- tert-Butyl 1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)carbamate (101) was obtained as a light brown solid (100 mg; 74.6%). MS: [M+H] + 557.41.
[0299] Step 8: N-(1-(4-((3-aminophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)ethyl)-N- Synthesis of benzylacetamide (102): The title compound was prepared in a manner substantially similar to that described in General Procedure I to give N-(1-(4-((3-aminophenyl)amino)-2-((1 -Methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)ethyl)-N-benzylacetamide (102) was obtained as a light brown solid (100 mg; yield: 98%). MS: [M-H] - 455.33.
[0300] Step 9: N-(3-((5-(1-(N-benzylacetamido)ethyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino) Synthesis of phenyl)acrylamide (compound 47) The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by preparative HPLC purification to give compound 47 as an off-white solid (6.0 mg, 6.7%). 1 H NMR (400 MHz, DMSO-d 6 ): δ 10.27 (s, 1H), 9.61 (bs, 1H), 7.87-7.94 (m, 2H), 7.55-7.57 (m, 2H), 7.10-7.37 (m, 8H), 6.45-6.51 (m, 1H), 6.24 (d, J = 16.8 Hz, 1H), 5.96-6.01 (m, 1H), 5.76 (d, J = 10.4 Hz, 1H), 4.60 (s, 2H), 3.66 (s 3H), 2.53 (s, 1H), 2.02 (s, 3H), 1.50 (d, J = 6.8 Hz, 3H). LCMS: [M+H] + 511.37.
[0301] Scheme 23: N-(3-((5-((N-benzylacetamido)methyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl) Synthesis of acrylamide (compound 48): [ka] Step 1: Synthesis of tert-butyl (3-((5-((N-benzylacetamido)methyl)-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (104): The title compound was prepared in a manner substantially similar to that described in General Procedure C to give (3-((5-((N-benzylacetamido)methyl)-2-(methylthio)pyrimidin-4-yl tert-Butyl)amino)phenyl)carbamate (104) was obtained as a brown solid (700 mg, quantitative yield). MS: [M+H] + 494.37.
[0302] Step 2: Synthesis of tert-butyl (3-((5-((N-benzylacetamido)methyl)-2-(methylsulfinyl)pyrimidin-4-yl)amino)phenyl)carbamate (105): The title compound was prepared in a manner substantially similar to that described in General Procedure G to afford the desired product (105) as an off-white solid (650 mg; yield: 90%). MS: [M+H] + 510.34.
[0303] Step 3: (3-((5-((N-benzylacetamido)methyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl)carbamic acid Synthesis of tert-butyl(106) The title compound was prepared in a manner substantially similar to that described in General Procedure H to afford the desired product (106) as an off-white solid (650 mg, yield: 92%). MS: [M+H] + 543.18.
[0304] Step 4: N-((4-((3-aminophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)methyl)-N-benzylacetamide Synthesis of (107): The title compound was prepared in a manner substantially similar to that described in General Procedure I to afford the desired product (107) as an off-white solid (450 mg; yield: 94.9%). MS: [M+H] + 443.19.
[0305] Step 5: N-(3-((5-((N-benzylacetamido)methyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)phenyl) Preparation of acrylamide (compound 48): The title compound was prepared in a manner substantially similar to that described in General Procedure K. The final compound was purified by preparative HPLC purification to produce N-(3-((5-((N-benzylacetamido)methyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidine. -4-yl)amino)phenyl)acrylamide (compound 48) was obtained as an off-white solid (30 mg; yield: 15%). 1 H-NMR (400 MHz, DMSO d 6 ): δ 10.15 (bs, 1H), 9.50 (bs, 1H), 9.01 (bs, 1H), 7.87 (s, 1H), 7.65 (s, 1H), 7.62 (s, 1H), 7.53 (d, J = 7.2 Hz, 1H), 7.40-7.36 (m, 4H), 7.31-7.27 (m, 3H), 7.24 (d, J = 7.6 Hz, 1H), 6.47 (d, J = 16.8 Hz, 1H), 6.23 (d, J = 1.6 Hz, 1H), 5.74 (d, J = 1.6 Hz, 1H), 4.62 (s, 2H), 4.37 (s, 2H), 3.68 (s, 3H), 2.12 (s, 3H) . LCMS: [M+H] + 497.31.
[0306] Scheme 24: 4-((5-acrylamido-2-fluorophenyl)amino)-N-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)-N-phenylpyrimidine-5-carboxamide Synthesis of (compound 49): [ka] Step 1: Synthesis of ethyl 2-chloro-4-((2-fluoro-5-nitrophenyl)amino)pyrimidine-5-carboxylate (108): The title compound was prepared in a manner substantially similar to that described in General Procedure A. The crude product was purified by silica gel column chromatography (100-200 mesh) using 20-25% ethyl acetate in hexane as eluent to give 2-chloro-4-((2-fluoro-5-nitrophenyl ) Ethyl amino)pyrimidine-5-carboxylate (108) was obtained as a brown solid (1.6 g, yield: 15.78%). MS: [M+H] + 341.04.
[0307] Step 2: Synthesis of 2-chloro-4-((2-fluoro-5-nitrophenyl)amino)pyrimidine-5-carboxylic acid (109): Ice-cooled ethyl 2-chloro-4-[(2-fluoro-5-nitrophenyl)amino]pyrimidine-5-carboxylate (108) (800 mg, 2.35 mmol) in tetrahydrofuran (10 mL) and water (2.00 mL). To the solution was added lithium hydroxide monohydrate (246 mg, 5.87 mmol). The resulting reaction mixture was stirred at room temperature for 2 hours. After the completion of the reaction (monitored by TLC), the reaction mass was concentrated under reduced pressure. The crude product was diluted with ice-cold water and adjusted to pH ~4 using 1N hydrochloric acid. The resulting precipitate was filtered and dried under reduced pressure to yield 2-chloro-4-((2-fluoro-5-nitrophenyl)amino)pyrimidine-5-carboxylic acid (109) as an off-white solid. (720 mg; yield: 98%). LCMS: [M-H] - 311.26.
[0308] Step 3: Synthesis of 2-chloro-4-((2-fluoro-5-nitrophenyl)amino)-N-methyl-N-phenylpyrimidine-5-carboxamide (111): The title compound was prepared in a manner substantially similar to that described in General Procedure J to give 2-chloro-4-((2-fluoro-5-nitrophenyl)amino)-N-methyl-N-phenyl. Pyrimidine-5-carboxamide (111) was obtained as an off-white solid (150 mg; yield: 20%). LCMS: [M+H] + 401.98.
[0309] Step 4: 4-((2-fluoro-5-nitrophenyl)amino)-N-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)-N-phenylpyrimidine-5-carboxamide Synthesis of (112): The title compound was prepared in a manner substantially similar to that described in General Procedure H. The residue was purified by CombiFlash, eluting with 60% ethyl acetate in hexanes to give the desired product (112) as an off-white solid (300 mg, yield: 52.13%). LCMS: [M+H] + 463.27.
[0310] Step 5: 4-((5-amino-2-fluorophenyl)amino)-N-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)-N-phenylpyrimidine-5-carboxamide Synthesis of (113): The title compound was prepared in a manner substantially similar to that described in General Procedure L to give 4-((5-amino-2-fluorophenyl)amino)-N-methyl-2-((1-methyl -1H-pyrazol-4-yl)amino)-N-phenylpyrimidine-5-carboxamide (113) was obtained as a light green solid (220 mg; yield: 48.62%). MS: [M+H] + 433.20.
[0311] Step 6: 4-((5-acrylamido-2-fluorophenyl)amino)-N-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)-N-phenylpyrimidine-5-carboxamide Synthesis of (compound 49): The title compound was prepared in a manner substantially similar to that described in General Procedure K. The residue was purified by preparative HPLC purification to give 4-((5-acrylamido-2-fluorophenyl)amino)-N-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino) -N-Phenylpyrimidine-5-carboxamide was obtained as an off-white solid (compound 49) (10 mg, yield: 8%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.25 (bs, 1H), 9.61 (bs, 1H), 9.48 (s, 1H), 7.94 (bs, 1H), 7.68 (s, 1H), 7.58 (s, 1H), 7.35-7.39 (m , 2H), 7.31 (d, J = 6.8 Hz, 3H), 7.23 (d, J = 7.2 Hz, 2H), 7.15 (s, 1H), 6.43 (d, J = 16.4 Hz, 1H), 6.25 (d , J = 17.6 Hz, 1H), 5.77 (d, J = 11.6 Hz, 1H), 3.56 (s, 3H), 3.37 (s, 3H). LCMS: [M+H] + 487.35.
[0312] Scheme 25: N-(4-((5-acrylamido-2-fluorophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)benzamide (Compound 50 ) composition: [ka] Step 1: Synthesis of tert-butyl (3-((2-chloro-5-nitropyridin-4-yl)amino)-4-fluorophenyl)carbamate (115): To an ice-cold solution of tert-butyl (3-amino-4-fluorophenyl)carbamate (83) (5.0 g, 22.12 mmol) in tetrahydrofuran (50 mL) was added N,N-diisopropylethylamine (7.82 mL, 44.24 mmol). , then 2,4-dichloro-5-nitropyrimidine (114) (4.24 g, 22.12 mmol) was added. The resulting reaction mixture was stirred at room temperature for 1 hour. The progress of the reaction was monitored by TLC and after completion of the reaction, the mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic components were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to yield (3-((2-chloro-5-nitropyridin-4-yl)amino)-4- Tert-butyl (fluorophenyl)carbamate (115) was obtained (6.1 g, yield: 60.24%). MS: [M+H] + 384.12.
[0313] Step 2: Synthesis of tert-butyl (3-((5-amino-2-chloropyrimidin-4-yl)amino)-4-fluorophenyl)carbamate (116): The title compound was prepared in a manner substantially similar to that described in General Procedure L to give (3-((5-amino-2-chloropyrimidin-4-yl)amino)-4-fluorophenyl)carbamine. Tert-butyl acid (116) was obtained (4.8 g, yield: 85.40%). LCMS: [M+H] + 353.81.
[0314] Step 3: Synthesis of tert-butyl (3-((5-benzamido-2-chloropyrimidin-4-yl)amino)-4-fluorophenyl)carbamate (117): Ice-cold solution of tert-butyl (3-((5-amino-2-chloropyrimidin-4-yl)amino)-4-fluorophenyl)carbamate (116) (1.0 g, 2.831 mmol) in tetrahydrofuran (10 mL) To the solution was added pyridine (810 mg, 11.32 mmol) followed by benzoyl chloride (62) (400 mg, 2.831 mmol) under nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction (TLC monitoring), the reaction mixture was diluted with water (100 mL) and extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash, eluting with 8% ethyl acetate in hexane to give (3-((5-benzamido-2-chloropyrimidin-4-yl)amino)-4-fluorophenyl)carbamic acid tert. -Butyl (117) was obtained (800 mg, yield: 61.53%). MS: [M+H] + 458.23.
[0315] Step 4: tert-butyl(3-((5-benzamido-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)carbamate( Synthesis of 118): The title compound was prepared in a manner substantially similar to that described in General Procedure H. The residue was purified by CombiFlash, eluting with 2% methanol in dichloromethane to give (3-((5-benzamide-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidine-4- tert-butyl)amino)-4-fluorophenyl)carbamate (118) was obtained (450 mg, yield: 49.61%). MS: [M+H] + 519.13.
[0316] Step 5: N-(4-((5-amino-2-fluorophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)benzamide (119) synthesis of. The title compound was prepared in a manner substantially similar to that described in General Procedure I to give N-(4-((5-amino-2-fluorophenyl)amino)-2-((1-methyl- 1H-pyrazol-4-yl)amino)pyrimidin-5-yl)benzamide (119) was obtained (280 mg, yield: 77.10%). MS: [M+H] + 419.24.
[0317] Step 6: N-(4-((5-acrylamido-2-fluorophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-5-yl)benzamide (Compound 50 ) composition. The title compound was prepared in a manner substantially similar to that described in General Procedure K. The crude product was purified by preparative HPLC purification to give N-(4-((5-acrylamido-2-fluorophenyl)amino)-2-((1-methyl-1H-pyrazol-4-yl)amino) Pyrimidin-5-yl)benzamide (Compound 50) was obtained (17 mg, yield: 10.03%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.22 (bs, 1H), 9.68 (bs, 1H), 9.04 (bs, 1H), 8.63 (bs, 1H), 8.06-8.08 (m, 2H), 7.95 (s, 1H), 7.84-7.85 (m, 1H), 7.50-7.59 (m, 4H) 7.21-7.31 (m, 3H), 6.37-6.44 (m, 1H), 6.22 (d, J = 16.8 Hz, 1H), 5.74 (d, J = 11.2 Hz, 1H), 3.57 (s, 3H). LCMS: [M+H] + 473.35.
[0318] Scheme 26: N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(phenylsulfonamido)pyrimidin-4-yl)amino)phenyl) Synthesis of acrylamide (compound 51): [ka] Step 1: Synthesis of tert-butyl (3-((2-chloro-5-(phenylsulfonamido)pyrimidin-4-yl)amino)-4-fluorophenyl)carbamate (120): Ice-cold solution of tert-butyl (3-((5-amino-2-chloropyrimidin-4-yl)amino)-4-fluorophenyl)carbamate (116) (1.0 g, 2.83 mmol) in tetrahydrofuran (10 mL) To the solution was added pyridine (0.95 mL, 11.32 mmol), benzenesulfonyl chloride (66) (0.36 mL, 2.83 mmol), and a catalytic amount of N,N-dimethylaminopyridine under nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for 16 hours. The progress of the reaction was monitored by TLC and after the completion of the reaction, the reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash, eluting with 40% ethyl acetate in hexane to give (3-((2-chloro-5-(phenylsulfonamido)pyrimidin-4-yl)amino)-4-fluorophenyl ) Tert-butyl carbamate (120) was obtained (600 mg, yield 42.85%). MS: [M+H] + 494.10.
[0319] Step 2: Synthesis of N-(4-((5-amino-2-fluorophenyl)amino)-2-chloropyrimidin-5-yl)benzenesulfonamide (121): The title compound was prepared in a manner substantially similar to that described in General Procedure I to afford the desired product (121) (410 mg; yield: 54.14%). MS: [M+H] + 394.21.
[0320] Step 3: Synthesis of N-(3-((2-chloro-5-(phenylsulfonamido)pyrimidin-4-yl)amino)-4-fluorophenyl)acrylamide (122): The title compound was prepared in a manner substantially similar to that described in General Procedure K to afford the desired product (122) (330 mg; yield: 29.48%). MS: [M+H] + 448.11.
[0321] Step 4: N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(phenylsulfonamido)pyrimidin-4-yl)amino)phenyl) Synthesis of acrylamide (compound 51): The title compound was prepared in a manner substantially similar to that described in General Procedure H. The final compound was purified by preparative HPLC to give the desired product N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-( Phenylsulfonamido)pyrimidin-4-yl)amino)phenyl)acrylamide (Compound 51) was obtained (43 mg; yield: 19.14%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.17 (bs, 1H), 9.02 (bs, 1H), 8.24 (bs, 1H), 7.74-7.79 (m, 3H), 7.53-7.60 (m, 5H), 7.38 (s, 1H), 7.19 -7.24 (m, 3H), 6.38-6.45 (m, 1H) 6.23-6.27 (m, 1H), 5.77 (d, J = 10.0 Hz, 1H), 3.56 (s, 3H). LCMS: [M+H] + 509.35.
[0322] Scheme 27: (E)-4-((3-(4-(dimethylamino)but-2-enamido)phenyl)amino)-2-((2-methoxy-4-(piperidin-1-yl)phenyl) Synthesis of amino)-N-methyl-N-phenylpyrimidine-5-carboxamide (compound 52): [ka] Step 1: Synthesis of tert-butyl (3-((2-chloro-5-(methyl(phenyl)carbamoyl)pyrimidin-4-yl)amino)phenyl)carbamate (124): The title compound was prepared in a manner substantially similar to that described in General Procedure J to give (3-((5-(methyl(phenyl)carbamoyl)-2-(methylthio)pyrimidin-4-yl)amino ) phenyl) tert-butyl carbamate (124) was obtained (1.8 g, yield: 75.21%), MS: [M+H] + 466.21.
[0323] Step 2: Synthesis of 4-((3-aminophenyl)amino)-N-methyl-2-(methylthio)-N-phenylpyrimidine-5-carboxamide (125). The title compound was prepared in a manner substantially similar to that described in General Procedure I to give 4-((3-aminophenyl)amino)-N-methyl-2-(methylthio)-N-phenylpyrimidine- 5-carboxamide (125) was obtained (1.1 g, yield: 78.15%). MS: [M+H] + 366.18.
[0324] Step 3: (E)-4-((3-(4-(dimethylamino)but-2-enamido)phenyl)amino)-N-methyl-2-(methylthio)-N-phenylpyrimidine-5-carboxamide( 126) synthesis: The title compound was prepared in a manner substantially similar to that described in General Procedure J. The crude product was purified by CombiFlash, eluting with 2.5% methanol in dichloromethane to give (E)-4-((3-(4-(dimethylamino)but-2-enamido)phenyl)amino)-N- Methyl-2-(methylthio)-N-phenylpyrimidine-5-carboxamide (126) was obtained (600 mg; yield: 46.15%). MS: [M+H] + 477.23.
[0325] Step 4: (E)-4-((3-(4-(dimethylamino)but-2-enamido)phenyl)amino)-N-methyl-2-(methylsulfonyl)-N-phenylpyrimidine-5-carboxamide Synthesis of (127): The title compound was prepared in a manner substantially similar to that described in General Procedure G to give (E)-4-((3-(4-(dimethylamino)but-2-enamido)phenyl)amino) -N-methyl-2-(methylsulfonyl)-N-phenylpyrimidine-5-carboxamide (127) was obtained (510 mg, yield: 79.68%). MS: [M+H] + 509.19.
[0326] Step 5: (E)-4-((3-(4-(dimethylamino)but-2-enamido)phenyl)amino)-2-((2-methoxy-4-(piperidin-1-yl)phenyl) Synthesis of amino)-N-methyl-N-phenylpyrimidine-5-carboxamide (compound 52): The title compound was prepared in a manner substantially similar to that described in General Procedure H. The final compound was purified by preparative HPLC to give compound 52 as an off-white solid (44 mg, yield: 7.06%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.01 (bs, 1H), 9.59 (bs, 1H), 7.84-7.86 (m, 2H), 7.62 (s, 1H), 7.47 (d, J = 6.4 Hz, 1H), 7.28-7.37 (m , 6H), 7.14-7.23 (m, 2H), 6.70-6.77 (m, 1H), 6.54 (s, 1H), 6.25-6.32 (m, 2H), 3.72 (s, 3H), 3.37 (s, 3H) ), 3.03-3.06 (m, 6H), 2.17 (s, 6H), 1.61 (s, 4H), 1.51-1.52 (m, 2H). LCMS: [M+H] + 635.18.
[0327] Scheme 28: (E)-N-(3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine Synthesis of -4-yl)amino)phenyl)-4-(dimethylamino)but-2-enamide (compound 53): [ka] Step 1: Synthesis of tert-butyl (3-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)carbamate (129): A solution of tert-butyl (3-aminophenyl)carbamate (7) (5 g, 22.13 mmol) in N,N-dimethylformamide (50 mL) was added with potassium carbonate (6.10 g, 44.26 mmol) and 5-bromo-2, 4-Dichloropyrimidine (88) (4.97g, 22.13mmol) was added at room temperature. The resulting reaction mixture was heated at 110°C for 16 hours. After completion of the reaction (TLC monitoring), the reaction mixture was cooled to room temperature and ice-cold water (100 mL) was added. The resulting solid precipitate was filtered and dried under reduced pressure to give tert-butyl (3-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)carbamate (129) (3.5 g ; yield: 39.98%). LCMS: [M+H] + 399.48.
[0328] Step 2: Synthesis of tert-butyl (3-((2-chloro-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)phenyl)carbamate (130): The title compound was prepared in a manner substantially similar to that described in General Procedure H to afford the desired product (130) (1.4 g; yield: 35.12%). LCMS: [M+H] + 465.38.
[0329] Step 3: (3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino ) Synthesis of tert-butyl) phenylcarbamate (132): The title compound was prepared in a manner substantially similar to that described in General Procedure H to afford the desired product (132) (600 mg; yield: 37.54%). LCMS: [M+H] + 559.17.
[0330] Step 4: N4-(3-aminophenyl)-N2-(3-chloro-1-methyl-1H-pyrazol-4-yl)-5-(4-(trifluoromethyl)phenyl)pyrimidine-2,4- Synthesis of diamine (133): The title compound was prepared in a manner substantially similar to that described in General Procedure I to afford the desired product (133) (320 mg, yield: 65.04%). MS: [M+H] + 460.48.
[0331] Step 5: (E)-N-(3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidine Synthesis of -4-yl)amino)phenyl)-4-(dimethylamino)but-2-enamide (compound 53): The title compound was prepared in a manner substantially similar to that described in General Procedure J. The final compound was purified by preparative HPLC purification to obtain the desired product, compound 53, as a white solid (35 mg, yield: 18.86%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.25 (bs, 1H), 10.13 (bs, 1H), 8.46-8.50 (m, 2H), 7.98 (s, 1H), 7.78-7.80 (m, 3H), 7.68-7.70 (m, 2H) , 7.39-7.41 (m, 1H), 7.22-7.32 (m, 2H) 6.70-6.77 (m, 1H), 6.42 (d, J = 15.2 Hz, 1H), 3.79 (s, 2H), 3.65 (s, 3H), 2.67 (s, 6H). LCMS: [M+H] + 571.12.
[0332] Scheme 29: (E)-N-(3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl) Synthesis of amino)phenyl)-4-(dimethylamino)but-2-enamide (compound 54): [ka] Step 1: Synthesis of tert-butyl (3-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)carbamate (134): A solution of tert-butyl (3-aminophenyl)carbamate (84) (5.0 g, 24.038 mmol) in N,N-dimethylformamide (50 mL) was added with potassium carbonate (6.63 g, 48.16 mmol) and 2,4-dichloro -5-(trifluoromethyl)pyrimidine (7) (5.16g, 24.038mmol) was added at room temperature. The resulting reaction mixture was heated at 100°C for 16 hours. After completion of the reaction (TLC monitoring), the reaction mixture was diluted with ice-cold water (200 mL). The resulting solid precipitate was filtered and dried under reduced pressure to give tert-butyl (3-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)carbamate (134 ) was obtained (4.4 g; yield: 48.88%). LCMS: [M+H] + 389.48.
[0333] Step 2: (3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)carbamic acid Synthesis of tert-butyl (135): The title compound was prepared in a manner substantially similar to that described in General Procedure H to afford the desired product (135) (400 mg; yield: 32.25%). MS: [M+H] + 484.24.
[0334] Step 3: N4-(3-aminophenyl)-N2-(3-chloro-1-methyl-1H-pyrazol-4-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine (136) Synthesis: The title compound was prepared in a manner substantially similar to that described in General Procedure H to afford the desired product (136) (310 mg; yield: 97.12%). LCMS: [M+H] + 384.11.
[0335] Step 4: (E)-N-(3-((2-((3-chloro-1-methyl-1H-pyrazol-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl) Synthesis of amino)phenyl)-4-(dimethylamino)but-2-enamide (compound 54): The title compound was prepared in a manner substantially similar to that described in General Procedure J to afford the desired product, Compound 54, as an off-white solid after preparative HPLC purification (40 mg, yield :15.56%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.22 (bs, 1H), 9.09 (bs, 1H), 8.84 (bs, 1H), 8.31 (s, 1H), 7.70 (s, 1H), 7.55-7.57 (m, 1H), 7.32-7.34 (m, 1H), 7.09 (s, 1H) 6.70-6.77 (m, 1H), 6.32 (d, J = 14.8 Hz, 1H), 3.86-3.65 (m, 1H), 3.52 (s, 3H), 3.32 -3.39 (m, 2H), 2.40 (s, 6H). LCMS: [M+H] + 495.16.
[0336] Scheme 30: N-[4-fluoro-3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-5-[6-(morpholin-4-yl)pyridin-3-yl Synthesis of ]pyrimidin-4-yl}amino)phenyl]prop-2-enamide (compound 55): [ka] Step 1: Synthesis of 5-bromo-N4-(2-fluoro-5-nitrophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (137): The title compound was prepared in a manner substantially similar to that described in General Procedure H to afford the desired product (137) as a pale yellow solid (yield: 70%). LCMS: [M+H] + 407.90.
[0337] Step 2: N4-(2-fluoro-5-nitrophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)-5-[6-(morpholin-4-yl)pyridin-3-yl] Synthesis of pyrimidine-2,4-diamine (139) The title compound was prepared in a manner substantially similar to that described in General Procedure M3 to afford the desired product (139) as a reddish solid. LCMS: [M+H] + 492.50.
[0338] Step 3: N4-(5-amino-2-fluorophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)-5-[6-(morpholin-4-yl)pyridin-3-yl] Synthesis of pyrimidine-2,4-diamine (140) The title compound was prepared in a manner substantially similar to that described in General Procedure L to afford the desired product (140) as a pale yellow solid. LCMS: [M+H] + 462.0.
[0339] Step 4: N-[4-fluoro-3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-5-[6-(morpholin-4-yl)pyridin-3-yl Synthesis of ]pyrimidin-4-yl}amino)phenyl]prop-2-enamide (compound 55) The title compound was prepared in a manner substantially similar to that described in General Procedure K to afford the desired product as an off-white solid. 1 H NMR (400 MHz, DMSO-d6): δ 10.19 (s, 1H), 9.08 (bs, 1H), 8.19 (s, 1H), 7.84 (s, 1H), 7.74 (d, J = 5.6 Hz, 1H ), 7.63 (d, J = 6.8 Hz, 1H), 7.55 (bs, 1H), 7.25 (bs, 2H), 7.13-7.11 (m, 2H), 6.92 (d, J = 8.8 Hz, 1H), 6.42 -6.36 (m, 1H), 6.24-6.20 (m, 1H), 5.74 (d, J = 11.6 Hz, 1H), 3.70 (s, 3H), 3.53-3.48 (m, 4H), 3.30 (4H, DMSO - merged with water peak). LCMS: [M+H] + 516.0.
[0340] Table 6: The following compounds were prepared using the procedure described above. [Table 6-1] [Table 6-2] [Table 6-3] [Table 6-4] [Table 6-5] [Table 6-6] [Table 6-7] [Table 6-8]
[0341] Scheme 31: N-[4-fluoro-3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-5-[3-(trifluoromethyl)phenyl]pyrimidin-4-yl Synthesis of}amino)phenyl]prop-2-enamide (compound 89): [ka] Step 1: N4-(2-fluoro-5-nitrophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)-5-[3-(trifluoromethyl)phenyl]pyrimidine-2,4- Synthesis of diamine (141) The title compound was prepared using general procedure M. 3 The desired product (141) was obtained as an off-white solid (0.4 g, 97% yield). LCMS: [M+H] + 474.1.
[0342] Step 2: N4-(5-amino-2-fluorophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)-5-[3-(trifluoromethyl)phenyl]pyrimidine-2,4- Synthesis of diamine (142) The title compound was prepared in a manner substantially similar to that described in General Procedure L1 to afford the desired product (142) as a brown liquid (0.2 g, crude product). LCMS: [M+H] + 444.2.
[0343] Step 3: N-[4-fluoro-3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-5-[3-(trifluoromethyl)phenyl]pyrimidin-4-yl Synthesis of}amino)phenyl]prop-2-enamide (compound 89) The title compound was prepared in a manner substantially similar to that described in General Procedure K and was obtained as an off-white solid (0.13 g, crude product). 1 H NMR (400 MHz, DMSO-d6): δ 10.22 (s, 1H), 9.40 (bs, 1H), 8.65 (bs, 1H), 7.96 (s, 1H), 7.77 (s, 2H), 7.68 (s , 2H), 7.55 (s, 2H), 7.28-7.10 (m, 3H), 6.40-6.35 (m, 1H), 6.24-6.20 (m, 1H), 5.74 (d, J = 10.0 Hz, 1H), 3.53 (s, 3H). LCMS: [M+H] + 498.3.
[0344] [Table 7-1] [Table 7-2]
[0345] Scheme 32: N-(4-fluoro-3-{[5-(1H-indol-5-yl)-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl] Synthesis of amino}phenyl)prop-2-enamide (compound 97): [ka] Step 1: 5-{4-[(2-fluoro-5-nitrophenyl)amino]-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-5-yl}-1H-indole Synthesis of tert-butyl -1-carboxylate (144) 5-bromo-N4-(2-fluoro-5-nitrophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)pyrimidine in 1,4-dioxane (4.50 mL), water (0.5 mL) A stirred solution of -2,4-diamine (137) (0.35 g, 0.85 mmol) was added with cesium carbonate (0.83 g, 2.57 mmol) and {1-[(tert-butoxy)carbonyl]-1H-indol-5-yl.}Boronic acid (143) (0.269g, 1.2eq, 1.03mmol) was added. The reaction mixture was then purged with nitrogen for 5 min, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.7 g, 0.085 mmol) was added, and the reaction mixture was heated at 100 °C for 16 h. Heated. The progress of the reaction was monitored by TLC / LCMS. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with water (25 mL x 2), brine (25 mL), dried over anhydrous sodium sulfate, and evaporated. The crude product was purified by column chromatography using a CombiFlash purifier, eluting with 40-60% ethyl acetate in hexanes to give the title compound (144) as a pale yellow solid. LCMS: [M+H] + 545.2.
[0346] Step 2: 5-{4-[(5-amino-2-fluorophenyl)amino]-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-5-yl}-1H-indole Synthesis of tert-butyl -1-carboxylate (145) The title compound was prepared in a manner substantially similar to that described in General Procedure L to afford the desired product (145) as a brown solid (0.2 g, crude). LCMS: [M+H] + 515.2.
[0347] Step 3: 5-(4-{[2-fluoro-5-(prop-2-enamido)phenyl]amino}-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidine-5- Synthesis of tert-butyl)-1H-indole-1-carboxylate (146) The title compound was prepared in a manner substantially similar to that described in General Procedure K to afford the desired product (146) as a white solid (0.19 g). LCMS: [M+H] + 569.3.
[0348] Step 4: N-(4-fluoro-3-{[5-(1H-indol-5-yl)-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl] Synthesis of amino}phenyl)prop-2-enamide (compound 97) 5-(4-{[2-fluoro-5-(prop-2-enamido)phenyl]amino}-2-[(1-methyl-1H-pyrazol-4-yl)amino] in dichloromethane (10.0 mL) To a stirred solution of tert-butyl (pyrimidin-5-yl)-1H-indole-1-carboxylate (0.15 g, 0.264 mmol) was added trifluoroacetic acid (1.00 mL) and stirred at room temperature for 2 hours. The progress of the reaction was monitored by LCMS / TLC. The reaction mixture was then concentrated under reduced pressure. The crude compound was purified by preparative HPLC to give the title compound (0.05 g, 0.107 mmol) as a light brown solid. 1 H NMR (400 MHz, DMSO-d6): δ 11.24 (s, 1H), 10.6 (s, 1H), 9.99 (s, 1H), 9.38 (s,1H), 7.88 (s, 2H), 7.77 (s , 1H), 7.67-7.43 (m, 2H), 7.33 (s, 1H), 7.27 (s, 2H), 7.18 (d, J = 8.0 Hz, 2H), 6.51 (s,1H), 6.42-6.24 ( m, 1H), 6.21 (s, 1H), 5.76-5.73 (m, 1H), 3.53 (s, 3H). LCMS: [M+H] + 469.3.
[0349] Table 8: The following compounds were prepared using the procedure described above. [Table 8-1] [Table 8-2] [Table 8-3] [Table 8-4] [Table 8-5] [Table 8-6] [Table 8-7] [Table 8-8] [Table 8-9] [Table 8-10]
[0350] Scheme 33: N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(pyridin-4-yl)pyrimidin-4-yl)amino) Synthesis of phenyl)acrylamide (compound 137): [ka] Step 1: N4-(2-fluoro-5-nitrophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)pyrimidine-2,4-diamine (148 ) synthesis 5-bromo-N4-(2-fluoro-5-nitrophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)pyrimidine in 1,4-dioxane (4.00 mL), water (1.0 mL) To a stirred solution of -2,4-diamine (137) (300 mg, 0.73 mmol) was added cesium carbonate (599 mg, 1.84 mmol) and (pyridin-4-yl)boronic acid (147) (111 mg, 0.904 mmol). . The reaction mixture was then purged with nitrogen for 5 min, [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride (60.0 mg, 0.073 mmol) was added, and the reaction mixture was heated at 100 °C for 16 h. Heated. The progress of the reaction was monitored by TLC. The reaction water was diluted with water (20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with water (20 mL), brine (20 mL), dried over anhydrous sodium sulfate and evaporated. The crude compound was purified by CombiFlash column chromatography using 20% ethyl acetate in hexane as eluent to give the title compound (155) (300 mg, 100%). LCMS: [M+H] + 407.0.
[0351] Step 2: N4-(5-amino-2-fluorophenyl)-N2-(1-methyl-1H-pyrazol-4-yl)-5-(pyridin-4-yl)pyrimidine-2,4-diamine (149 ) synthesis The title compound was prepared using general procedure L. 1 The desired product (149) was obtained as a brown solid (0.22 g, crude). LCMS: [M+H] + 377.
[0352] Step 3: N-(4-fluoro-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(pyridin-4-yl)pyrimidin-4-yl)amino) Synthesis of phenyl)acrylamide (compound 137) The title compound was prepared in a manner substantially similar to that described in General Procedure K to give an off-white solid (0.028 g, 12.24%). 1 H NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H), 9.30 (bs, 1H), 8.58-8.577 (m, 3H), 8.02 (s, 1H), 7.27 (s, 1H), 7.56 -7.50 (m, 3H), 7.28 (bs, 2H), 7.13-7.05 (m, 2H), 6.42-6.35 (m, 1H), 6.23 (d, J = 16.8 Hz, 1H), 5.73 (d, J = 10.0 Hz, 1H), 3.51 (s, 3H). LCMS: [M+H] + 431.2.
[0353] Table 9: The following compounds were prepared using the procedure described above. [Table 9-1] [Table 9-2] [Table 9-3] [Table 9-4]
[0354] Scheme 34: N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)oxy)phenyl ) Synthesis of acrylamide (compound 151): [ka] Step 1: Synthesis of 5-bromo-2-chloro-4-(3-nitrophenoxy)pyrimidine (151) Stirred solution of 5-bromo-2,4-dichloropyrimidine (88) (20.0 g, 87.76 mmol) and 3-nitrophenol (150) (12.20 g, 87.76 mmol) in N,N-dimethylformamide (100.0 mL) To this, potassium carbonate (14.53 g, 105.31 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to room temperature and diluted with ice-cold water (250 mL). The precipitated solid was filtered and washed with ice-cold water (2 x 100 mL). The solid was dried under reduced pressure to obtain the desired product (151) as an off-white solid (25 g, yield: 86%). 1 H NMR (400 MHz, DMSO-d 6 ): δ 8.94 (s, 1H), 8.28 (s, 1H), 8.21-8.23 (m, 1H), 7.78-7.830 (m, 2H). LCMS: [M+H] + 330.22.
[0355] Step 2: Synthesis of 5-bromo-N-(1-methyl-1H-pyrazol-4-yl)-4-(3-nitrophenoxy)pyrimidin-2-amine (152) The title compound was prepared in a manner substantially similar to that described in General Procedure H to afford the desired compound as a yellow solid (5.0 g, yield: 30%). LCMS: [M+H] + 391.27.
[0356] Step 3: Synthesis of N-(1-methyl-1H-pyrazol-4-yl)-4-(3-nitrophenoxy)-5-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine (153) : The title compound was prepared in a manner substantially similar to that described in General Procedure M3 to afford the desired compound as an off-white solid (0.2 g, yield: 38%). LCMS: [M+H] + 457.13.
[0357] Step 4: Synthesis of 4-(3-aminophenoxy)-N-(1-methyl-1H-pyrazol-4-yl)-5-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine (154) : The title compound was prepared in a manner substantially similar to that described in General Procedure L to afford the desired compound as an off-white solid (0.12 g, yield: 65%). LCMS: [M+H] + 427.07.
[0358] Step 5: N-(3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)oxy)phenyl ) Synthesis of acrylamide (compound 151): The title compound was prepared in a manner substantially similar to that described in General Procedure K to afford the desired compound as an off-white solid (0.010 g, yield: 15%) after preparative HPLC purification. . 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.37 (bs, 1H), 9.78 (bs, 1H), 8.52 (s, 1H), 7.93-7.95 (m, 2H), 7.80-7.82 (m, 2H), 7.72 (s, 1H), 7.61 (s, 1H), 7.51 (s, 1H), 7.11 (s, 1H), 7.03 (d, J = 6.4 Hz, 1H), 6.86 (s, 1H), 6.39-6.46 (m, 1H), 6.23- 6.27 (m, 1H), 5.75 (d, J = 10.0 Hz, 1H), 3.51 (s, 3H). LCMS: [M+H] + 481.17.
[0359] Scheme 35: N-(3-((3-chloro-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)amino)-4-fluorophenyl)acrylamide (Compound 153 ) composition: [ka] Step 1: Synthesis of tert-butyl (6-bromo-3-chloropyrazin-2-yl)carbamate (156): A solution of 6-bromo-3-chloropyridin-2-amine (155) (500 mg, 2.40 mmol) in dichloromethane (10.0 mL) contains triethylamine (170 mg, 1.68 mmol), N,N-dimethylpyridin-4-amine ( 29.3 mg, 0.240 mmol) and di-tert-butyl dicarbonate (1.05 g, 4.80 mmol) were added at room temperature. The resulting reaction mixture was stirred at the same temperature for 16 hours. After completion of the reaction (according to TLC monitoring), the reaction mixture was concentrated under reduced pressure and the residue was taken up in water (30 mL) and extracted with dichloromethane (3 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by CombiFlash column chromatography to give tert-butyl (6-bromo-3-chloropyrazin-2-yl)carbamate (156), eluting with 10-40% ethyl acetate in heptane. Obtained as a white solid (600 mg, yield: 81%). LCMS: [M-tBu+H] + 251.97.
[0360] Step 2: Synthesis of tert-butyl (3-chloro-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)carbamate (157): To a solution of tert-butyl (6-bromo-3-chloropyrazin-2-yl)carbamate (156) (400 mg, 1.30 mmol) in 1,4-dioxane (10.0 mL) was added cesium carbonate (845 mg, 2.59 mmol). was added, then the reaction mixture was purged with nitrogen for 15 min and 1-methyl-1H-pyrazol-4-amine (22) (126 mg, 1.30 mmol), tris(dibenzylideneacetone)dipalladium (0) (119 mg , 0.130 mmol), and xanthophos (150 mg, 0.26 mmol) were added at room temperature. The resulting reaction mixture was heated at 120°C for 16 hours. After completion of the reaction (according to TLC monitoring), the reaction was cooled to room temperature, filtered through a pad of Celite, and washed with ethyl acetate (3 x 30 mL). The combined filtrates were concentrated under reduced pressure to give tert-butyl (3-chloro-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)carbamate (157) (800 mg , yield: 68.41%), which was used in the next step without further purification. MS: [M+H] + 325.16.
[0361] Step 3: Synthesis of 5-chloro-N2-(1-methyl-1H-pyrazol-4-yl)pyrazine-2,6-diamine (158): The title compound was prepared in a manner substantially similar to that described in General Procedure H to give 5-chloro-N2-(1-methyl-1H-pyrazol-4-yl)pyrazine-2,6-diamine ( 158) was obtained as a green solid (150 mg, yield: 27.1%). LC-MS: [M+H] + 225.12.
[0362] Step 4: Synthesis of 3-chloro-N2-(2-fluoro-5-nitrophenyl)-N6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2,6-diamine (160) 5-chloro-N2-(1-methyl-1H-pyrazol-4-yl)pyrazine-2,6-diamine (158) (50.0 mg, 0.223 mmol) and 2- in 1,4-dioxane (2.0 mL). To a stirred solution of bromo-1-fluoro-4-nitrobenzene (159) (49.0 mg, 0.223 mmol) was added cesium carbonate (145 mg, 0.45 mmol) at room temperature. The reaction mass was purged with nitrogen for 15 min, then tris(dibenzylideneacetone)dipalladium(0) (20.4 mg, 0.022 mmol) and [5-(diphenylphosphanyl)-9,9-dimethyl-9H-xanthene- 4-yl]diphenylphosphane (25.8 mg, 0.044 mmol) was added to the reaction mixture. The resulting reaction mixture was heated at 120°C for 16 hours. After completion of the reaction (according to TLC monitoring), the reaction was cooled to room temperature, poured into ice-cold water (50 mL), and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 3-chloro-N2-(2-fluoro-5-nitrophenyl)-N6-(1-methyl-1H-pyrazole). -4-yl)pyrazine-2,6-diamine (160) was obtained as a semi-solid (30.0 mg, yield: 13%). MS: [M+H] + 364.23.
[0363] Step 5: Synthesis of N2-(5-amino-2-fluorophenyl)-3-chloro-N6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2,6-diamine (161): The title compound is prepared in a manner substantially similar to that described in General Procedure L to give N2-(5-amino-2-fluorophenyl)-3-chloro-N6-(1-methyl-1H-pyrazole -4-yl)pyrazine-2,6-diamine (161) was obtained (60.0 mg, yield: 63%). MS: [M+H]+ 334.09.
[0364] Step 6: N-(3-((3-chloro-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)amino)-4-fluorophenyl)acrylamide (Compound 153 ) composition: The title compound was prepared in a manner substantially analogous to that described in General Procedure J and was prepared as N2-(5-amino-2-fluorophenyl)-3-chloro-N6-(1-methyl-1H-pyrazole- N-(3-((3-chloro-6-((1-methyl-1H-pyrazol-4-yl)amino ) pyrazin-2-yl)amino)-4-fluorophenyl)acrylamide (compound 153) was obtained as a white solid after preparative HPLC purification (8.0 mg, yield: 4.92%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.27 (s, 1H), 9.27 (s, 1H), 8.48 (s, 1H), 7.80-7.78 (m, 1H), 7.64-7.62 (m, 1H), 7.33 (t, J = 9.6 Hz , 1H), 7.25 (s, 1H), 7.15-7.14 (m, 2H), 6.38-6.45 (m, 1H), 6.23 (d, J = 15.6 Hz, 1H), 5.74 (d, J = 11.2 Hz, 1H), 3.54 (s, 3H). LCMS: [M+H] + 388.21.
[0365] Scheme 36: Synthesis of N-(3-((3-chloro-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)oxy)phenyl)acrylamide (compound 218): [ka] Step 1: Synthesis of tert-butyl (3-((6-bromo-3-chloropyrazin-2-yl)oxy)phenyl)carbamate (164): To a stirred solution of tert-butyl (3-hydroxyphenyl)carbamate (163) (1.84 g, 8.81 mmol) in acetonitrile (10.0 mL) was added triethylamine (3.01 mL, 22.0 mmol) and 3,5-dibromo-2- Chloropyrazine (162) (2.0 g, 7.34 mmol) was added at room temperature. The reaction mixture was stirred at 85°C for 16 hours. After consumption of starting material (according to TLC monitoring), the reaction mixture was diluted with water (100 mL) and then extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel flash column chromatography (5-25% ethyl acetate in heptane) to give (3-((6-bromo-3-chloropyrazin-2-yl)oxy)phenyl)carbamic acid tert. -Butyl (164) was obtained as a yellow solid (1.90 g, yield: 64.57%). LCMS: [M-H] - 397.97.
[0366] Step 2: Synthesis of tert-butyl (3-((3-chloro-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)oxy)phenyl)carbamate (165) : To a stirred solution of 1-methyl-1H-pyrazol-4-amine (22) (654 mg, 6.74 mmol) in toluene (10.0 mL) was added cesium carbonate (2.20 g, 6.74 mmol) and (3-((6-bromo tert-Butyl-3-chloropyrazin-2-yl)oxy)phenyl)carbamate (164) (900 mg, 2.25 mmol) was added. The resulting reaction mixture was purged with nitrogen for 20 min, and then [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane complex (367 mg, 0.449 mmol) was added and the resulting The reaction mixture was stirred at 110°C for 20 hours. After completion of the reaction (according to TLC monitoring), the reaction mixture was filtered through a pad of Celite and concentrated under reduced pressure. The crude residue was taken up in water (20 mL) and extracted with ethyl acetate (3 x 50 mL). The organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give (3-((3-chloro-6-((1-methyl-1H-pyrazole- tert-Butyl 4-yl)amino)pyrazin-2-yl)oxy)phenyl)carbamate (165) (1.30 g, yield: 28.75%) was obtained as a brown solid, which was used directly in the next step. MS: [M+H] + 417.28.
[0367] Step 3: Preparation of 6-(3-aminophenoxy)-5-chloro-N-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-amine (166): The title compound was prepared in a manner substantially similar to that described in General Procedure I to give (3-((3-chloro-6-((1-methyl-1H-pyrazol-4-yl)amino) tert-butyl pyrazin-2-yl)oxy)phenyl)carbamate (165) gives 6-(3-aminophenoxy)-5-chloro-N-(1-methyl-1H-pyrazol-4-yl)pyrazine- 2-Amine (166) was obtained as a green solid (720 mg; yield: 72.89%). MS: [M+H] + 317.15.
[0368] Step 4: Synthesis of N-(3-((3-chloro-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)oxy)phenyl)acrylamide (compound 154): The title compound was prepared in a manner substantially similar to that described in General Procedure J to give 6-(3-aminophenoxy)-5-chloro-N-(1-methyl-1H-pyrazol-4-yl ) pyrazine-2-amine (166) and acryloyl chloride (18) yl)oxy)phenyl)acrylamide (compound 154) was obtained as a brown solid after preparative HPLC purification (64.0 mg, yield: 7.81%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.38 (s, 1H), 9.71 (s, 1H), 7.67-7.61 (m, 3H), 7.50 (t, J = 8.0 Hz, 1H), 7.14 (s, 1H), 7.09-6.98 (m , 2H), 6.39-6.45 (m, 1H), 6.23 (d, J = 16.0 Hz, 1H), 5.76 (d, J = 10.0 Hz, 1H), 3.53 (s, 3H). LCMS: [M+H] + 371.18.
[0369] Scheme 37: N-(3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)amino)-4- Synthesis of fluorophenyl)acrylamide (compound 155): [ka] Step 1: Synthesis of tert-butyl (3-((3,6-dichloro-1,2,4-triazin-5-yl)amino)-4-fluorophenyl)carbamate (168): To a stirred solution of 3,5,6-trichloro-1,2,4-triazine (167) (1.40 g, 7.59 mmol) in dichloromethane (10 mL) was added triethylamine (1.54 g, 15.2 mmol) and (3-amino-4 tert-Butyl -fluorophenyl)carbamate (83) (2.06 g, 9.11 mmol) was added at 0°C. The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction (according to TLC monitoring), the reaction mixture was diluted with water (20 mL) and extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give (3-((3,6-dichloro-1,2,4-triazin-5-yl) tert-Butyl)amino)-4-fluorophenyl)carbamate (168) was obtained as a yellow solid (1.70 g, yield: 13.2%), which was used directly in the next step. MS: [M+H] + 374.04.
[0370] Step 2: (3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)amino)-4-fluorophenyl ) Synthesis of tert-butyl carbamate (169): tert-butyl (3-((3,6-dichloro-1,2,4-triazin-5-yl)amino)-4-fluorophenyl)carbamate (168) (1.10 g) in isopropanol (3.0 mL), To a stirred solution of 2.94 mmol) was added 1-methyl-1H-pyrazol-4-amine (22) (714 mg, 7.35 mmol) and camphorsulfonic acid (478 mg, 2.06 mmol). The reaction mixture was heated at 100°C for 16 hours. After completion of the reaction (according to TLC monitoring), the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give (3-((6-chloro-3-((1-methyl-1H-pyrazole-4 -yl)amino)-1,2,4-triazin-5-yl)amino)-4-fluorophenyl)tert-butyl)carbamate (169) was obtained as a viscous liquid (2.20g, yield: 44.13%) . MS: [M+H] + 435.53.
[0371] Step 3: N5-(5-amino-2-fluorophenyl)-6-chloro-N3-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazine-3,5-diamine( Preparation of 170) The title compound was prepared in a manner substantially similar to that described in General Procedure I to give (3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino) tert-butyl -1,2,4-triazin-5-yl)amino)-4-fluorophenyl)carbamate (169) gives N5-(5-amino-2-fluorophenyl)-6-chloro-N3- (1-Methyl-1H-pyrazol-4-yl)-1,2,4-triazine-3,5-diamine (170) was obtained as a viscous liquid (700 mg; yield: 20.58%). MS: [M+H] + 335.12.
[0372] Step 4: N-(3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)amino)-4- Synthesis of fluorophenyl)acrylamide (compound 155) The title compound is prepared in a manner substantially similar to that described in General Procedure K to give N5-(5-amino-2-fluorophenyl)-6-chloro-N3-(1-methyl-1H-pyrazole N-(3-((6-chloro-3-((1-methyl-1H -pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)amino)-4-fluorophenyl)acrylamide (compound 155) was obtained as a white solid after preparative HPLC purification (3.5 mg, Yield: 5.29%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.34 (s, 1H), 9.81-9.58 (bs, 2H), 7.83 (s, 1H), 7.66 (s, 1H), 7.38 (s, 1H), 7.20 (bs, 2H), 6.38-6.45 (m, 1H), 6.25 (d, J = 16.8 Hz, 1H), 5.77 (d, J = 11.6 Hz, 1H), 3.60 (s, 3H). LCMS: [M+H] + 389.21.
[0373] Scheme 38: N-(3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)amino)phenyl)acrylamide Synthesis of (compound 156): [ka] Step 1: Synthesis of tert-butyl (3-((3,6-dichloro-1,2,4-triazin-5-yl)amino)phenyl)carbamate (171): To a stirred solution of 3,5,6-trichloro-1,2,4-triazine (167) (3.0 g, 16.3 mmol) in dichloromethane (30.0 mL) was added triethylamine (3.29 g, 32.5 mmol) and (3-amino tert-Butyl phenyl)carbamate (7) (2.37 g, 11.4 mmol) was added at room temperature. The reaction mixture was stirred at the same temperature for 3 hours. After completion of the reaction (according to TLC monitoring), the reaction mixture was diluted with water (20 mL) and extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by CombiFlash column chromatography (10-20% ethyl acetate in heptane) to give (3-((3,6-dichloro-1,2,4-triazin-5-yl)amino)phenyl ) Tert-butyl carbamate (171) was obtained as a yellow solid (2.0 g, yield: 34.51%). LCMS: [M+H] + 356.09.
[0374] Step 2: (3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)amino)phenyl)carbamic acid tert -Synthesis of butyl(172): tert-butyl (3-((3,6-dichloro-1,2,4-triazin-5-yl)amino)phenyl)carbamate (171) (1.50 g) in propan-2-ol (5.0 mL), To a stirred solution of 1-methyl-1H-pyrazol-4-amine (22) (1.02 g, 10.5 mmol) and camphorsulfonic acid (685 mg, 2.95 mmol) were added. The reaction mixture was stirred at 80°C for 16 hours. After completion of the reaction (according to TLC monitoring), the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by CombiFlash column chromatography, eluting with 10-20% ethyl acetate in heptane to give (3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl) ) tert-butyl)-1,2,4-triazin-5-yl)amino)phenyl)carbamate (172) was obtained as a yellow solid (700 mg, 1.68 mmol). [M+H] + 417.49.
[0375] Step 3: Synthesis of N5-(3-aminophenyl)-6-chloro-N3-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazine-3,5-diamine (173) : The title compound was prepared in a manner substantially similar to that described in General Procedure I to give (3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino) tert-butyl -1,2,4-triazin-5-yl)amino)phenyl)carbamate (172) gives N5-(3-aminophenyl)-6-chloro-N3-(1-methyl-1H-pyrazole) -4-yl)-1,2,4-triazine-3,5-diamine (173) was obtained as a reddish solid (350 mg; yield: 76%). MS: [M+H] + 317.17.
[0376] Step 4: N-(3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)amino)phenyl)acrylamide Synthesis of (compound 156): The title compound was prepared in a manner substantially similar to that described in General Procedure K to give N5-(3-aminophenyl)-6-chloro-N3-(1-methyl-1H-pyrazol-4-yl. N-(3-((6-chloro-3-((1-methyl-1H-pyrazole-4 -yl)amino)-1,2,4-triazin-5-yl)amino)phenyl)acrylamide (compound 156) was obtained as a white solid after preparative HPLC purification (15.0 mg, yield: 4.21%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.26 (s, 1H), 9.52 (bs, 2H), 7.88 (s, 1H), 7.59-7.57 (m, 1H), 7.42-7.30 (m, 4H), 6.42-6.48 (m, 1H) , 6.23 (dd, J = 16.8 Hz, 2.0 Hz 1H), 5.75 (d, J = 10.4 Hz, 1H), 3.63 (bs, 3H). LCMS: [M+H] + 371.15.
[0377] Scheme 39: N-(3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)oxy)phenyl)acrylamide Synthesis of (compound 157): [ka] Step 1: Synthesis of tert-butyl (3-((3,6-dichloro-1,2,4-triazin-5-yl)oxy)phenyl)carbamate (174): To a stirred solution of 3,5,6-trichloro-1,2,4-triazine (177) (2.0 g, 10.8 mmol) in dichloromethane (30 mL) was added triethylamine (1.44 g, 14.2 mmol) and (3-hydroxyphenyl ) tert-Butyl carbamate (163) (1.75 g, 8.34 mmol) was added at 0° C., then allowed to warm up naturally to room temperature and stirred at the same temperature for 16 hours. After completion of the reaction (according to TLC monitoring), water (50 mL) was added and extracted with dichloromethane (5 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by CombiFlash column chromatography, eluting with 5-10% ethyl acetate in heptane to give (3-((3,6-dichloro-1,2,4-triazin-5-yl)oxy) ) phenyl) tert-butyl carbamate (174) was obtained as a white solid (1.90 g; yield: 63.76%). LCMS: [M-H] - 355.11.
[0378] Step 2: (3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)oxy)phenyl)carbamic acid tert -Synthesis of butyl(175): tert-Butyl (3-((3,6-dichloro-1,2,4-triazin-5-yl)oxy)phenyl)carbamate (174) (500 mg, 1.40 mmol) in toluene (3.0 mL) and 1 -To a stirred solution of methyl-1H-pyrazol-4-amine (22) (136 mg, 1.40 mmol) was added cesium carbonate (1.37 g, 4.20 mmol) at room temperature. The resulting reaction mixture was purged with nitrogen for 15 minutes, then a complex of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) and dichloromethane (229 mg, 0.28 mmol) was added. The resulting reaction mixture was heated at 110°C for 16 hours. After completion of the reaction (according to TLC monitoring), the reaction mixture was concentrated under reduced pressure. The crude product was taken into water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give (3-((6-chloro-3-((1-methyl-1H-pyrazole-4 tert-Butyl (-yl)amino)-1,2,4-triazin-5-yl)oxy)phenyl)carbamate (175) was obtained as a yellow gel (200 mg; yield: 34.19%). MS: [M+H] + 418.32.
[0379] Step 3: Synthesis of 5-(3-aminophenoxy)-6-chloro-N-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazin-3-amine (176): The title compound was prepared in a manner substantially similar to that described in General Procedure I to give (3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino) 5-(3-aminophenoxy)-6-chloro-N-(1-methyl-1H-pyrazole) by tert-butyl -1,2,4-triazin-5-yl)oxy)phenyl)carbamate (175) -4-yl)-1,2,4-triazin-3-amine (176) was obtained as a brown solid (280 mg; yield: 28%). MS: [M+H] + 318.08.
[0380] Step 4: N-(3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl)amino)-1,2,4-triazin-5-yl)oxy)phenyl)acrylamide Synthesis of (compound 157): The title compound was prepared in a manner substantially similar to that described in General Procedure K to give 5-(3-aminophenoxy)-6-chloro-N-(1-methyl-1H-pyrazol-4-yl )-1,2,4-triazin-3-amine (176) and acryloyl chloride (18), N-(3-((6-chloro-3-((1-methyl-1H-pyrazol-4-yl) )amino)-1,2,4-triazin-5-yl)oxy)phenyl)acrylamide (compound 157) was obtained as a white solid after preparative HPLC purification (20 mg, yield: 6.1%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.37-10.35 (m, 2H), 7.70 (s, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.49-7.45 (m, 2H), 7.41 (s, 1H), 7.00 (d , J = 8.0 Hz, 1H), 6.39-6.46 (m, 1H), 6.24 (d, J = 16.8 Hz, 1H), 5.77 (d, J = 10.0 Hz, 1H), 3.64 (s, 3H). LCMS: [M+H] + 372.15.
[0381] Scheme 40: Synthesis of N-(3-((3-methyl-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)oxy)phenyl)acrylamide (compound 158): [ka] Step 1: Synthesis of tert-butyl (3-((6-chloro-3-methylpyrazin-2-yl)oxy)phenyl)carbamate (178) A solution of 3,5-dichloro-2-methylpyrazine (177) (1.00 g, 6.13 mmol) in dimethyl sulfoxide (10.0 mL) was added with cesium fluoride (2.80 g, 18.4 mmol) and (3-hydroxyphenyl)carbamic acid. tert-Butyl (163) (1.28g, 6.13mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 5 hours. After completion of the reaction (according to TLC monitoring), the reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel flash column chromatography, eluting with 15-25% ethyl acetate in heptane to give (3-((6-chloro-3-methylpyrazin-2-yl)oxy)phenyl)carbamine. Tert-butyl acid (178) was obtained as a white solid (1.90 g; yield: 82.08%). LCMS: [M+H] + 336.25.
[0382] Step 2: Synthesis of tert-butyl (3-((3-methyl-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)oxy)phenyl)carbamate (179) To a stirred solution of 1-methyl-1H-pyrazol-4-amine (22) (1.30 g, 3 eq., 13.4 mmol) in toluene (15.0 mL) was added cesium carbonate (4.37 g, 13.4 mmol) and (3-(( Tert-butyl 6-chloro-3-methylpyrazin-2-yl)oxy)phenyl)carbamate (178) (1.50 g, 4.47 mmol) was added at room temperature. The reaction mixture was degassed with nitrogen for 15 minutes, then a complex of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) and dichloromethane (1.09 g, 1.34 mmol) was added at room temperature. The resulting reaction mixture was stirred at 110°C for 16 hours. After completion of the reaction (according to TLC monitoring), the reaction mixture was cooled to room temperature, ice-cold water (100 mL) was added and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give (3-((3-methyl-6-((1-methyl-1H- Tert-butyl pyrazol-4-yl)amino)pyrazin-2-yl)oxy)phenyl)carbamate (179) was obtained as a viscous liquid (1.00 g). MS: [M+H] + 397.32.
[0383] Step 3: Synthesis of 6-(3-aminophenoxy)-5-methyl-N-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-amine (180) The title compound was prepared in a manner substantially similar to that described in General Procedure I to give (3-((3-methyl-6-((1-methyl-1H-pyrazol-4-yl)amino) tert-butyl pyrazin-2-yl)oxy)phenyl)carbamate (179) gives 6-(3-aminophenoxy)-5-methyl-N-(1-methyl-1H-pyrazol-4-yl)pyrazine- 2-Amine (180) was obtained as a brown liquid (1.40 g; yield: 28.95%). MS: [M+H] + 297.36.
[0384] Step 4: Synthesis of N-(3-((3-methyl-6-((1-methyl-1H-pyrazol-4-yl)amino)pyrazin-2-yl)oxy)phenyl)acrylamide (compound 158) The title compound was prepared in a manner substantially similar to that described in General Procedure K to give 6-(3-aminophenoxy)-5-methyl-N-(1-methyl-1H-pyrazol-4-yl ) pyrazine-2-amine (180) and acryloyl chloride (18) yl)oxy)phenyl)acrylamide (compound 158) was obtained as a light brown solid after preparative HPLC purification (76.0 mg, yield: 5.09%). 1 H-NMR (400 MHz, DMSO-d 6 ): δ 10.33 (s, 1H), 9.25 (s, 1H), 7.70 (s, 1H), 7.62 (s, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.46 (t, J = 8.0 Hz, 1H), 7.12 (s, 1H), 7.02 (s, 1H), 6.92 (d, J = 6.4 Hz, 1H), 6.38-6.45 (m, 1H), 6.23 (d, J = 16.8 Hz, 1H) ), 5.76 (d, J = 11.6, 1H), 3.52 (s, 3H), 2.40 (s, 3H). LCMS: [M+H] + 351.18.
[0385] Scheme 41: N-(3-{5-chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-4-fluorophenyl)prop-2-enamide (compound 159) synthesis: [ka] Step 1: Synthesis of 2,5-dichloro-4-(2-fluoro-5-nitrophenyl)pyrimidine (182) To a stirred solution of 2,4,5-trichloropyrimidine (13) (0.3 g, 1.64 mmol) in 1,4-dioxane (5.00 mL), water (0.5 mL) was added 2-(2-fluoro-5-nitro Add phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (181) (0.52 g, 1.96 mmol), sodium carbonate (0.34 g, 3.27 mmol) and purge with nitrogen for 5 min. did. Then, a complex of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) and dichloromethane (0.067 g, 0.081 mmol) was added and stirred at 90° C. for 2 hours. The progress of the reaction was monitored by LCMS. After the completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x 2). The combined organic layers were concentrated under reduced pressure. The crude product was purified by using a CombiFlash purifier, eluting with 1-5% ethyl acetate in hexanes to give the title compound (182) as an off-white solid (0.5 g, 90%). LCMS: [M+H] + 288.0.
[0386] Step 2: Synthesis of 5-chloro-4-(2-fluoro-5-nitrophenyl)-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine (183) 1-Methyl-1H -Pyrazole-4-amine (22) (0.118 g, 1.22 mmol) and N,N-diisopropylethylamine (0.43 mL, 2.43 mmol) were added, and the mixture was stirred at 100° C. for 16 hours in a shielded tube. The progress of the reaction was monitored by LCMS. After the completion of the reaction, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (50 mL x 2). The combined organic layers were concentrated under reduced pressure. The crude product was purified by CombiFlash column chromatography, eluting with 5-7% methanol in dichloromethane to give the title compound (183) (0.36 g, 84%). LCMS: [M+H] + 349.1.
[0387] Step 3: Synthesis of 4-(5-amino-2-fluorophenyl)-5-chloro-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine (184): 5-chloro-4-(2-fluoro-5-nitrophenyl)-N-(1-methyl-1H-pyrazol-4-yl) in tetrahydrofuran (10.0 mL), methanol (10.0 mL), water (10.0 mL). ) To a stirred solution of pyrimidine-2-amine (183) (0.36 g, 1.03 mmol) was added zinc (0.34 g, 5.16 mmol) and ammonium chloride (0.27 g, 5.16 mmol) at 0°C. The reaction mixture was stirred at room temperature for 16 hours. The progress of the reaction was monitored by LCMS. After completion of the reaction, the reaction mixture was filtered through a Celite bed and washed with ethyl acetate. The filtrate was diluted with water (20 mL) and extracted with ethyl acetate (100 mL x 2). The combined organic layers were concentrated under reduced pressure. The crude product was purified by CombiFlash purification equipment and the product was eluted with 4-6% methanol in dichloromethane to give the title compound (184) as a reddish-brown sticky solid (0.2 g, 60.7%). 1 H NMR (400 MHz, DMSO-d6) δ 9.66 (s, 1H), 8.48 (s, 1H), 7.75 (s, 1H), 7.45 (s, 1H), 6.97-6.93 (m, 1H), 6.67- 6.62 (m, 2H), 5.07 (s, 2H), 3.75 (s, 3H). LCMS [M+H] + 319.0.
[0388] Step 4: N-(3-{5-chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-4-fluorophenyl)prop-2-enamide (compound 159) synthesis 4-(5-Amino-2-fluorophenyl)-5-chloro-N-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-amine (184) (0.1 g) in dichloromethane (10.0 mL) , 0.314 mmol) in dichloromethane (2 mL) was added triethylamine (0.088 mL, 0.63 mmol) and prop-2-enoyl chloride (0.031 g, 0.35 mmol) at -30°C. The progress of the reaction was immediately monitored by TLC. After the completion of the reaction, the reaction mixture was quenched with saturated sodium bicarbonate solution (5 mL) at −30° C. and extracted with ethyl acetate (50 mL×2). The combined organic layers were concentrated under reduced pressure. The crude product was purified by CombiFlash chromatography, eluting with 2-4% methanol in dichloromethane to give the crude product. The crude product was purified by preparative HPLC to give the title compound as an off-yellow solid (0.038g, 33.1%). 1 H NMR (400 MHz, DMSO-d6) δ 10.35 (s, 1H), 8.55 (s, 1H), 7.94 (s, 2H), 7.82 (s, 1H), 7.73 (s, 1H), 7.45 (s, 1H), 7.35-7.31 (m, 1H), 6.43-6.36 (m, 1H), 6.27-6.23 (d, J = 16.0 Hz, 1H), 5.77-5.75 (d, J = 11.6 Hz, 1H), 3.76 (s, 3H). LCMS: [M+H] + 372.9.
[0389] Scheme 42: (E)-N-(3-(5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-4-fluorophenyl)-4- Synthesis of (dimethylamino)but-2-enamide (compound 160): [ka] The title compound was prepared as a yellow solid (0.016 g; yield: 12%) in a manner substantially similar to that described in General Procedure J. 1 H NMR (400 MHz, DMSO-d6) δ 10.57 (s, 1H), 9.85 (s, 1H), 9.65 (s, 1H), 8.56 (s, 1H), 7.94-7.75 (m, 3H), 7.46 ( s, 1H), 7.35 (s, 1H), 6.71 (s, 1H), 6.43-6.39 (d, J = 15.2 Hz, 1H), 3.93 (s, 2H), 3.76 (s, 3H), 2.78 (s , 6H). LCMS: [M+H] + 430.2.
[0390] Scheme 46: N-[4-fluoro-3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-5-(2-phenylethynyl)pyrimidin-4-yl}amino)phenyl ]Prop-2-enamide TFA salt (compound 161): [ka] Step 1: Synthesis of tert-butyl (3-((5-bromo-2-chloropyrimidin-4-yl)amino)-4-fluorophenyl)carbamate (185) In a microwave vial, 5-bromo-2,4-dichloropyrimidine (88) (1.00 g, 4.39 mmol), tert-butyl N-(3-amino-4-fluorophenyl)carbamate (83) (0.993 g) , 4.39 mmol), N,N-dimethylformamide (10.0 mL), and dipotassium carbonate (1.21 g, 8.78 mmol) were added. The reaction mixture was heated in the microwave to 100°C for 1 hour. The reaction was monitored by TLC and LCMS. After the completion of the reaction, the reaction mixture was diluted with cold water (25 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine (20 mL), water (20 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure to obtain the crude compound. The crude residue was purified on a CombiFlash purifier using 50% ethyl acetate in hexane to give the title compound (185) as a pale yellow solid (1.1 g, crude product). LCMS: [M+H] + 417.0.
[0391] Step 2: N-[3-({5-bromo-2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}amino)-4-fluorophenyl]carbamic acid tert- Synthesis of butyl(186) tert-Butyl N-{3-[(5-bromo-2-chloropyrimidin-4-yl)amino]-4-fluorophenyl}carbamate (185) (1.00 g) in propan-2-ol (10.0...
Claims
1. Formula (I): 【Chemistry 1】 or a pharma- ceutically acceptable salt or stereoisomer thereof, wherein R 1 is -(C(R 4 ) 2 ) n R 5 and X is -NH; n is 0, R 5 is 0 or 1 R 5’ is a phenyl substituted with R 2 is at least one R 7 and 0, 1, or 2 R 8 is a phenyl substituted with R 3 is 0, 1, 2, or 3 R 12 is a pyrazolyl substituted with Each R 5’ is independently alkyl, haloalkyl, heterocycloalkyl, halo, hydroxy, or alkoxy; R 7 teeth, 【Chemistry 2】 and R 8 is fluoro, Y is -C(=O)-, R 9 , R 9’ , and R 9’’ is hydrogen, R 10 is hydrogen, Each R 12 is independently methyl, isopropyl, tert-butyl, hydroxyethyl, methoxyethyl, trifluoromethyl, trifluoroethyl, chloro, cyano, morpholinyl, or cyclopropyl, or a pharma- ceutically acceptable salt or stereoisomer thereof.
2. Each R 5’ The compound of claim 1, wherein is independently methyl, ethyl, tert-butyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, fluoro, chloro, hydroxy, methoxy, ethoxy, fluoromethyl, difluoromethyl, or trifluoromethyl.
3. Each R 5’ The compound of claim 2, wherein is independently methyl, morpholinyl, fluoro, chloro, methoxy, fluoromethyl, difluoromethyl, or trifluoromethyl.
4. R 2 , 1 or 2 R 8 The compound according to any one of claims 1 to 3, substituted with
5. R 2 The compound of any one of claims 1 to 3, wherein is unsubstituted.
6. R 3 The compound of any one of claims 1 to 5, wherein is unsubstituted.
7. R 3 At least one R 12 The compound according to any one of claims 1 to 5, substituted with
8. R 3 At least two R 12 8. The compound of claim 7 , substituted with:
9. Each R 12 The compound of claim 8 , wherein is independently methyl, hydroxyethyl, methoxyethyl, trifluoroethyl, or chloro.
10. Each R 12 The compound of claim 9 , wherein is independently methyl or chloro.
11. R 5’ The compound according to any one of claims 1 to 10, wherein is fluoromethyl, difluoromethyl, or trifluoromethyl.
12. R 12 The compound according to any one of claims 1 to 11, wherein is methyl.
13. The compound has formula IA, IB, IC, ID, IE, IF, or IG: 【Chemistry 3-1】 【Chemistry 3-2】 or a pharma- ceutically acceptable salt or stereoisomer thereof.
14. The compound is 【Table 1-1】 【Table 1-2】 【Table 1-3】 【Table 1-4】 【Table 1-5】 【Table 1-6】 【Table 1-7】 2. The compound of claim 1 selected from:
15. The compound of claim 1, 【Chemistry 4】 or a pharma- ceutically acceptable salt or stereoisomer thereof.
16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt or stereoisomer thereof, and a pharma- ceutically acceptable carrier.
17. 16. A pharmaceutical composition for use in the treatment of cancer, comprising a compound according to any one of claims 1 to 15 or a pharma- ceutically acceptable salt or stereoisomer thereof.
18. 18. The pharmaceutical composition of claim 17, wherein the cancer is bladder cancer, prostate cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, glioblastoma, head and neck cancer, lung cancer, or non-small cell lung cancer.
19. 19. The pharmaceutical composition of claim 18, wherein the cancer in the subject comprises an EGFR mutation comprising a substitution in exon 18, a deletion in exon 19, a substitution in exon 20, an insertion in exon 20, a mutation in the extracellular domain, or a substitution in exon 21.
20. The EGFR mutations are del19 / T790M EGFR, L858R / T790M EGFR, L858R EGFR, L861Q EGFR, G719X EGFR, 763insFQEA EGFR, 767insTLA EGFR, 769insASV EGFR, 769insGE EGFR, 770insSVD EGFR, 770insNPG EGFR, 770insGT EGFR, 770insGF EGFR, 770insG EGFR, 771insH EGFR, 771insN EGFR, 772insNP EGFR, 773insNPH EGFR, 773insH EGFR, 773insPH 20. The pharmaceutical composition of claim 19, wherein the EGFR is selected from EGFR, EGFRvii, EGFRviii, A767_dupASV EGFR, 773insAH EGFR, M766_A767insAI EGFR, and any combination thereof.
